(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 1 April 2004 (01.04.2004) (10) International Publication Number WO 2004/026888 A2

(51) International Patent Classification⁷:

C07H

(21) International Application Number:

PCT/US2003/029577

(22) International Filing Date:

19 September 2003 (19.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/412,479


19 September 2002 (19.09.2002) US

(71) Applicants (for all designated States except US): COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE). UNIVERSITY OF SASKATCHEWAN [CA/CA]; Kirk Hall, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). QIAGEN GMBH [DE/DE]; Max-Volmer-Strasse 4, 40724 Hilden (DE).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LIPFORD, Grayson, B. [US/US]; 38 Bates Road, Watertown, MA 02472 (US). MOOKHERJEE, Neeloffer [IN/CA]; Apt 408, 2233 Allison Road,, Vancouver, BC V6T IT7 (CA). BABIUK, Lorne [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA). BROWNLIE, Robert [CA/CA]; 123 O'Brien Crescent, Saskatoon, Saskatchewan S7K 5K3 (CA). GRIEBEL, Philip [CA/CA]; Box 36, RR5, Saskatoon, Saskatchewan S7K 3J8 (CA). MUTWIRI, George [CA/CA]; 569 Nordstrum Road, Saskatoon, Saskatchewan S7K 7X6 (CA). HECKER, Rolf [DE/DE]; Benrodestr. 60, 40597 Düsseldorf (DE).
- (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (81) Designated States (national): AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

[Continued on next page]

(54) Title: TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES



ODN (M)

(57) Abstract: Novel amino acid and nucleotide sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine)
Toll-like receptor 9 (TLR9) are provided. Also provided are amino acid and nucleotide sequences for dog (canine), cat (feline), mouse (murine), and human TLR9. Comparison of these sequences, especially in combination with functional assessment for species-specific CpG motif preferences, permits identification of specific regions and amino acid residues of interest in TLR9 ligand interaction. Novel chimeric TLR9 receptor molecules, cells expressing these molecules, and methods for their use in screening assays for TLR9 ligands are also provided.





MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES

Background of the Invention

Synthetic oligodeoxynucleotides (ODN) and DNA containing immunostimulatory CpG motifs (CpG DNA) function as potent adjuvants and activators of the innate immune system. Heeg K et al. (2000) *Int Arch Allergy Immunol* 121:87-97; Krieg AM (2001) *Vaccine* 19:618-22. A wide variety of CpG-containing sequences have been screened for biological activity and it is reported that optimal CpG DNA sequences can vary among species. Rankin R et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:333-40.

5

10

15

20

25

30

Toll-like receptor 9 (TLR9) has recently been identified as a receptor for CpG ODN. Hemmi H et al. (2000) *Nature* 408:740-5. The molecular mechanism by which TLR9 recognizes CpG DNA is not understood.

Summary of the Invention

Toll-like receptor 9 (TLR9) is known to be involved in innate immunity and to signal in response to CpG DNA. To date, the amino acid sequences only of human and murine TLR9 have been reported, and, interestingly, these two species are known to prefer different CpG motifs. The structural basis for this species-specific CpG motif preference has not yet been fully elucidated. The instant invention provides, in part, novel amino acid and nucleotide sequences of rat, pig, cow, and horse TLR9. These novel TLR9 sequences are useful for elucidating certain key structural features of TLR9. Specifically, comparison of sequences of murine, human, and these novel TLR9 sequences permits identification of areas of highly conserved sequence, areas of group conservation, and areas of hypervariability. In addition, such comparisons permit an assessment of evolutionary relatedness among TLR9 molecules of the various species, as well as an assessment of inter-species homologies. Importantly, such comparisons permit a rational basis for identifying amino acids in TLR9 that may be involved in the CpG binding site, as well as amino acids involved in conferring species specificity for particular CpG motifs. Such information may be used to design and construct novel TLR9 molecules which incorporate specific point or regional mutations and which possess desired ligand binding characteristics. Such information may also be useful in designing and identifying novel ligands for TLR9 of a given species.

-2-

In one aspect, the invention provides isolated polypeptides having amino acid sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) TLR9 polypeptides. These amino acid sequences correspond to SEQ ID NOs 1, 5, 9, 13, and 17, respectively. Each of these sequences is believed to include at least a majority of an extracellular domain, as well as a transmembrane region and at least part of a TLR/IL-1 receptor (TIR) domain. To the extent any such sequence may lack an amino-terminal and/or carboxy-terminal sequence, such sequence is ascertainable, without undue experimentation, using conventional molecular biology techniques and the sequence information provided herein.

5

10

15

20

25

30

In another aspect the invention provides isolated polypeptides having amino acid sequences for essentially the whole extracellular domain, optionally including a signal peptide, of each of rat, porcine, bovine, equine, and ovine TLR9. These amino acid sequences correspond to SEQ ID NOs 2, 6, 10, 14, and 18, respectively. Such extracellular domains are believed to include sequence specifically involved in binding to TLR9 ligand, such as CpG DNA. In addition, such extracellular domains are believed to include sequence that confers species specificity for particular CpG motifs.

Isolated nucleic acid molecules encoding the polypeptides just described above are also provided according to further aspects of the invention. Such nucleic acid molecules include, but are not limited to, nucleic acid molecules having sequences provided by SEQ ID NOs 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively. Isolated nucleic acid molecules encoding the TLR9 polypeptides of SEQ ID NOs 1, 5, 9, 13, 17; and 2, 6, 10, 14, and 18 also include nucleic acid molecules that differ in sequence from SEQ ID NOs 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively, due to degeneracy of the genetic code. Such nucleic acid molecules will hybridize, under stringent conditions, with suitably selected nucleic acid molecules having sequences selected from SEQ ID NOs 3, 4, 7, 8, 11, 12, 15, 16, 19, and 20.

In another aspect the invention provides a vector which includes an isolated nucleic acid molecule of the invention. In one embodiment the vector is an expression vector and the isolated nucleic acid molecule of the invention is operably linked to a regulatory sequence in the vector. When present within a cell, an expression vector according to this aspect of the invention causes the cell to express a polypeptide of the invention.

The invention according to another aspect provides a cell in which a vector of the invention is present. In one embodiment the cell containing the vector expresses a

- 3 -

polypeptide of the invention. In certain embodiments the cell also contains a reporter construct that transduces a TLR9-mediated signal in response to contact of the polypeptide of the invention or a TLR9 with a suitable TLR9 ligand. The cell containing the vector, and optionally containing the reporter construct, can be used in screening methods also provided by the invention.

5

10

15

20

25

30

In yet another aspect the invention provides an antibody or antibody fragment that binds specifically to an isolated polypeptide of the invention. In certain embodiments the antibody or antibody fragment binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide. More specifically, the antibody or antibody fragment binds uniquely to one of the isolated polypeptides of the invention. In one embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide also binds to either mouse or human TLR9. In another embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide does not also bind to either mouse or human TLR9. In some embodiments the antibody or antibody fragment binds selectively to a chimeric TLR9 polypeptide of the invention. In certain embodiments the antibody or antibody fragment of the invention is a monoclonal antibody or fragment of a monoclonal antibody.

In one aspect the invention provides a method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species. The method involves aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species; generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

-4-

In another aspect the invention provides a method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9. The method according to this aspect of the invention involves aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9; generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids. In one embodiment the method according to this aspect of the invention is performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

5

10

15

20

25

30

In another aspect the invention also provides an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (extracellular domain (ECD) of murine TLR9) except for substitution of at least one key amino acid identified according to the method above. The polypeptide according to this aspect of the invention is a chimeric TLR9 polypeptide. Preferably the polypeptide according to this aspect of the invention binds to CpG DNA optimized for human TLR9 better than does the isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (ECD of murine TLR9). In one embodiment the polypeptide includes only one substituted amino acid. The isolated polypeptide according to this aspect of the invention may further include sequence involved in TLR/IL-1R signal transduction, e.g., intracellular domain of TLR9 as provided in SEQ ID NOs 29 and 33. For example, in one embodiment a polypeptide according to this aspect of the invention is an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:29 (full length murine TLR9) except for substitution of at least one key amino acid identified according to the method above.

5

10

15

20

In another aspect the invention provides an isolated nucleic acid molecule including a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described. In one embodiment the isolated nucleic acid molecule has a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described.

In yet another aspect, the invention provides a screening method to identify a TLR9 ligand. The method involves contacting a polypeptide (including a chimeric TLR9 polypeptide) of the invention with a candidate TLR9 ligand; measuring a signal in response to the contacting; and identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling. In one embodiment the candidate TLR9 ligand is an immunostimulatory nucleic acid. In one embodiment the candidate TLR9 ligand is a CpG DNA.

The invention also provides, in yet a further aspect, a screening method to identify species-specific CpG-motif preference of an isolated polypeptide of the invention. The method according to this aspect of the invention involves contacting an isolated polypeptide of the invention with a CpG DNA including a hexamer sequence selected from the group consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACGTT, GA

(SEQ ID NO:39), TCCATGACGTTTTTGATGTT TCCATAACGTTTTTTGATGTT (SEQ ID NO:40), (SEQ ID NO:41), TCCATCACGTTTTTGATGTT (SEQ ID NO:42), TCCATTACGTTTTTGATGTT 25 (SEQ ID NO:43), TCCATGGCGTTTTTGATGTT (SEQ ID NO:44), TCCATGCCGTTTTTGATGTT (SEQ ID NO:45), TCCATGTCGTTTTTGATGTT (SEQ ID NO:46), TCCATGATGTTTTTGATGTT (SEQ ID NO:47), TCCATGAAGTTTTTGATGTT 30 (SEQ ID NO:48), TCCATGAGGTTTTTGATGTT (SEQ ID NO:49), TCCATGACATTTTTGATGTT TCCATGACCTTTTTGATGTT (SEQ ID NO:50), TCCATGACTTTTTTGATGTT (SEQ ID NO:51), TCCATGACGCTTTTGATGTT (SEQ ID NO:52), 35 (SEQ ID NO:53), TCCATGACGATTTTGATGTT TCCATGACGGTTTTGATGTT (SEQ ID NO:54),

- 6 -

TCCATGACGTCTTTGATGTT TCCATGACGTATTTGATGTT TCCATGACGTGTTTGATGTT

(SEQ ID NO:55), (SEQ ID NO:56), and

(SEQ ID NO:57).

In certain embodiments of the screening methods of the invention, the signal includes expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway. In one embodiment the reporter gene is operatively linked to a promoter sensitive to NF-kB. In one embodiment the signal in response to contacting is binding of the candidate TLR9 ligand or CpG DNA to the polypeptide of the invention.

In one embodiment the screening method is performed on a plurality of test compounds. In one embodiment the response mediated by the TLR9 signal transduction pathway is measured quantitatively and the response mediated by the TLR9 signal transduction pathway associated with each of the plurality of test compounds is compared with a response arising as a result of an interaction between the functional TLR9 and a reference immunostimulatory compound.

15

10

5

Brief Description of the Figures

Figure 1 depicts a Clustal W multiple sequence alignment of deduced amino acid sequences for cat (feline), dog (canine), cow (bovine), mouse (murine), sheep (ovine), pig (porcine), horse (equine), human, and rat TLR9 polypeptides. The deduced amino acid sequences for feline, canine, bovine, murine, ovine, porcine, equine, human, and rat TLR9 polypeptides shown in the figure correspond to SEQ ID NOs 25, 21, 9, 29, 17, 5, 13, 33, and 1, respectively. Lines labeled "multiple" refer to the multiple sequence alignment of all six sequences shown. Lines labeled "mo/hu" refer to a paired sequence alignment of mouse and human TLR9 sequences alone.

25

20

Figure 2 is a cladogram depicting an evolutionary relatedness tree for rat, murine, porcine, bovine, equine, and human TLR9 polypeptides in Figure 1.

Figure 3 is a graph depicting species specificity of TLR9 signaling with selected oligonucleotides having strong specificity for human (2006), mouse (5890), or neither (1982).

30

Detailed Description of the Invention

The present invention provides novel amino acid and nucleotide sequences for TLR9 derived from rat, pig, cow, horse, and sheep. These sequences can be used to identify key features of the primary sequences of these and related TLR molecules, including previously

5

10

15

20

25

30

known primary sequences of human and mouse (murine) TLR9. Such key features include binding site information and species specificity toward particular CpG motifs. Native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to identify and to design novel TLR9 ligands. Additionally, the native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to compare various TLR9 ligands, including CpG DNA.

In one aspect the invention provides isolated TLR9 polypeptides, and isolated nucleic acid molecules encoding them, from rat, pig, cow, horse, and sheep. The term "isolated" as used herein with reference to a nucleic acid molecule or polypeptide means substantially free of or separated from components with which it is normally associated in nature, e.g., other nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids or polypeptides are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid or polypeptide of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the nucleic acid or polypeptide may represent only a small percentage by weight of such a preparation. The nucleic acid or polypeptide is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

An amino acid sequence of rat TLR9 is provided as SEQ ID NO:1. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:1 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of rat TLR9 (See Figure 1). Amino acids numbered 1-821 of SEQ ID NO:1 are presumptively extracellular domain and correspond to SEQ ID NO:2. SEQ ID NO:3 is a nucleotide sequence of rat TLR9 cDNA having an open reading frame corresponding to nucleotides 1-3096. SEQ ID NO:4 is a nucleotide sequence of rat cDNA encoding amino acids 1-821 of SEQ ID NO:1.

An amino acid sequence of porcine TLR9 is provided as SEQ ID NO:5. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:5 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of porcine TLR9

-8-

(See Figure 1). Amino acids numbered 1-819 of SEQ ID NO:5 are presumptively extracellular domain and correspond to SEQ ID NO:6. SEQ ID NO:7 is a nucleotide sequence of porcine TLR9 cDNA having an open reading frame corresponding to nucleotides 77-3166. SEQ ID NO:8 is a nucleotide sequence of porcine cDNA encoding amino acids 1-819 of SEQ ID NO:5.

5

10

15

20

25

30

An amino acid sequence of bovine TLR9 is provided as SEQ ID NO:9. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:9 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of bovine TLR9 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:9 are presumptively extracellular domain and correspond to SEQ ID NO:10. SEQ ID NO:11 is a nucleotide sequence of bovine TLR9 cDNA having an open reading frame corresponding to nucleotides 84-3170. SEQ ID NO:12 is a nucleotide sequence of bovine cDNA encoding amino acids 1-818 of SEQ ID NO:9.

An amino acid sequence of equine TLR9 is provided as SEQ ID NO:13. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:13 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of equine TLR9 (See Figure 1). Amino acids numbered 1-820 of SEQ ID NO:13 are presumptively extracellular domain and correspond to SEQ ID NO:14. SEQ ID NO:15 is a nucleotide sequence of equine TLR9 cDNA having an open reading frame corresponding to nucleotides 115-3207. SEQ ID NO:16 is a nucleotide sequence of equine cDNA encoding amino acids 1-820 of SEQ ID NO:13.

An amino acid sequence of ovine TLR9 is provided as SEQ ID NO:17. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:17 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of ovine TLR9 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:17 are presumptively extracellular domain and correspond to SEQ ID NO:18. SEQ ID NO:19 is a nucleotide sequence of ovine TLR9 cDNA having an open reading frame corresponding to nucleotides 92-3178. SEQ ID NO:20 is a nucleotide sequence of ovine cDNA encoding amino acids 1-818 of SEQ ID NO:17.

SEQ ID NO:1 (Rat TLR9)

MVLCRRTLHPLSLLVQAAVLAEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAEPRSNITSLSLIANRI HHLHNLDFVHLPNVRQLNLKWNCPPPGLSPLHFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSL SHTNILVLDASSLAGLHSLRVLFMDGNCYYKNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYL LLSYNLIVKLGAEDLANLTSLRMLDVGGNCRRCDHAPDLCTECRQKSLDLHPQTFHHLSHLEGLVLKDSSLHSLN SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSFKSLVSLQELNMNGIF FRLLNKNTLRWLAGLPKLHTLHLQMNFINQAQLSVFSTFRALRFVDLSNNRISGPPTLSRVAPEKADEAEKGVPW PASLTPALPSTPVSKNFMVRCKNLRFTMDLSRNNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK VLDLSYNKLDLYHSKSFSELPQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS 10 VEYLDFSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKLSFRDNHLSFFNWSSLA FLPNLRDLDLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV MNLTVLDVSSNPLHCACGAPFVDLLLEVQTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFGLSLL AVAVGTVLPLLQHLCGWDVWYCFHLCLAWLPLLTRGRRSAQALPYDAFVVFDKAQSAVADWVYNELRVRLEERRG RRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQQRLLEDRKDVVVLVILRPDA 15 HRSRYVRLRORLCROSVLFWPHOPNGOGSFWAOLSTALTRDNHHFYNRNFCRGPTAE

SEQ ID NO:2 (Rat TLR9)

MVLCRRTLHPLSLLVQAAVLAEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAEPRSNITSLSLIANRI

HHLHNLDFVHLPNVRQLNLKWNCPPPGLSPLHFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSL
SHTNILVLDASSLAGLHSLRVLFMDGNCYYKNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYL
LLSYNLIVKLGAEDLANLTSLRMLDVGGNCRRCDHAPDLCTECRQKSLDLHPQTFHHLSHLEGLVLKDSSLHSLN
SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSFKSLVSLQELNMNGIF
FRLLNKNTLRWLAGLPKLHTLHLQMNFINQAQLSVFSTFRALRFVDLSNNRISGPPTLSRVAPEKADEAEKGVPW

PASLTPALPSTPVSKNFMVRCKNLRFTMDLSRNNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK
VLDLSYNKLDLYHSKSFSELPQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS
VEYLDFSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKLSFRDNHLSFFNWSSLA
FLPNLRDLDLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV
MNLTVLDVSSNPLHCACGAPFVDLLLEVQTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFG

SEQ ID NO:3 (Rat TLR9)

30

35

40

45

50

atggttctctgtcgcaggaccctgcaccccttgtctctcctggtacaggccgcagtgctgggctgaggctctggcc ctgggtaccctgcctgccttcctaccctgtgaactgaagcctcatggcctggtagactgcaactggctcttcctg aagtctgtgcctcacttctctgccgcagaaccccgttccaacatcaccagcctttccttgatcgccaaccgcatc caccacctgcacaacctcgactttgtccacctgcccaacgtgcgacagctgaacctcaagtggaactgtccgccc cctggcctcagcccttgcacttctcctgccgcatgaccattgagcccaaaaccttcctggctatgcgcatgctg gaagagctgaacctgagctataacggtatcaccactgtgccccgcctgcccagctccctgacgaatctgagccta agccacaccaacatcctggtactcgatgccagcagcctcgctggcctgcacagcctgcgagttctcttcatggac gggaactgctactacaagaacccctgcaacgggggggtgaacgtgaccccggacgccttcctgggcttgagcaac ctcacccacttgtcccttaagtataacaacctcacagaggtgccccgccaactgcccccagcctggagtacctc ctgctgtcctataacctcatcgtcaagctgggggccgaagacctagccaacctgacctcccttcgaatgcttgat gtgggtgggaattgccgtcgctgtgatcacgcccccgacctctgtacagaatgccggcagaagtcccttgatctg caccctcagactttccatcacctgagccaccttgaaggcctggtgctgaaggacagttctctccactcgctgaac tccaagtggttccagggtctggcgaacctctcggtgctggacctaagcgagaactttctctacgagagcatcaac aaaaccagcgcctttcagaacctgacccgtctgcgcaagctcgacctgtccttcaattactgcaagaaggtatcg ttcgcccgcctccacctggcaagttccttcaagagcctggtgtcgctgcaggagctgaacatgaacggcatcttc aatttcatcaaccaggcgcagctcagcgtctttagtaccttccgagcccttcgctttgtggacctgtccaataat cgcatcagcgggcctccaacgctgtccagagtcgccccgaaaaggcagacgaggcggagaagggggttccatgg cctgcaagtctcaccccagctctcccgagcactcccgtctcaaagaacttcatggtcaggtgtaagaacctcaga ttcaccatggacctgtctcggaacaaccaggtgactatcaagccagagatgttcgtcaacctctcccatctccag tgtctgagcctgagccacaactgcatcgcgcaggctgtcaatggctctcagttcctgccgctgaccaacctgaag gtgctggacctgtcctataacaagctggacctgtaccattcgaaatcgttcagtgagctcccacagttgcaggcc

- 10 -

ctggacctgagctacaacagccagccattcagcatgcaggggataggccacaacttcagttttctggccaatctg tccaggttacagaaccttagcctggcacacaatgacattcacagccgcgtgtcctcacgcctctacagcacctca gtggagtatctggacttcagcggcaacggtgtgggccgcatgtgggacgaggaggacctttacctctatttcttc caagacctgagaagcctgattcatctggacctgtctcagaataagctgcacatcctccggccccagaacctcaac ttcctgcccaatctgcgagacctggacctggcaggcaatctactaaaggccctgaccaacggcaccctgcctaat ggcacgctcctccagaaactggatgtcagtagcaacagtatcgtctttgtggtcccagccttctttgctctggcg gtagagctaaaagaggtcaacctcagccataacatcctcaagactgtggatcgctcctggtttgggcccattgtg atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgcctgcggtgcaccctttgtagacttactg ctggaagtgcagaccaaggtgcctggctaacggtgtgaagtgtggcagtccccgccagctgcaggccgc agcatctttgcgcaagacctgcggctgtgcctggatgacgtcctttctcgggactgcttttggcctttcactcctg gctgtggccgtgggcacggtgttgcctttactgcagcatctctgcggctgggacgtctggtactgtttccatctg tgcctggcatggctacctttgctgacccgtggccggcgcagcgcccaagctctcccttatgatgccttcgtggtg ttcgataaggcgcagagcgcggttgctgactgggtgtataacgagcttcgagtgcggctagagggggcgcggt cgccgagccctacgcttgtgtctggaggaccgagattggctgcctggccagacactcttcgagaacctctgggcc tccatctatggcagccgcaagactctgtttgtgctggcccacacggacaaggtcagtggcctcctgcgcaccagc ttcctgctggctcagcagcgcctgctggaggaccgcaaggacgtggtggtgttggtgatcctgccctgatgcc caccgctcccgctacgtgcgactgcgccagcgcctctgccgccagagtgtgctcttctggccccatcagcccaac gggcaggcagcttctgggcccagctgagtacagccctgactagggacaaccaccacttctataaccggaacttc tgccggggacctacagcagaatag

SEQ ID NO:4 (Rat TLR9)

5

10

15

20

ctgggtaccctgcctgccttcctaccctgtgaactgaagcctcatggcctggtagactgcaactggctcttcctg 25 aagtctgtgcctcacttctctgccgcagaaccccgttccaacatcaccagcctttccttgatcgccaaccgcatc caccacctgcacaacctcgactttgtccacctgcccaacgtgcgacagctgaacctcaagtggaactgtccgccc cctggcctcagcccttgcacttctcctgccgcatgaccattgagcccaaaaccttcctggctatgcgcatgctg gaagagctgaacctgagctataacggtatcaccactgtgccccgcctgcccagctccctgacgaatctgagccta agccacaccaacatcctggtactcgatgccagcagcctcgctggcctgcacagcctgcgagttctcttcatggac *30* gggaactgctactacaagaacccctgcaacgggggggtgaacgtgaccccggacgccttcctgggcttgagcaac ctcacccacttgtcccttaagtataacaacctcacagaggtgccccgccaactgcccccagcctggagtacctc ctgctgtcctataacctcatcgtcaagctgggggccgaagacctagccaacctgacctcccttcgaatgcttgat gtgggtgggaattgccgtcgctgtgatcacgccccgacctctgtacagaatgccggcagaagtcccttgatctg caccctcagactttccatcacctgagccaccttgaaggcctggtgctgaaggacagttctctccactcgctgaac *35* tccaagtggttccagggtctggcgaacctctcggtgctggacctaagcgagaactttctctacgagagcatcaac aaaaccagcgcctttcagaacctgacccgtctgcgcaagctcgacctgtccttcaattactgcaagaaggtatcg ttcgcccgcctccacctggcaagttccttcaagagcctggtgtcgctgcaggagctgaacatgaacggcatcttc aatttcatcaaccaggcgcagctcagcgtctttagtaccttccgagcccttcgctttgtggacctgtccaataat 40 cgcatcagcgggcctccaacgctgtccagagtcgcccccgaaaaggcagacgaggcggagaagggggttccatgg cctgcaagtctcaccccagctctcccgagcactcccgtctcaaagaacttcatggtcaggtgtaagaacctcaga ttcaccatggacctgtctcggaacaaccaggtgactatcaagccagagatgttcgtcaacctctcccatctccag tgtctgagcctgagccacaactgcatcgcgcaggctgtcaatggctctcagttcctgccgctgaccaacctgaag gtgctggacctgtcctataacaagctggacctgtaccattcgaaatcgttcagtgagctcccacagttgcaggcc 45 ctggacctgagctacaacagccagccattcagcatgcaggggataggccacaacttcagttttctggccaatctg tccaggttacagaaccttagcctggcacacaatgacattcacagccgcgtgtcctcacgcctctacagcacctca gtggagtatctggacttcagcggcaacggtgtgggccgcatgtgggacgaggaggacctttacctctatttcttc caagacctgagaagcctgattcatctggacctgtctcagaataagctgcacatcctccggccccagaacctcaac 50 ttcctgcccaatctgcgagacctggcctggcaggcaatctactaaaggccctgaccaacggcaccctgcctaat ggcacgctcctccagaaactggatgtcagtagcaacagtatcgtctttgtggtcccagccttctttgctctggcg gtagagctaaaagaggtcaacctcagccataacatcctcaagactgtggatcgctcctggtttgggcccattgtg atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgcctgcggtgcaccctttgtagacttactg ctggaagtgcagaccaaggtgcctggcctaacggtgtgaagtgtggcagtccccgccagctgcagggccgc *55* agcatctttgcgcaagacctgcggctgtgcctggatgacgtcctttctcgggactgctttggc

- 11 -

SEQ ID NO:5 (Porcine TLR9)

MGPRCTLHPLSLLVQVTALAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRANVTSLSLLSNRIH HLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNSITTVPALPDSLVSLSLS RTNILVLDPTHLTGLHALRYLYMDGNCYYKNPCQGALEVVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLL 5 LSYNHIVTLTPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKDHPKLHSDTFSHLSRLEGLVLKDSSLYNLDT RWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSFGHLRSLKELDMHGIFF RSLSETTLQPLVQLPMLQTLRLQMNFINQAQLSIFGAFPGLLYVDLSDNRISGAARPVAITREVDGRERVWLPSR NLAPRPLDTLRSEDFMPNCKAFSFTLDLSRNNLVTIOSEMFARLSRLECLRLSHNSISOAVNGSOFVPLTSLRVL DLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFTMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASLC 10 ALDFSGNDLSRMWAEGDLYLRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKSLKHLHLRDNNLAFFNWSSLTLL PKLETLDLAGNQLKALSNGSLPSGTQLRRLDLSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWFGSMVGN LKVLDVSANPLHCACGATFVGFLLEVQAAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFGISLLAM ALGLVVPMLHHLCGWDLWYCFHLCLAWLPHRGQRRGADALFYDAFVVFDKAQSAVADWVYNELRVQLEERRGRRA LRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPDAYRS 15 RYVRLRORLCROSVLLWPHOPRGOGSFWAOLGTALTRDNHHFYNRNFCRGPTTAE

SEQ ID NO:6 (Porcine TLR9)

20

25

35

40

45

50

MGPRCTLHPLSLLVQVTALAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRANVTSLSLLSNRIH
HLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNSITTVPALPDSLVSLSLS
RTNILVLDPTHLTGLHALRYLYMDGNCYYKNPCQGALEVVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLL
LSYNHIVTLTPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKDHPKLHSDTFSHLSRLEGLVLKDSSLYNLDT
RWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSFGHLRSLKELDMHGIFF
RSLSETTLQPLVQLPMLQTLRLQMNFINQAQLSIFGAFPGLLYVDLSDNRISGAARPVAITREVDGRERVWLPSR
NLAPRPLDTLRSEDFMPNCKAFSFTLDLSRNNLVTIQSEMFARLSRLECLRLSHNSISQAVNGSQFVPLTSLRVL
DLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFTMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASLC
ALDFSGNDLSRMWAEGDLYLRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKSLKHLHLRDNNLAFFNWSSLTLL
PKLETLDLAGNQLKALSNGSLPSGTQLRRLDLSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWFGSMVGN
LKVLDVSANPLHCACGATFVGFLLEVQAAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFG

30 SEQ ID NO:7 (Porcine TLR9)

gggcaggctgcctgccttcctgccctgtgagctccagccccacggcctggtgaactgcaactggctcttcctgaa gtccgtgccccacttctcggcggcagcgccccgggccaacgtcaccagcctctccttactctccaaccgcatcca ccacctgcacgactccgacttcgtccacctgtccagcctacgaactctcaacctcaagtggaactgcccgccggc tggcctcagccccatgcacttcccctgccacatgaccatcgagcccaacaccttcctggccgtgcccaccctgga caactgctactacaagaacccctgccagggggcgctggaggtggtgccggggtgccctcctcggcctgggcaacct cacacatctctcactcaagtacaacaatctcacggaggtgccccgcagcctgcccccagcctggagaccctgct gttgtcctacaaccacattgtcaccctgacgcctgaggacctggccaatctgactgccctgcgcgtgcttgatgt gggggggaactgccgctgtgaccatgcccgcaacccctgcagggagtgcccaaaggaccaccccaagctgca ctctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaagacagttctctctacaacctggacac gaccacggccttccagggcctggcccgactgcgcagcctcaacctgtccttcaattaccacaagaaggtgtcctt ccgctcgctcagtgagaccacgctccaacctctggtccaactgcctatgctccagaccctgcgcctgcagatgaa cttcattaaccaggcccagctcagcatctttggggccttccctggcctgctgtacgtggacctatcggacaaccg catcagcggagctgcaaggccagtggccattactagggaggtggatggtagggagaggggtctggcttccag gaacctcgctccacgtccactggacactctccgctcagaggacttcatgccaaactgcaaggccttcagcttcac cttggacctgtctcggaacaacctggtgacaatccagtcggagatgtttgctcgcctctcacgcctcgagtgcct gcgcctgagccacaacagcatctcccaggcggtcaatggctctcagtttgtgccgctgaccagcctgcgggtgct ggacctgtcccacaacaagctggacctgtatcacgggcgctcgttcacggagctgccgcgcctggaagcactgga cctcagctacaatagccagccctttaccatgcagggtgtggggccacaacctcagcttcgtggcccagctgcccgc

- 12 -

cctgcgctacctcagcctggcgcacaatgacatccatagccgagtgtcccagcagctctgtagcgcctcactgtg cgccctggactttagcggcaacgatctgagccggatgtggggctgagggagacctctatctccgcttcttccaagg cctaagaagcctagtctggacctgtcccagaaccacctgcacaccctcctgccacgtgccctggacaacct ccccaaaagcctgaagcatctgcatctccgtgacaataacctggccttcttcaactggagcagcctgaccctcct gcccaagctggaaaccctggacttggctggaaaccagctgaaggccctaagcaatggcagcctgccatctggcac ccagctgcggaggctggacctcagtggcaacagcatcggctttgtgaaccctggcttctttgccctggccaagca gttagaagagctcaacctcagcgccaatgccctcaagacagtggagccctcctggtttggctcgatggtgggcaa cctgaaagtcctagacgtgagcgccaaccctctgcactgtgcctgtggggcgaccttcgtgggcttcctgctgga ggtacaggctgccgtgcctggcccagccgcgtcaagtgtggcagtccggggcagctccagggccatagcat ctttgcgcaagacctgcgcctctgcctggatgagaccctctcgtggaactgttttggcatctcgctgctggccat ggccctgggcctggttgtgcccatgctgcaccacctctgcggctgggacctctggtactgcttccacctgtgcct ggcctggctgccccaccgagggcagcggggggcgcagacgccctgttctatgatgccttcgtggtctttgacaa agctcagagtgctgtggccgactgggtgtacaacgagctgcgggtgcagctggaggagcgccgtgggcgccgcgc actgcgcctgtgcctggaggagcgagactggttacctggcaagacgctcttcgagaacctgtgggcctcagtcta cagcagccgcaagaccctgtttgtgctggcccacacggaccgtgtcagcggcctcttgcgtgccagtttcctgct ggcccagcagcgcctgctggaggaccgcaaggacgttgtagtgctggtgatcctgcgccccgatgcctaccgctc ccgctacgtgcggctgcgccagcgcctctgccgccagagtgtcctcctctggccccaccagcccgtgggcaggg cagcttctgggcccagctgggcacagccctgaccagggacaaccaccacttctataaccggaacttctgccgggg ccccacgacagccgaatagcactgagtgacagcccagttgccccagccccctggatttgcctctctgcctgggg tgccccaacctgctttgctcagccacaccactgctctgctccctgttccccaccccacccccagcctggcatgt

SEQ ID NO:8 (Porcine TLR9)

5

10

15

20

25 ggcaggctgcctgccttcctgccctgtgagctccagccccacggcctggtgaactgcaactggctcttcctgaag tccgtgccccacttctcggcggcagcgccccgggccaacgtcaccagcctctccttactctccaaccgcatccac cacctgcacgactccgacttcgtccacctgtccagcctacgaactctcaacctcaagtggaactgcccgccggct ggcctcagccccatgcacttcccctgccacatgaccatcgagcccaacaccttcctggccgtgcccaccctggag *30* aactgctactacaagaacccctgccagggggcgctggaggtggtgccgggtgccctcctcggcctgggcaacctc acacatctctcactcaagtacaacaatctcacggaggtgccccgcagcctgccccccagcctggagaccctgctg ttgtcctacaaccacattgtcaccctgacgcctgaggacctggccaatctgactgccctgcgcgtgcttgatgtg ggggggaactgccgccgctgtgaccatgcccgcaacccctgcagggagtgcccaaaggaccaccccaagctgcac 35 tctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaagacagttctctctacaacctggacacc accacggccttccagggcctggcccgactgcgcagcctcaacctgtccttcaattaccacaagaaggtgtccttt cgctcgctcagtgagaccacgctccaacctctggtccaactgcctatgctccagaccctgcgcctgcagatgaac 40 ttcattaaccaggcccagctcagcatctttggggccttccctggcctgctgtacgtggacctatcggacaaccgc atcagcggagctgcaaggccagtggccattactagggaggtggatggtagggagaggggtctggcttccagg aacctcgctccacgtccactggacactctccgctcagaggacttcatgccaaactgcaaggccttcagcttcacc ttggacctgtctcggaacaacctggtgacaatccagtcggagatgtttgctcgcctctcacgcctcgagtgcctg cgcctgagccacaacagcatctcccaggcggtcaatggctctcagtttgtgccgctgaccagcctgcgggtgctg 45 gacctgtcccacaacaagctggacctgtatcacgggcgctcgttcacggagctgccgcgcctggaagcactggac ctcagctacaatagccagcctttaccatgcagggtgtgggccacaacctcagcttcgtggccagctgccgcc ctgcgctacctcagcctggcgcacaatgacatccatagccgagtgtcccagcagctctgtagcgcctcactgtgc gccctggactttagcggcaacgatctgagccggatgtggggctgagggagacctctatctccgcttcttccaaggc ctaagaagcctagtctggctggacctgtcccagaaccacctgcacaccttcctgccacgtgccctggacaacctc *50* cccaaaagcctgaagcatctgcatctccgtgacaataacctggccttcttcaactggagcagcctgaccctcctg cccaagctggaaaccctggacttggcagaccagctgaaggccctaagcaatggcagcctgccatctggcacc cagctgcggaggctggacctcagtggcaacagcatcggctttgtgaaccctggcttctttgccctggccaagcag ttagaagagctcaacctcagcgccaatgccctcaagacagtggagccctcctggtttggctcgatggtgggcaac ctgaaagtcctagacgtgagcgccaaccctctgcactgtgcctgtggggcgaccttcgtgggcttcctgctggag *55* gtacaggctgccgtgcctgggctgcccagccgcgtcaagtgtggcagtccggggcagctccagggccatagcatc tttgcgcaagacctgcgcctctgcctggatgagaccctctcgtggaactgttttggc

- 13 -

SEQ ID NO:9 (Bovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGAPRANVTSLSLISNRIH HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS 5 HTSILVLGPTHFTGLHALRFLYMDGNCYYMNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL LSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK DWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHLASSFGSLVSLEKLDMHGIFF RSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFVDLSDNRISGAATPAAALGEVDSRVEVWRLPR GLAPGPLDAVSSKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLD 10 LSHNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSOKLSSASLRA LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP RLEALDLAGNQLKALSNGSLPPGIRLQKLDVSSNSIGFVIPGFFVRATRLIELNLSANALKTVDPSWFGSLAGTL KILDVSANPLHCACGAAFVDFLLERQEAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGLSLLMVA LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEERRGRRAL 15 RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPAAYRSR YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNRHFYNRNFCRGPTTAE

SEQ ID NO:10 (Bovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGAPRANVTSLSLISNRIH

HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS
HTSILVLGPTHFTGLHALRFLYMDGNCYYMNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL
LSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHLASSFGSLVSLEKLDMHGIFF
RSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFVDLSDNRISGAATPAAALGEVDSRVEVWRLPR

GLAPGPLDAVSSKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLD
LSHNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
RLEALDLAGNQLKALSNGSLPPGIRLQKLDVSSNSIGFVIPGFFVRATRLIELNLSANALKTVDPSWFGSLAGTL
KILDVSANPLHCACGAAFVDFLLERQEAVPGLSRRVTCGSPGOLOGRSIFTODLRLCLDETLSLDCFG

SEQ ID NO:11 (Bovine TLR9)

30

35

40

45

50

gggaagtgggcgccaagcatccttccctgcagctgcctcccaacctgcccgccagaccctctggagaagccgcat tccctgtcatgggcccctactgtgccccgcacccctttctctctggtgcaggcggcgcactggcagcggccc tggccgagggcaccctgccttcctgccctgtgagctccagccccatggtcaggtggactgcaactggctgt tcctgaagtctgtgccgcacttttcggctggagccccccgggccaatgtcaccagcctctccttaatctccaacc gcatccaccacttgcatgactctgacttcgtccacctgtccaacctgcgggtcctcaacctcaagtggaactgcc cgccggccggcctcagccccatgcacttcccctgccgtatgaccatcgagcccaacaccttcctggctgtgccca tggacggcaactgctactacatgaacccctgcccgcgggccctggaggtggccccaggcgccctcctcggcctgg gcaacctcacgcacctgtcgctcaagtacaaccacctcacggaggtgccccgccgcctgcccccagcctggaca ccctgctgctgtcctacaaccacattgtcaccctggcacccgaggacctggccaacctgactgccctgcgcgtgc ttgacgtgggtgggaactgccgctgcgaccatgcccgcaacccctgcagggagtgcccaaagaacttcccca agctgcaccctgacaccttcagtcacctgagccgcctcgaaggcctggtgttgaaggacagttctctctacaaac tcaccaagaccaccatcttcaacgacctgacccagctgcgcagactcaacctgtccttcaattaccacaagaagg tgtccttcgcccacctgcacctagcgtcctcctttgggagtctggtgtccctggagaagctggacatgcacggca tcttcttccgctccctcaccaacatcacgctccagtcgctgacccggctgcccaagctccagagtctgcatctgc agetgaactteateaaceaggeeeageteageatetttggggeetteeegageetgetettegtggaeetgtegg acaaccgcatcagcggagccgccagcggccgccctgggggaggtggacagcagggtggaagtctggcgat tgcccaggggcctcgctccaggcccgctggacgccgtcagctcaaaggacttcatgccaagctgcaacctcaact tcaccttggacctgtcacggaacaacctggtgacaatccagcaagagatgtttacccgcctctcccgcctccagt gcctgcgcctgagccacaacagcatctcgcaggcggttaatggctcccagttcgtgccgctgaccagcctgcgag

- 14 -

tgctcgacctgtcccacaacaagctggacctgtaccatgggcgctcattcacggagctgccgcagctggaggcac tggacctcagctacaacagccagccttcagcatgcagggcgtgggccacaacctcagcttcgtggcccagctgc cctccctgcgctacctcagccttgcgcacaatggcatccacagccgcgtgtcacagaagctcagcagcgcctcgt tgcgcgccctggacttcagcggcaactccctgagccagatgtgggccgaggggagacctctatctctgctttttca aaggettgaggaacetggteeagetggaeetgteegagaaceatetgeacaceteetgeetegteacetggaea acctgcccaagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcagcctgaccg tcctgccccggctggaagccctggatctggcaggaaaccagctgaaggccctgagcaacggcagcctgccgcctg gcatccggctccagaagctggacgtgagcagcaacagcatcggcttcgtgatccccggcttcttcgtccgcgcga ctcggctgatagagcttaacctcagcgccaatgccctgaagacagtggatccctcctggttcggttccttagcag ggaccctgaaaatcctagacgtgagcgccaacccgctccactgcgcctgcgggggggcctttgtggacttcctgc tggagagacaggaggccgtgcccgggctgtccaggcgcgtcacatgtggcagtccgggccagctccagggccgca gcatcttcacacaggacctgcgcctctgcctggatgagaccctctccttggactgcttttggcctctcactgctaa tggtggcgctggcctggcagtgcccatgctgcaccacctctgtggctgggacctctggtactgcttccacctgt gtctggcccatttgccccgacggcggcggcagcggggggaggacaccctgctctatgatgccgtcgtggtcttcg acaaggtgcagagtgcagtggctgattgggtgtacaacgagctccgcgtgcagctggaggagcgccggggggcgcc gggcgctccgcctctgcctggaggagcgagactggctccctggtaagacgctcttcgagaacctgtgggcctcgg tctacagcagccgcaagaccatgttcgtgctggaccacacggaccgggtcagcggcctcctgcgcgccagcttcc ggtcccgctacgtgcgctgcgccagcgcctctgccgccagagcgtcctcctctggccccaccagcccagtggcc agggtagtttctgggccaacctgggcatagccctgaccagggacaaccgtcacttctataaccggaacttctgcc ggggccccacgacagccgaatagcacagagtgactgcccag

SEQ ID NO:12 (Bovine TLR9)

5

10

15

20

atgggcccctactgtgccccgcacccctttctctctggtgcaggcggcgcactggcagcggccctggccgag 25 ggcaccctgcctgccttcctgccctgtgagctccagccccatggtcaggtggactgcaactggctgttcctgaag tctgtgccgcacttttcggctggagccccccgggccaatgtcaccagcctctccttaatctccaaccgcatccac ggcctcagccccatgcacttcccctgccgtatgaccatcgagcccaacaccttcctggctgtgcccaccctggag *30* cacaccagcatcctggtgctaggccccacccacttcaccggcctgcacgccctgcgctttctgtacatggacggc aactgctactacatgaacccctgcccgcgggccctggaggtggccccaggcgccctcctcggcctgggcaacctc acgcacctgtcgctcaagtacaaccacctcacggaggtgccccgccgcctgcccccagcctggacaccctgctg ctgtcctacaaccacattgtcaccctggcacccgaggacctggccaacctgactgccctgcgcgtgcttgacgtg ggtgggaactgccgctgcgaccatgcccgcaacccctgcagggagtgcccaaagaacttccccaagctgcac cctgacaccttcagtcacctgagccgcctcgaaggcctggtgttgaaggacagttctctctacaaactagagaaa accaccatcttcaacgacctgacccagctgcgcagactcaacctgtccttcaattaccacaagaaggtgtccttc gcccacctgcacctagcgtcctcctttgggagtctggtgtccctggagaagctggacatgcacggcatcttcttc cgctccctcaccaacatcacgctccagtcgctgacccggctgcccaagctccagagtctgcatctgcagctgaac 40 ttcatcaaccaggcccagctcagcatctttggggccttcccgagcctgctcttcgtggacctgtcggacaaccgc atcagcggagccgccagcggccgccctgggggaggtggacagcagggtggaagtctggcgattgcccagg ggcctcgctccaggcccgctggacgccgtcagctcaaaggacttcatgccaagctgcaacctcaacttcaccttg gacctgtcacggaacaacctggtgacaatccagcaagagatgtttacccgcctctcccgcctccagtgcctgcgc ctgagccacaacagcatctcgcaggcggttaatggctcccagttcgtgccgctgaccagcctgcgagtgctcgac 45 ctgtcccacaacaagctggacctgtaccatgggcgctcattcacggagctgccgcagctggaggcactggacctc agctacaacagccagccttcagcatgcagggcgtgggccacaacctcagcttcgtggcccagctgccctcctg cgctacctcagccttgcgcacaatggcatccacagccgcgtgtcacagaagctcagcagcgcctcgttgcgcgcc ctggacttcagcggcaactccctgagccagatgtgggccgagggagacctctatctctgctttttcaaaggcttg aggaacctggtccagctggacctgtccgagaaccatctgcacaccctcctgcctcgtcacctggacaacctgccc *50* aagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcagcctgaccgtcctgccc cggctggaagccctggatctggcaggaaaccagctgaaggccctgagcaacggcagcctgccgcctggcatccgg ctccagaagctggacgtgagcagcaacagcatcggcttcgtgatccccggcttcttcgtccgcgcgactcggctg atagagcttaacctcagcgccaatgccctgaagacagtggatccctcctggttcggttccttagcagggaccctg aaaatcctagacgtgagcgccaacccgctccactgcgcctgcgggggggcctttgtggacttcctgctggagaga 55 caggaggccgtgcccgggctgtccaggcgcgtcacatgtggcagtccggggccagctccagggccgcagcatcttc acacaggacctgcgcctctgcctggatgagaccctctccttggactgctttggc

SEQ ID NO:13 (Equine TLR9)

MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRDNVTSLSLLSNRI HHLHDSDFAQLSNLQKLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLIL SRTNILOLDPTSLTGLHALRFLYMDGNCYYKNPCGRALEVAPGALLGLGNLTHLSLKYNNLTTVPRSLPPSLEYL 5 LLSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCVECPHKFPQLHSDTFSHLSRLEGLVLKDSSLYQLN PRWFRGLGNLTVLDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSFAHLTLAPSFGSLLSLQELDMHGIF FRSLSQKTLQPLARLPMLQRLYLQMNFINQAQLGIFKDFPGLRYIDLSDNRISGAVEPVATTGEVDGGKKVWLTS RDLTPGPLDTPSSEDFMPSCKNLSFTLDLSRNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPTLRYLSLAHNGIHSRVSQQLCSTSL 10 WALDFSGNSLSQMWAEGDLYLRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLLRLRNNYLAFFNWSSLTL LPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRNSIIFVVPGFFALATRLRELNLSANALRTEEPSWFGFLAG SLEVLDVSANPLHCACGAAFVDFLLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFGLSLLV VALGLAMPMLHHLCGWDLWYCFHLGLAWLPRRGWQRGADALSYDAFVVFDKAQSAVADWVYNELRVRLEERRGRR 15 ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDARR SRYVRLRORLCROSVLFWPHOPSGQRSFWAQLGMALTRDNRHFYNQNFCRGPTMAE

SEQ ID NO:14 (Equine TLR9)

20

25

30

35

40

45

50

MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRDNVTSLSLLSNRI
HHLHDSDFAQLSNLQKLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLIL
SRTNILQLDPTSLTGLHALRFLYMDGNCYYKNPCGRALEVAPGALLGLGNLTHLSLKYNNLTTVPRSLPPSLEYL
LLSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCVECPHKFPQLHSDTFSHLSRLEGLVLKDSSLYQLN
PRWFRGLGNLTVLDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSFAHLTLAPSFGSLLSLQELDMHGIF
FRSLSQKTLQPLARLPMLQRLYLQMNFINQAQLGIFKDFPGLRYIDLSDNRISGAVEPVATTGEVDGGKKVWLTS
RDLTPGPLDTPSSEDFMPSCKNLSFTLDLSRNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV
LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPTLRYLSLAHNGIHSRVSQQLCSTSL
WALDFSGNSLSQMWAEGDLYLRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLLRLRNNYLAFFNWSSLTL
LPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRNSIIFVVPGFFALATRLRELNLSANALRTEEPSWFGFLAG
SLEVLDVSANPLHCACGAAFVDFLLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFG

SEQ ID NO:15 (Equine TLR9)

ctctgttctctgagctgttgccgcgtgaagggactgcgagcacaaagcatcctcctctgcagctgcccagtg tgccagctggaccctctggatcatctcccactccctgtcatgggcccttgccatggtgccctgcagcccctgtct ctcctggtgcaggcggccatgctggccgtggctctggcccaaggcaccctgcctcccttcctgccctgtgagctc cagccccacggcctggtgaactgcaactggctgttcctgaagtccgtgccccacttctcagcagcagcacccgg gacaatgtcaccagcctttccttgctctccaaccgcatccaccacctccacgactccgactttgcccaactgtcc aacctgcagaaactcaacctcaaatggaactgcccgccagccggcctcagccccatgcacttcccctgccacatg accatcgagcccaacactttcctggctgtacccaccctggaggagctgaacctgagctacaacggcatcacgact gtgcctgccctgcccagctccctcgtgtccctgatcctgagccgcaccaacatcctgcagctagaccccaccagc acggtgccccgcagcctgcccctagcctggagtacctgctgttgtcctacaaccacattgtcaccctggcacct aacccctgcgtggagtgcccacataaattcccccagctgcactccgacaccttcagccacctaagccgcctagaa ggcctcgtgttgaaggatagttctctctaccagctgaaccccagatggttccgtggcctgggcaacctcacagtg ctcgacctgagtgagaacttcctctacgactgcatcaccaaaaccaaggcattccagggcctggcccagctgcga agactcaacttgtccttcaattaccataagaaggtgtccttcgcccacctgacgctggcaccctccttcgggagc gcccgcctgcccatgctccagcgtctgtatctgcagatgaacttcatcaaccaggcccagctcggcatcttcaag gacttccctggtctgcgctacatagacctgtcagacaaccgcatcagtggagctgtggagccggtggccaccaca ggggaggtggatggtgggaagaaggtctggctgacatccagggacctcactccaggcccactggacaccccagc tctgaggacttcatgccaagctgcaagaacctcagcttcaccttggacctgtcacggaacaacctggtaacagtc cagccagagatgtttgcccagctctcgcgcctccagtgcctgcgcctgagccacaacagcatctcgcaggcggtc

- 16 -

aatggctcacagttcgtgccactgaccagcctgcaggtgctggacctgtcccataacaaactggacctgtaccat ggtgtgggccacaacctcagctttgtggcccagctgcccaccttgcgctacctcagcctggcacacaatggcatc cacagccgtgtgtcccagcagctctgcagcacctcgctgtgggccctggacttcagcggcaattccctgagccag atgtgggctgagggagacctctatctccgcttcttccaaggcctgagaagcctaatccggctagacctgtcccag aatcgtctgcataccctcctgccatgcaccctgggcaacctccccaagagcttgcagctgctgcgtctccgtaac cagctgaaggctctgagcaatggcagcctgccttctggcacccagctccagaggctggacgtcagcaggaacagc atcatcttcgtggtccctggcttctttgctctggccacgaggctgcgagagctcaacctcagtgccaacgccctc aggacagaggagccctcctggtttggtttcctagcaggctcccttgaagtcctagatgtgagcgccaaccctctg cactgcgcctgtggggcagcctttgtggacttcctgctgcaggttcaggctgccgtgcctggtctgcccagccgc gtcaagtgtggcagtccgggccagctccagggccgcagcatcttcgcacaagacctgcgcctctgcctggacaag tccctctcctgggactgttttggtctctcattgctggttgtggccctgggcctggccatgcctatgttgcaccac ctctgcggctgggacctctggtactgcttccacctgggcctggcctggctgccccggcggggtggcagcggggc gcggatgccctgagctatgatgcctttgtggtcttcgacaaggcacagagcgcagtggccgactgggtgtacaat gaactgcgggtgcggctagaggagcgccgtgggcgccgggcgctccgcctgtgtctggaggagcgtgactggcta cctggcaagacgctgttcgaaaacctgtgggcctcagtctacagcagccgcaagatgctgtttgtgctggcccac acggaccaggtcagtggcctcttgcgtgccagcttcctgctggcccagcagcgtctgctggaggaccgcaaggac gttgtggtgctggtaatcctgagccctgacgccgcttcccgttacgtgcggctgcgccagcgcctctgccgc cagagtgtcctcttctggcccaccagcctagtggccagcgcagcttctgggcccagctaggcatggccctgacc agggacaaccgccacttctataaccagaacttctgccggggcccgacgatggctgagtagcacagagtgacagcc tggcatgtacaacccccagccctgaccttgcctctctgcctatgatgcccagtctgcctcactctgtgacgccc tgctctgcctccgccaccctcacccctggcatacagcaggcactcaataaatgccactggcaggccaaacagcca aaaaaaaaaaaaaa

25

30

40

45

50

55

5

10

15

20

SEQ ID NO:16 (Equine TLR9)

atgggcccttgccatggtgccctgcagccctgtctctcctggtgcaggcggccatgctggccgtggctctggcc caaggcaccctgcctcccttcctgccctgtgagctccagccccacggcctggtgaactgcaactggctgttcctg aagtccgtgccccacttctcagcagcaccccgggacaatgtcaccagcctttccttgctctccaaccgcatc caccacctccacgactccgactttgcccaactgtccaacctgcagaaactcaacctcaaatggaactgcccgcca agccgcaccaacatcctgcagctagaccccaccagcctcacgggcctgcatgccctgcgcttcctatacatggat ggcaactgctactacaagaacccctgcgggcgggccctggaggtggccccaggcgccctccttggcctgggcaac ctcacccacctgtcactcaagtacaaccacctcacaacggtgccccgcagcctgccccctagcctggagtacctg ctgttgtcctacaaccacattgtcaccctggcacctgaggacctggccaatctgactgccctgcgtgtgctcgat gtgggtggaaactgccgccgctgtgaccatgcacgcaacccctgcgtggagtgcccacataaattcccccagctg cactccgacaccttcagccacctaagccgcctagaaggcctcgtgttgaaggatagttctctctaccagctgaac aaaaccaaggcattccagggcctggcccagctgcgaagactcaacttgtccttcaattaccataagaaggtgtcc ttccgctcactcagccagaagacgctccagccactggcccgcctgcccatgctccagcgtctgtatctgcagatg aacttcatcaaccaggcccagctcggcatcttcaaggacttccctggtctgcgctacatagacctgtcagacaac cgcatcagtggagctgtggagccggtggccaccacaggggaggtggatggtgggaagaagatgtctggctgacatcc agggacctcactccaggcccactggacacccccagctctgaggacttcatgccaagctgcaagaacctcagcttc ctgcgcctgagccacaacagcatctcgcaggcggtcaatggctcacagttcgtgccactgaccagcctgcaggtg ctggacctgtcccataacaactggacctgtaccatgggcgctcgtttacggagctgccgcgactggaggccctg gacctcagctacaacagccagcccttcagcatgcggggtgtggggccacaacctcagctttgtggcccagctgccc accetgegetaceteageetggeacaeaatggeateeacageegtgtgteecageagetetgeageacetegetg tgggccctggacttcagcggcaattccctgagccagatgtgggctgagggagacctctatctccgcttcttccaa ggcctgagaagcctaatccggctagacctgtcccagaatcgtctgcataccctcctgccatgcaccctgggcaac ctccccaagagcttgcagctgctgcgtctccgtaacaattacctggccttcttcaattggagcagcctgaccctc acccagctccagaggctggacgtcagcaggaacagcatcatcttcgtggtccctggcttcttttgctctggccacg aggctgcgagagctcaacctcagtgccaacgccctcaggacagaggagccctcctggtttggtttcctagcaggc tcccttgaagtcctagatgtgagcgccaaccctctgcactgcgcctgtggggcagcctttgtggacttcctgctg

caggttcaggctgccgtgcctggtctgcccagccgcgtcaagtgtggcagtccgggccagctccagggccgcagcatcttcgcacaagacctgcgcctctgcctggacaagtccctctcctgggactgttttggt

SEQ ID NO:17 (Ovine TLR9)

5 MGPYCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGKVNCNWLFLKSVPRFSAGAPRANVTSLSLISNRIH HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS RTSILVLGPTHFTGLHALRFLYMDGNCYYKNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL LSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF 10 RSLTNTTLRPLTQLPKLQSLSLQLNFINQAELSIFGAFPSLLFVDLSDNRISGAARPVAALGEVDSGVEVWRWPR GLAPGPLAAVSAKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLD LSYNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSKNHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP QLEALDLAGNQLKALSNGSLPPGTRLOKLDVSSNSIGFVTPGFFVLANRLKELNLSANALKTVDPFWFGRLTETL 15 NILDVSANPLHCACGAAFVDFLLEMQAAVPGLSRRVTCGSPGQLQGRSIFAQDLRLCLDETLSLDCFGFSLLMVA LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAFVVFDKAQSAVADWVYNELRVQLEERRGRRAL RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPAAYRSR YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGMALTRDNRHFYNRNFCRGPTTAE

20 SEQ ID NO:18 (Ovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGKVNCNWLFLKSVPRFSAGAPRANVTSLSLISNRIH
HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS
RTSILVLGPTHFTGLHALRFLYMDGNCYYKNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF
RSLTNTTLRPLTQLPKLQSLSLQLNFINQAELSIFGAFPSLLFVDLSDNRISGAARPVAALGEVDSGVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSKNHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
QLEALDLAGNQLKALSNGSLPPGTRLQKLDVSSNSIGFVTPGFFVLANRLKELNLSANALKTVDPFWFGRLTETL
NILDVSANPLHCACGAAFVDFLLEMQAAVPGLSRRVTCGSPGQLQGRSIFAQDLRLCLDETLSLDCFG

SEQ ID NO:19 (Ovine TLR9)

gtcggcacgggaagtgagcgccaagcatccttccctgcagctgccgcccaacttgcccgccagaccctctggaga 35 agcagccctggcccagggcaccctgcctgccttcctgccctgtgagctccagccccggggtaaggtgaactgcaa ctggctgttcctgaagtctgtgccgcgcttttcggccggagccccccgggccaatgtcaccagcctctccttaat ctccaaccgcatccaccacttgcacgactctgacttcgtccacctgtccaacctgcgggtcctcaacctcaagtg gaactgcccgccggcctcagccccatgcacttcccctgccgcatgaccatcgagcccaacaccttcctggc 40 tctgtacatggacggcaactgctactataagaacccctgccagcaggccgtggaggtggccccaggcgccctcct tggcctgggcaacctcacgcacctgtcgctcaagtacaaccacctcacggaggtgccccgccgcctgcccccag cctggacaccctgctgctgtcctacaaccacatcatcaccctggcacccgaggacctggccaatctgactgccct 45 gcgtgtgcttgatgtgggcgggaactgccgccgctgcgaccacgcccgcaacccctgcagggagtgcccaaagaa cttccccaagctgcaccctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaggacagttctct tgactacatcaccaagaccaccatcttcaggaacctgacccagctgcgcagactcaacctgtccttcaattacca caagaaggtgtccttcgcccacctgcaactggcaccctcctttgggggcctggtgtccctggagaagctggacat *50* gcacggcatcttcttccgctccctcaccaacaccacgctccggccgctgacccagctgcccaagctccagagtct gagtctgcagctgaacttcatcaaccaggccgagctcagcatctttgggggccttcccgagcctgctcttcgtgga cctgtcggacaaccgcatcagcggagctgcgaggccggtggccgccctcggggaggtggacagcgggggggaggtggaagt ctggcggtggcccaggggcctcgctcaggcccgctggccgtcagcgcaaaggacttcatgccaagctgcaa

cctcaacttcaccttggacctgtcacggaacaacctggtgacgatccagcaggagatgtttacccgcctctcccg cctccagtgcctgcgcctgagccacaacagcatctcgcaggcggttaatggctcgcagttcgtgccgctgacccg cctgcgagtgctcgacctgtcctacaacaagctggacctgtaccatgggcgctcgttcacggagctgccgcagct ggaggcactggacctcagctacaacagccagcccttcagcatgcagggcgtgggccacaacctcagcttcgtggc ccagctgccgtccctgcgctacctcagccttgcgcacaacggcatccacagccgcgtgtcacagaagctcagcag cgcctcgctgcgcgccctggacttcagcggcaactccctgagccagatgtgggccgaggggagacctctatctctg cttcttcaaaggcttgaggaacctggtccagctggacctgtccaagaaccacctgcacaccctcctgcctcgtca cctggataacctgcccaagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcag cctgactgttctgccccagctggaagccctggatctggcgggaaaccagctgaaggccctgagcaacggcagcct gccacctggcacccggctccagaagctggacgtgagcagcaacagcatcggctttgtgacccctggcttctttgt ccttgccaaccggctgaaagagcttaacctcagcgccaacgccctgaagacagtggatcccttctggttcggtcg cttaacagagaccctgaatatcctagacgtgagcgccaacccgctccactgtgcctgcggggggcggcctttgtgga cttcctgctggagatgcaggcggtgcctgggctgtccaggcgcgtcacgtgtggcagtccgggccagctcca gggccgcagcatcttcgcacaggacctgcgcctctgcctggatgagaccctctccttggactgctttggcttctc gctgctaatggtggcgctgggcctggcggtgcccatgctgcaccacctctgtggctgggacctgtggtactgctt ccacctgtgtctggcccatttgccccgacggcggcggcagcgggggggaggacaccctgctctacgatgccttcgt ggtcttcgacaaggcgcagagtgcagtggccgactgggtgtacaacgagctccgcgtgcagctggaggagcgccg cgggcgccgggcgctccgcctctgcctggaggagcgagactggctccctggcaagacgctcttcgagaacctgtg ggcctcggtctacagcagccgtaagaccatgttcgtgctggaccacacggaccgggtcagtggcctcctgcgcgc cagcttcctgctggcccagcagcgcctgttggaggaccgcaaggatgtcgtggtgctggtgatcctgcgcccgc cgcctaccggtcccgctacgtgcggctgcgccagcgcctctgccgccagagcgtcctcctctggccccaccagcc cagtggccagggtagcttctgggccaacctgggcatggccctgaccagggacaaccgccacttctataaccggaa cttctgccggggccccacgacagccgaatagcacagagtgactgcccag

25 SEQ ID NO:20 (Ovine TLR9)

5

10

15

20

30

35

40

45

50

55

atgggcccctactgtgccccgcacccctttctctctctggtgcaggcggcggcgctggcagcagccctggcccag ggcaccctgccttcctgccctgtgagctccagcccggggtaaggtgaactgcaactggctgttcctgaag tctgtgccgcgcttttcggccggagccccccgggccaatgtcaccagcctctccttaatctccaaccgcatccac cacttgcacgactctgacttcgtccacctgtccaacctgcgggtcctcaacctcaagtggaactgcccgccggcc ggcctcagccccatgcacttcccctgccgcatgaccatcgagcccaacaccttcctggctgtgcccaccctggag cgcaccagcatcctggtgctaggccccacccacttcaccggcctgcacgccctgcgctttctgtacatggacggc aactgctactataagaacccctgccagcaggccgtggaggtggccccaggcgccctccttggcctgggcaacctc acgcacctgtcgctcaagtacaaccacctcacggaggtgccccgccgcctgcccccagcctggacaccctgctg ctgtcctacaaccacatcatcaccctggcacccgaggacctggccaatctgactgccctgcgtgtgcttgatgtg ggcgggaactgccgccgctgcgaccacgcccgcaacccctgcagggagtgcccaaagaacttccccaagctgcac cctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaggacagttctctctacaaactagagaaa accaccatcttcaggaacctgacccagctgcgcagactcaacctgtccttcaattaccacaagaaggtgtccttc gcccacctgcaactggcaccctcctttgggggcctggtgtccctggagaagctggacatgcacggcatcttcttc cgctccctcaccaacaccacgctccggccgctgacccagctgcccaagctccagagtctgagtctgcagctgaac ttcatcaaccaggccgagctcagcatctttggggccttcccgagcctgctcttcgtggacctgtcggacaaccgc atcagcggagctgcgaggccggtggccgccctcggggaggtggacagcgggggtggaagtctggcggtggcccagg ggcctcgctccaggcccgctggccgccgtcagcgcaaaggacttcatgccaagctgcaacctcaacttcaccttg gacctgtcacggaacaacctggtgacgatccagcaggagatgtttacccgcctctcccgcctccagtgcctgcgc ctgagccacaacagcatctcgcaggcggttaatggctcgcagttcgtgccgctgacccgcctgcgagtgctcgac ctgtcctacaacaagctggacctgtaccatgggcgctcgttcacggagctgccgcagctggaggcactggacctc agctacaacagccagcccttcagcatgcagggcgtgggccacaacctcagcttcgtggcccagctgccgtccctg cgctacctcagccttgcgcacaacggcatccacagccgcgtgtcacagaagctcagcagcgcctcgctgcgcgcc ctggacttcagcggcaactccctgagccagatgtgggccgagggagacctctatctctgcttcttcaaaggcttg aggaacctggtccagctggacctgtccaagaaccacctgcacaccctcctgcctcgtcacctggataacctgccc aagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcagcctgactgttctgccc cagctggaagccctggatctggcgggaaaccagctgaaggccctgagcaacggcagcctgccacctggcacccgg ctccagaagctggacgtgagcagcaacagcatcggctttgtgacccctggcttctttgtccttgccaaccggctg aaagagcttaacctcagcgccaacgccctgaagacagtggatcccttctggttcggtcgcttaacagagaccctg aatatcctagacgtgagcgccaacccgctccactgtgcctgcggggcggcctttgtggacttcctgctggagatg

- 19 -

caggcggccgtgcctgggctgtccaggcgcgtcacgtgtggcagtccggggccagctaccagggccgcagcatcttcgcaggacctgcgcctctgcctggatgagaccctctccttggactgctttggc

Complete nucleotide and amino acid sequences for canine and feline TLR9 are publicly available. For example, an amino acid sequence for canine TLR9 is available as GenBank accession number BAC65192 and its corresponding nucleotide sequence is available as GenBank accession number AB104899. An amino acid sequence for feline TLR9 is available as GenBank accession number AAN15751 and its corresponding nucleotide sequence is available as GenBank accession number AY137581.

Complete nucleotide and amino acid sequences for canine and feline TLR9 were also determined independently from those available from public databases.

An amino acid sequence of canine TLR9 is provided as SEQ ID NO:21. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:21 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of canine TLR9 (See Figure 1). Amino acids numbered 1-822 of SEQ ID NO:21 are presumptively extracellular domain and correspond to SEQ ID NO:22. SEQ ID NO:23 is a nucleotide sequence of canine TLR9 cDNA having an open reading frame corresponding to nucleotides 91-3186. SEQ ID NO:24 is a nucleotide sequence of canine cDNA encoding amino acids 1-822 of SEQ ID NO:21.

An amino acid sequence of feline TLR9 is provided as SEQ ID NO:25. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:25 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of feline TLR9 (See Figure 1). Amino acids numbered 1-820 of SEQ ID NO:25 are presumptively extracellular domain and correspond to SEQ ID NO:26. SEQ ID NO:27 is a nucleotide sequence of feline TLR9 cDNA having an open reading frame corresponding to nucleotides 87-3179. SEQ ID NO:28 is a nucleotide sequence of feline cDNA encoding amino acids 1-820 of SEQ ID NO:25.

30

25

5

10

15

20

SEQ ID NO:21 (Canine TLR9)

MGPCRGALHPLSLLVQAAALALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPRFSAAAPRGNVTSLSLYSNRI HHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNTFLAVPTLEDLNLSYNSITTVPALPSSLVSLSL SRTNILVLDPATLAGLYALRFLFLDGNCYYKNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYL

- 20 -

LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD PRWFHGLGNLMVLDLSENFLYDCITKTKAFYGLARLRRLNLSFNYHKKVSFAHLHLASSFGSLLSLQELDIHGIF FRSLSKTTLQSLAHLPMLQRLHLQLNFISQAQLSIFGAFPGLRYVDLSDNRISGAAEPAAATGEVEADCGERVWP QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLSRNNLVTVQPEMFVRLARLQCLGLSHNSISQAVNGSQFVPLSNL RVLDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA SLRALDFSGNTLSQMWAEGDLYLRFFQGLRSLVQLDLSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSSL ALLPKLEALDLAGNQLKALSNGSLPNGTQLQRLDLSGNSIGFVVPSFFALAVRLRELNLSANALKTVEPSWFGSL AGALKVLDVTANPLHCACGATFVDFLLEVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDEALSWVCFSLSL LAVALSLAVPMLHQLCGWDLWYCFHLCLAWLPRRGRRRGVDALAYDAFVVFDKAQSSVADWVYNELRVQLEERRG RRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLARTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILCPDA HRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNRHFYNQNFCRGPTTA

SEQ ID NO:22 (Canine TLR9)

5

10

25

MGPCRGALHPLSLLVQAAALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPRFSAAAPRGNVTSLSLYSNRI
HHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNTFLAVPTLEDLNLSYNSITTVPALPSSLVSLSL
SRTNILVLDPATLAGLYALRFLFLDGNCYYKNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYL
LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD
PRWFHGLGNLMVLDLSENFLYDCITKTKAFYGLARLRRLNLSFNYHKKVSFAHLHLASSFGSLLSLQELDIHGIF
FRSLSKTTLQSLAHLPMLQRLHLQLNFISQAQLSIFGAFPGLRYVDLSDNRISGAAEPAAATGEVEADCGERVWP
QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLSRNNLVTVQPEMFVRLARLQCLGLSHNSISQAVNGSQFVPLSNL
RVLDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA
SLRALDFSGNTLSQMWAEGDLYLRFFQGLRSLVQLDLSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSSL
ALLPKLEALDLAGNQLKALSNGSLPNGTQLQRLDLSGNSIGFVVPSFFALAVRLRELNLSANALKTVEPSWFGSL
AGALKVLDVTANPLHCACGATFVDFLLEVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDEALSWVCFS

SEQ ID NO:23 (Canine TLR9)

ccccgctccctgtcatgggcccctgccgtggcgccctgcaccccctgtctctcctggtgcaggctgccgcgcta gccctggccctggcccagggcaccctgccttcctgccctgtgagctccagccccatggcctggtgaactgc 30 aactggctgttcctcaagtccgtgccccgcttctcggcagctgcaccccgcggtaacgtcaccagcctttccttq tactccaaccgcatccaccacctccatgactatgactttgtccacttcgtccacctgcggcgtctcaatctcaag tggaactgcccgcccgccagcctcagccccatgcactttccctgtcacatgaccattgagcccaacaccttcctg gtgtccctgtccctgagccgcaccaacatcctggtgctggaccctgccaccctggcaggcctttatgccctgcgc 35 ttcctgttcctggatggcaactgctactacaagaacccctgccagcaggccctgcaggtggccccaggtgccctc ctgggcctgggcaacctcacacctgtcactcaagtacaaccacctcaccgtggtgccgcggggcctgccccc agcctggagtacctgctcttgtcctacaaccacatcatcaccctggcacctgaggacctggccaatctgactgcc ctgcgtgtcctcgatgtggggaactgtcgccgctgtgaccatgcccgtaacccctgcagggagtgcccaag ggcttcccccagctgcaccccaacaccttcggccacctgagccacctcgaaggcctggtgttgagggacagctct 40 tatgactgcatcaccaaaaccaaagccttctacggcctggcccggctgcgcagactcaacctgtccttcaattat cataagaaggtgtcctttgcccacctgcatctggcatcctccttcgggagcctactgtccctgcaggagctggac atacatggcatcttcttccgctcgctcagcaagaccacgctccagtcgctggcccacctgcccatgctccagcgt ctgcatctgcagttgaactttatcagccaggcccagctcagcatcttcggcgccttccctggactgcggtacgtg 45 gacttgtcagacaaccgcatcagtggagctgcagagcccgcggctgccacaggggaggtagaggcagactgtggg gagagagtctggccacagtcccgggaccttgctctgggcccactgggcacccccggctcagaggccttcatgccg agctgcaggaccctcaacttcaccttggacctgtctcggaacaacctagtgactgttcagccggagatgtttgtc cggctggcgcctccagtgcctgggcctgagccacaacagcatctcgcaggcggtcaatggctcgcagttcgtg cctctgagcaacctgcgggtgctggacctgtcccataacaagctggacctgtaccacgggcgctcgttcacggag 50 agctttgtggcacagctgccagccttgcgctacctcagcctggcgcacaatggcatccacagccgcgtgtcccag cagctccgcagcgcctcgctccgggccctggacttcagtggcaataccctgagccagatgtgggccgagggagac ctctatctccgcttcttccaaggcctgagaagcctggttcagctggacctgtcccagaatcgcctgcataccctc ctgccacgcaacctggacaacctccccaagagcctgcggctcctgcggctccgtgacaattacctggctttcttc 55 aactggagcagcctggccctcctacccaagctggaagccctggacctggcgggaaaccagctgaaggccctgagc

aatggcagcttgcccaacggcacccagctccagaggctggacctcagcggcaacagcatcggcttcgtggtcccc agettttttgeeetggeegtgaggettegagageteaaceteagegeeaaegeeeteaagaeggtggageeetee tggtttggttccctggcgggtgccctgaaagtcctagacgtgaccgccaaccccttgcattgcgcttgcggcgca ggccagctccagggccgcagcatcttcgcacaggacctgcgcctctgcctggacgaagcgctctcctgggtctgt ttcagcctctcgctgctggctgtggccctgagcctggctgtgcccatgctgcaccagctctgtggctgggacctc gacgccttcgtggtcttcgacaaggcgcagagctcggtggcggactgggtgtacaatgagctgcgggtacagcta gaggagcgccgtgggcgccaacgcctgtgtctggaggaacgtgactgggtacccggcaaaaccctcttc gagaacctctgggcctcagtttacagcagccgcaagacgctgtttgtgctggcccgcacggacagagtcagcggc ctcctgcgtgccagcttcctgctggcccaacagcgcctgctggaggaccgcaaggacgtcgtggtgctggtgatc ctgtgccccgacgcccaccgctcccgctatgtgcggctgcgccagcgcctctgccgccagagtgtcctcctctgg ccccaccagcccagtggccagcgcagcttctgggcccagctgggcacggccctgaccagggacaaccgccacttc tacaaccagaacttctgccggggccccacgacagcctgataggcagacagcccagcaccttcgcgcccctacacc ctgcctgtctgtctgggatgcccgacctgctggctctacaccgccgctctgtctcccctacacccagccctggca taaagcgaccgctcaataaatgctgctggtagac

SEQ ID NO:24 (Canine TLR9)

5

10

15

55

20 cagggcaccctgcctgccttcctgccctgtgagctccagccccatggcctggtgaactgcaactggctgttcctc aagtccgtgccccgcttctcggcagctgcaccccgcggtaacgtcaccagcctttccttgtactccaaccgcatc gccagcctcagccccatgcactttccctgtcacatgaccattgagcccaacaccttcctggctgtgcccacccta 25 agccgcaccaacatcctggtgctggaccctgccaccctggcaggcctttatgccctgcgcttcctgttcctggat ggcaactgctactacaagaacccctgccagcaggccctgcaggtggccccaggtgccctcctgggcctgggcaac ctcacacacctgtcactcaagtacaaccacctcaccgtggtgccgcgggggcctgcccccagcctggagtacctg ctcttgtcctacaaccacatcatcaccctggcacctgaggacctggccaatctgactgccctgcgtgtcctcgat gtgggtgggaactgtcgccgctgtgaccatgcccgtaacccctgcagggagtgccccaagggcttcccccagctg *30* aaaaccaaagccttctacggcctggcccggctgcgcagactcaacctgtccttcaattatcataagaaggtgtcc ttccgctcgctcagcaagaccacgctccagtcgctggcccacctgcccatgctccagcgtctgcatctgcagttg 35 aactttatcagccaggcccagctcagcatcttcggcgccttccctggactgcggtacgtggacttgtcagacaac cgcatcagtggagctgcagagcccgcggctgccacaggggaggtagaggcagactgtggggagagagtctggcca cagtcccgggaccttgctctgggcccactgggcacccccggctcagaggccttcatgccgagctgcaggaccctc aacttcaccttggacctgtctcggaacaacctagtgactgttcagccggagatgtttgtccggctggcgcctc cagtgcctgggcctgagccacaacagcatctcgcaggcggtcaatggctcgcagttcgtgcctctgagcaacctg 40 cgggtgctggacctgtcccataacaagctggacctgtaccacgggcgctcgttcacggagctgccgcggctggag gccttggacctcagctacaacagccagcccttcagcatgcggggcgtgggccacaatctcagctttgtggcacag ctgccagccctgcgctacctcagcctggcgcacaatggcatccacagccgcgtgtcccagcagctccgcagcgcc tcgctccgggccctggacttcagtggcaataccctgagccagatgtgggccgaggggagacctctatctccgcttc ttccaaggcctgagaagcctggttcagctggacctgtcccagaatcgcctgcataccctcctgccacgcaacctg 45 gacaacctccccaagagcctgcggctcctgcggctccgtgacaattacctggctttcttcaactggagcagcctg gccctcctacccaagctggaagccctggacctggcgggaaaccagctgaaggccctgagcaatggcagcttgccc aacggcacccagctccagaggctggacctcagcggcaacagcatcggcttcgtggtccccagcttttttgccctg gccgtgaggcttcgagagctcaacctcagcgccaacgccctcaagacggtggagccctcctggtttggttccctg gcgggtgccctgaaagtcctagacgtgaccgccaaccccttgcattgcgcttgcggcgcaaccttcgtggacttc 50 ttgctggaggtgcaggctgccggcctgcctagccgtgtcaagtgcggcagcccgggccagctccagggc cgcagcatcttcgcacaggacctgcgcctctgcctggacgaagcgctctcctgggtctgtttcagc

SEQ ID NO:25 (Feline TLR9)

MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRI HHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTVPALPSSLVSLSL

- 22 -

SRTNILVLDPANLAGLHSLRFLFLDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEYL
LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLEGLVLKDSSLYNLN
PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSFGSLLSLQQLDMHGIF
FRSLSETTLRSLVHLPMLQSLHLQMNFINQAQLSIFGAFPGLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS
GDLALGPPGTPSSEGFMPGCKTLNFTLDLSRNNLVTIQPEMFARLSRLQCLLLSRNSISQAVNGSQFMPLTSLQV
LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASL
RALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHTLLPRTLDNLPKSLRLLRLRDNYLAFFNWSSLVL
LPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG
TLKVLDVTGNPLHCACGAAFVDFLLEVQAAVPGLPGHVKCGSPGQLQGRSIFAQDLRLCLDEALSWDCFGLSLLT
VALGLAVPMLHHLCGWDLWYCFHLCLAWLPRRGRRRGADALPYDAFVVFDKAQSAVADWVYNELRVRLEERRGRR
ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPDAHR
SRYVRLRORLCRQSVLLWPHOPSGORSFWAQLGTALTRDNQHFYNQNFCRGPTTAE

SEQ ID NO:26 (Feline TLR9)

5

10

15 MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRI
HHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTVPALPSSLVSLSL
SRTNILVLDPANLAGLHSLRFLFLDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEYL
LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLEGLVLKDSSLYNLN
PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSFGSLLSLQQLDMHGIF
FRSLSETTLRSLVHLPMLQSLHLQMNFINQAQLSIFGAFPGLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS
GDLALGPPGTPSSEGFMPGCKTLNFTLDLSRNNLVTIQPEMFARLSRLQCLLLSRNSISQAVNGSQFMPLTSLQV
LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASL
RALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHTLLPRTLDNLPKSLRLLRLRDNYLAFFNWSSLVL
LPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG
TLKVLDVTGNPLHCACGAAFVDFLLEVQAAVPGLPGHVKCGSPGQLQGRSIFAQDLRLCLDEALSWDCFG

SEQ ID NO:27 (Feline TLR9)

agggtctgcgagctccaggcattcttctctgccatcgctgcccagtctgccatccagaccctctggagaagcccc cactccctgtcatgggcccctgccatggcgccctgcaccccctgtctctcctggtgcaggctgccgcgctggccg tggccctggcccagggcaccctgcctttctgccctgtgagctccagcgccacggcctggtgaattgcgact 30 ggctgttcctcaagtccgtgcccacttctcggcggcagcgccccgtggtaacgtcaccagcctttccctgtact ccaaccgcatccaccacctccacgacttcgactttgtccacctgtccagcctgcggcgtctcaacctcaaatgga actgcccacccgccagcctcagccccatgcacttcccctgtcacatgaccattgagccccacaccttcctggccg tgcccaccctggaggagctgaacctgagctacaacagcatcacgacagtacccgccctgcccagttccctcgtgt 35 ccctgtccttgagccgtaccaacatcctggtgctggaccctgccaacctcgcagggctgcactccctgcgctttc tgttcctggatggcaactgctactacaagaacccctgccgcaggccctgcaggtggccccgggcgccctccttg gcctgggcaaccttacgcacctgtcactcaagtacaaccacctcactgcggtgccccgcggcctgcccccagcc tggagtacctgctattgtcctacaaccacatcatcaccctggcacctgaggacctggccaacctgaccgccctgc gtgtgctcgatgtggggaactgccgtcgctgtgaccacgcccgcaacccctgtatggagtgccccaagggct 40 actgcatcaccaaaaccacagccttccagggcctggcccagctgcgcagactcaacttgtctttcaattaccaca agaaggtgtcctttgcccacctgcatctggcgccctccttcgggagcctgctctccctgcagcagctggacatgc atggcatcttcttccgctcgctcagcgagaccacgctccggtcgctggtccacctgcccatgctccagagtctgc 45 acctgcagatgaacttcatcaatcaggcccagctcagcatcttcgggggccttccctggcctgcgatacgtggacc ggctgccatctggggacctagctctgggcccaccgggcacccctagctccgagggcttcatgccaggctgcaaga 50 gcctgcaggtgctggacctgtcccataacaagctggacctgtaccatgggcgctctttcacggagctgccgcggc tggaggccctggacctcagctacaacagccagcccttcagcatgcagggcgtgggtcacaacctcagctttgtgg cacagctgccggccctgcgctatctcagcctggcgcacaacgacatccacagccgtgtgtcccagcagctctgca gcgcctcgctgcgggccttggacttcagcggcaatgccttgagccggatgtggggccgagggagacctgtatctcc acttcttccgaggcctgaggagcctggtccggttggatctgtcccagaatcgcctgcataccctcttgccacgca 55 ccctggacaacctccccaagagcctgcggctgctgcgtctccgtgacaattatctggctttcttcaactggagca

- 23 -

gcctggtcctcctccccaggctggaagccctggacctggcgggaaaccagctgaaggccctgagcaacggcagct tgcctaatggaacccagctccagaggctggacctcagcagcaacagtatcagcttcgtggcctccagcttttttg ctctggccaccaggctgcgagagctcaacctcagtgccaacgccctcaagacggtggagccctcctggttcggtt ctctagcgggcaccctgaaagtcctagatgtgactggcaaccccttgcactgcgccttgtgggcggccttcgtgg acttcttgctggaggtgcaggctgcagtgccggcctgccaggccacgtcaagtgtggcagtccaggtcagctcc agggccgcagcatctttgcgcaggatctgcgcctctgcctggatgaggccctctcctgggactgttttggcctct cgctgctgaccgtggccctggccgtgcccatgctgcaccacctctgtggctgggacctctggtactgct tggtcttcgacaaggcacagagcgcggtggccgactgggtgtacaacgagctgcgggtacggctagaggagcgcc gtggacgccgagcgctccgcctgtgcctggaggaacgtgactggctacccggtaaaacgctctttgagaacctgt ccagctttctgctggcccagcagcgcctgctggaggaccgcaaggacgttgtggtgctggtgatcctgcgcccg acgcccaccgctcccgctatgtgcggctgcgccagcgcctctgccgccagagcgtcctcctctggccccaccagc ccagtggccagcgcagcttctgggcccagctgggcacggccctgaccagggacaaccagcacttctataaccaga acttctgccggggccccacgacggcagagtgaccgcccagcaccccaagcctcctacaccttgcctgtctgcctg ggatgccggg

SEQ ID NO:28 (Feline TLR9)

5

10

15

atgggcccctgccatggcgccctgcacccctgtctctctggtgcaggctgccgcgctggccgtggccctggcc 20 cagggcaccctgcctttctgccctgtgagctccagcgccacggcctggtgaattgcgactggctgttcctc aagtccgtgccccacttctcggcggcagcgccccgtggtaacgtcaccagcctttccctgtactccaaccgcatc caccacctccacgactccgactttgtccacctgtccagcctgcggcgtctcaacctcaaatggaactgcccaccc gccagcctcagccccatgcacttcccctgtcacatgaccattgagcccacaccttcctggccgtgcccaccctg gaggagctgaacctgagctacaacagcatcacgacagtacccgccctgcccagttccctcgtgtccctgtccttg *25* agccgtaccaacatcctggtgctggaccctgccaacctcgcagggctgcactccctgcgctttctgttcctggat ggcaactgctactacaagaacccctgcccgcaggccctgcaggtggccccggggcgccctccttggcctgggcaac cttacgcacctgtcactcaagtacaaccacctcactgcggtgccccgcggcctgcccccagcctggagtacctg ctattgtcctacaaccacatcatcaccctggcacctgaggacctggccaacctgaccgccctgcgtgtgctcgat gtgggtgggaactgccgtcgctgtgaccacgcccgcaacccctgtatggagtgccccaagggcttcccgcacctg 30 aaaaccacagccttccagggcctggcccagctgcgcagactcaacttgtctttcaattaccacaagaaggtgtcc ttccgctcgctcagcgagaccacgctccggtcgctggtccacctgcccatgctccagagtctgcacctgcagatg 35 aacttcatcaatcaggcccagctcagcatcttcggggccttccctggcctgcgatacgtggacctgtcagacaac ggggacctagctctgggcccaccgggcacccctagctccgagggcttcatgccaggctgcaagaccctcaacttc ctgctcctgagccgcaacagcatctcgcaggcagtcaacggctcacaatttatgccgctgaccagcctgcaggtg 40 ctggacctgtcccataacaagctggacctgtaccatgggcgctctttcacggagctgccgcggctggaggccctg gacctcagctacaacagccagcccttcagcatgcagggcgtgggtcacaacctcagctttgtggcacagctgccg gccctgcgctatctcagcctggcgcacaacgacatccacagccgtgtgtcccagcagctctgcagcgcctcgctg cgggccttggacttcagcggcaatgccttgagccggatgtgggccgagggagacctgtatctccacttcttccga ggcctgaggagcctggtccggttggatctgtcccagaatcgcctgcataccctcttgccacgcaccctggacaac 45 ctccccaagagcctgcggctgctgcgtctccgtgacaattatctggctttcttcaactggagcagcctggtcctc ctccccaggctggaagccctggacctggcgggaaaccagctgaaggccctgagcaacggcagcttgcctaatgga acccagctccagaggctggacctcagcagcaacagtatcagcttcgtggcctccagctttttttgctctggccacc aggctgcgagagctcaacctcagtgccaacgccctcaagacggtggagccctcctggttcggttctctagcgggc accctgaaagtcctagatgtgactggcaaccccttgcactgcgcctgtggggcggccttcgtggacttcttgctg *50* gaggtgcaggctgcagtgccggcctgccaggccacgtcaagtgtggcagtccaggtcagctccagggccgcagc atctttgcgcaggatctgcgcctctgcctggatgaggccctctcctgggactgttttggc

Complete nucleotide and amino acid sequences for murine and human TLR9 are publicly available. For example, an amino acid sequence of murine TLR9 is available as

5

10

GenBank accession no. AAK29625, provided as SEQ ID NO:29. Amino acids numbered 1-821 of SEQ ID NO:29 presumptively include the entire extracellular domain and correspond to SEQ ID NO:30. SEQ ID NO:31 corresponds to GenBank accession number AF348140, which is a nucleotide sequence of murine TLR9 cDNA. SEQ ID NO:32 is a nucleotide sequence of murine cDNA encoding amino acids 1-821 of SEQ ID NO:29.

An amino acid sequence of human TLR9 is available as GenBank accession no. AAF78037, provided as SEQ ID NO:33. Amino acids numbered 1-820 of SEQ ID NO:33 presumptively include the entire extracellular domain and correspond to SEQ ID NO:34. SEQ ID NO:35 corresponds to GenBank accession number AF245704, which is a nucleotide sequence of human TLR9 cDNA. SEQ ID NO:36 is a nucleotide sequence of human cDNA encoding amino acids 1-820 of SEQ ID NO:33.

SEQ ID NO:29 (Murine TLR9)

MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPRFSAAASCSNITRLSLISNRI 15 HHLHNSDFVHLSNLRQLNLKWNCPPTGLSPLHFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL SHTNILVLDANSLAGLYSLRVLFMDGNCYYKNPCTGAVKVTPGALLGLSNLTHLSLKYNNLTKVPRQLPPSLEYL LVSYNLIVKLGPEDLANLTSLRVLDVGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGLVLKDSSLHTLN SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRLRKLNLSFNYRKKVSFARLHLASSFKNLVSLQELNMNGIF FRSLNKYTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFVDLSDNRISGPSTLSEATPEEADDAEQEELL SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ 20 VLDLSHNKLDLYHWKSFSELPQLQALDLSYNSQPFSMKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLNSNS VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSLS FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV ${\tt MNLTVLDVRSNPLHCACGAAFVDLLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFGLSLL}$ 25 AVAVGMVVPILHHLCGWDVWYCFHLCLAWLPLLARSRRSAQALPYDAFVVFDKAQSAVADWVYNELRVRLEERRG RRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDRVSGLLRTSFLLAQQRLLEDRKDVVVLVILRPDA HRSRYVRLRQRLCRQSVLFWPQQPNGQGGFWAQLSTALTRDNRHFYNONFCRGPTAE

SEQ ID NO:30 (Murine TLR9)

30 MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPRFSAAASCSNITRLSLISNRI
HHLHNSDFVHLSNLRQLNLKWNCPPTGLSPLHFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL
SHTNILVLDANSLAGLYSLRVLFMDGNCYYKNPCTGAVKVTPGALLGLSNLTHLSLKYNNLTKVPRQLPPSLEYL
LVSYNLIVKLGPEDLANLTSLRVLDVGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGLVLKDSSLHTLN
SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRLRKLNLSFNYRKKVSFARLHLASSFKNLVSLQELNMNGIF
FRSLNKYTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFVDLSDNRISGPSTLSEATPEEADDAEQEELL
SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ
VLDLSHNKLDLYHWKSFSELPQLQALDLSYNSQPFSMKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLNSNS
VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSLS
FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV
MNLTVLDVRSNPLHCACGAAFVDLLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFG

SEQ ID NO:31 (Murine TLR9)

- 25 -

aagcctcatggcctggtggactgcaattggctgttcctgaagtctgtaccccgtttctctgcggcagcatcctgc tccaacatcaccgcctctccttgatctccaaccgtatccaccacctgcacaactccgacttcgtccacctgtcc accattgagcccagaaccttcctggctatgcgtacactggaggagctgaacctgagctataatggtatcaccact gtgccccgactgcccagctccctggtgaatctgagcctgagccacaccaacatcctggttctagatgctaacagc ctcgccggcctatacagcctgcgcgttctcttcatggacgggaactgctactacaagaacccctgcacaggagcg gtgaaggtgaccccaggcgccctcctgggcctgagcaatctcacccatctgtctctgaagtataacaacctcaca aaggtgccccgccaactgcccccagcctggagtacctcctggtgtcctataacctcattgtcaagctggggcct aatccctgtatagaatgtggccaaaagtccctccacctgcaccctgagaccttccatcacctgagccatctggaa ggcctggtgctgaaggacagctctctccatacactgaactcttcctggttccaaggtctggtcaacctctcggtg ctggacctaagcgagaactttctctatgaaagcatcaaccacaccaatgcctttcagaacctaacccgcctgcgc aagctcaacctgtccttcaattaccgcaagaaggtatcctttgcccgcctccacctggcaagttccttcaagaac gccgatctgcccaaactccacactctgcatcttcaaatgaacttcatcaaccaggcacagctcagcatctttggt accttccgagcccttcgctttgtggacttgtcagacaatcgcatcagtgggccttcaacgctgtcagaagccacc cctgaagaggcagatgatgcagagcaggaggtgttgttgtctgcggatcctcacccagctccactgagcacccct gcttctaagaacttcatggacaggtgtaagaacttcaagttcaccatggacctgtctcggaacaacctggtgact atcaagccagagatgtttgtcaatctctcacgcctccagtgtcttagcctgagccacaactccattgcacaggct gtcaatggctctcagttcctgccgctgactaatctgcaggtgctggacctgtcccataacaaactggacttgtac aagggtataggccacaatttcagttttgtggcccatctgtccatgctacacagccttagcctggcacacaatgac attcatacccgtgtgtcctcacatctcaacagcaactcagtgaggtttcttgacttcagcggcaacggtatgggc cgcatgtgggatgaggggggcctttatctccatttcttccaaggcctgagtggcctgctgaagctggacctgtct caaaataacctgcatatcctccggccccagaaccttgacaacctccccaagagcctgaagctgctgagcctccga aaccagctaaaggccctgaccaatggcaccctgcctaatggcaccctcctccagaaactggatgtcagcagcaac agtatcgtctctgtggtcccagccttcttcgctctggcggtcgagctgaaagaggtcaacctcagccacaacatt ctcaagacggtggatcgctcctggtttgggcccattgtgatgaacctgacagttctagacgtgagaagcaaccct ctgcactgtgcctgtgggcagccttcgtagacttactgttggaggtgcagaccaaggtgcctggcctggctaat ggtgtgaagtgtggcagcccggccagctgcagggccgtagcatcttcgcacaggacctgcggctgtgcctggat gaggtcctctcttgggactgcttttggcctttcactcttggctgtggccgtgggcatggtggtgcctatactgcac catctctgcggctgggacgtctggtactgttttcatctgtgcctggcatggctacctttgctggcccgcagccga cgcagcgcccaagctctcccctatgatgccttcgtggtgttcgataaggcacagagcgcagttgcggactgggtg tataacgagctgcgggtgcggctggaggagcggcgggtcgccgagccctacgcttgtgtctggaggaccgagat tggctgcctggccagacgctcttcgagaacctctgggcttccatctatgggagccgcaagactctatttgtgctg gcccacacggaccgcgtcagtggcctcctgcgcaccagcttcctgctggctcagcagcgcctgttggaagaccgc aaggacgtggtggtgttggtgatcctgcgtccggatgcccaccgctcccgctatgtgcgactgcgccagcgtctc tgccgccagagtgtgctcttctggccccagcagcccaacgggcaggggggcttctgggcccagctgagtacagcc ctgactagggacaaccgccacttctataaccagaacttctgccggggacctacagcagaatagctcagagcaaca

SEQ ID NO:31 (Murine TLR9)

5

10

15

20

25

30

35

40

45

50

55

tttgcccgcctccacctggcaagttccttcaagaacctggtgtcactgcaggagctgaacatgaacggcatcttc ttccgctcgctcaacaagtacacgctcagatggctggccgatctgcccaaactccacactctgcatcttcaaatg aacttcatcaaccaggcacagctcagcatctttggtaccttccgagcccttcgctttgtggacttgtcagacaat cgcatcagtgggccttcaacgctgtcagaagccacccctgaagaggcagatgatgcagagcaggaggagctgttg tctgcggatcctcacccagctccactgagcacccctgcttctaagaacttcatggacaggtgtaagaacttcaag ttcaccatggacctgtctcggaacaacctggtgactatcaagccagagatgtttgtcaatctctcacgcctccag tgtcttagcctgagccacaactccattgcacaggctgtcaatggctctcagttcctgccgctgactaatctgcag gtgctggacctgtcccataacaaactggacttgtaccactggaaatcgttcagtgagctaccacagttgcaggcc ctggacctgagctacaacagccagccctttagcatgaagggtataggccacaatttcagttttgtggcccatctg tccatgctacacagccttagcctggcacacaatgacattcatacccgtgtgtcctcacatctcaacagcaactca gtgaggtttcttgacttcagcggcaacggtatgggccgcatgtgggatgaggggggcctttatctccatttcttc caaggcctgagtggcctgctgaagctggacctgtctcaaaataacctgcatatcctccggccccagaaccttgac ttcctgcccaacctggaagtcctagacctggcaggcaaccagctaaaggccctgaccaatggcaccctgcctaat ggcaccctcctccagaaactggatgtcagcagcaacagtatcgtctctgtggtcccagccttcttcgctctggcg gtcgagctgaaagaggtcaacctcagccacaacattctcaagacggtggatcgctcctggtttgggcccattgtg atgaacctgacagttctagacgtgagaagcaaccctctgcactgtgcctgtggggcagccttcgtagacttactg ttggaggtgcagaccaaggtgcctggcctggctaatggtgtgaagtgtggcagccccggccagctgcagggccgt agcatcttcgcacaggacctgcggctgtgcctggatgaggtcctctcttgggactgctttggc

20

25

30

35

40

45

10

15

SEQ ID NO:33 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAAPRGNVTSLSLSSNRI
HHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSL
SHTNILMLDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYL
LLSYNRIVKLAPEDLANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN
ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSFGSLVALKELDMHGIF
FRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQP
GDLAPAPVDTPSSEDFRPNCSTLNFTLDLSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
LDLSRNKLDLYHEHSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL
RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHF
LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLAS
ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLA
VALGLGVPMLHHLCGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRG
RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDG
RRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHFYNRNFCQGPTAE

SEQ ID NO:34 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAAPRGNVTSLSLSSNRI
HHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSL
SHTNILMLDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYL
LLSYNRIVKLAPEDLANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN
ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSFGSLVALKELDMHGIF
FRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQP
GDLAPAPVDTPSSEDFRPNCSTLNFTLDLSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
LDLSRNKLDLYHEHSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL
RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHF
LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLAS
ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFA

50 SEQ ID NO:35 (Human TLR9)

aggctggtataaaaatcttacttcctctattctctgagccgctgctgcccctgtgggaagggacctcgagtgtgaagcatccttccctgtagctgctgccagtctgcccagaccctctggagaagcccctgccccagcatgggttctctgccgcagaccatcatgctggccatgaccctggccctgggt

accttgcctgccttcctaccctgtgagctccagccccacggcctggtgaactgcaactggctgttcctgaagtct gtgccccacttctccatggcagcacccgtggcaatgtcaccagcctttccttgtcctccaaccgcatccaccac ctccatgattctgactttgcccacctgccagcctgcggcatctcaacctcaagtggaactgcccgccggttggc ctcagccccatgcacttcccctgccacatgaccatcgagcccagcaccttcttggctgtgcccaccctggaagag ctaaacctgagctacaacaacatcatgactgtgcctgcgctgcccaaatccctcatatccctgtccctcagccat accaacatcctgatgctagactctgccagcctcgccggcctgcatgccctgcgcttcctattcatggacggcaac tgttattacaagaacccctgcaggcaggcactggaggtggccccgggtgccctccttggcctgggcaacctcacc cacctgtcactcaagtacaaccacctcactgtggtgccccgcaacctgccttccagcctggagtatctgctgttg $\verb|tcctacaaccgcatcgtcaaactggcgcctgaggacctggccaatctgaccgccctgcgtgtgctcgatgtgggc|$ ggaaattgccgccgctgcgaccacgctcccaacccctgcatggagtgccctcgtcacttccccagctacatccc aaggccttccagggcctaacacagctgcgcaagcttaacctgtccttcaattaccaaaagagggtgtcctttgcc cacctgtctctggccccttccttcgggagcctggtcgccctgaaggagctggacatgcacggcatcttcttccgc tcactcgatgagaccacgctccggccactggcccgcctgcccatgctccagactctgcgtctgcagatgaacttc atcaaccaggcccagctcggcatcttcagggccttccctggcctgcgctacgtggacctgtcggacaaccgcatc cttgctccggccccagtggacactcccagctctgaagacttcaggcccaactgcagcaccctcaacttcaccttg gatctgtcacggaacaacctggtgaccgtgcagccggagatgtttgcccagctctcgcacctgcagtgcctgcgc ctgagccacaactgcatctcgcaggcagtcaatggctcccagttcctgccgctgaccggtctgcaggtgctagac ctgtcccgcaataagctggacctctaccacgagcactcattcacggagctaccgcgactggaggccctggacctc agctacaacagccagccctttggcatgcagggcgtgggccacaacttcagcttcgtggctcacctgcgcaccctg cgccacctcagcctggcccacaacaacatccacagccaagtgtcccagcagctctgcagtacgtcgctgcgggcc ctggacttcagcggcaatgcactgggccatatgtgggccgagggagacctctatctgcacttcttccaaggcctg agcggtttgatctggctggacttgtcccagaaccgcctgcacaccctcctgccccaaaccctgcgcaacctcccc aagagcctacaggtgctgcgtctccgtgacaattacctggccttctttaagtggtggagcctccacttcctgccc ctccggaggctggatgtcagctgcaacagcatcagcttcgtggcccccggcttcttttccaaggccaaggagctg cgagagctcaaccttagcgccaacgccctcaagacagtggaccactcctggtttgggcccctggcgagtgccctg caaatactagatgtaagcgccaaccctctgcactgcgcctgtggggcggcctttatggacttcctgctggaggtg caggctgccgtgcccggtctgcccagccgggtgaagtgtggcagtccgggccagctccagggcctcagcatcttt gcacaggacctgcgcctctgcatgaggccctctcctgggactgtttcgccctctcgctgctgtggct ctgggcctgggtgtgcccatgctgcatcacctctgtggctgggacctctggtactgcttccacctgtgcctggcc tggcttccctggcggggggggcaaagtgggcgagatgaggatgccctgccctacgatgccttcgtggtcttcgac aaaacgcagagcgcagtggcagactgggtgtacaacgagcttcgggggcagctggaggagtgccgtgggcgctgg gcactccgcctgtgcctggaggaacgcgactggctgcctggcaaaaccctctttgagaacctgtgggcctcggtc tatggcagccgcaagacgctgtttgtgctggcccacacggaccgggtcagtggtctcttgcgcgccagcttcctg ctggcccagcagcgcctgctggaggaccgcaaggacgtcgtggtgctggtgatcctgagccctgacggccgccgc tecegetaegtgeggetgegeeagegeetetgeegeeagagtgteeteetetggeeeeagegeeagtggteag cgcagcttctgggcccagctgggcatggccctgaccagggacaaccaccacttctataaccggaacttctgccag tggtctgaccctccctgctcgcctccctcaccccacacctgacacagagca

SEQ ID NO:36 (Human TLR9)

5

10

15

20

25

30

35

40

45 atgggtttctgccgcagcgccctgcacccgctgtctctcctggtgcaggccatcatgctggccatgaccctggcc ctgggtaccttgcctgcctaccctgtgagctccagcccacggcctggtgaactgcaactgctgttcctg aagtctgtgccccacttctccatggcagcaccccgtggcaatgtcaccagcctttccttgtcctccaaccgcatc caccacctccatgattctgactttgcccacctgcccagcctgcggcatctcaacctcaagtggaactgcccgccg gttggcctcagccccatgcacttcccctgccacatgaccatcgagcccagcaccttcttggctgtgcccaccctg *50* gaagagctaaacctgagctacaacaacatcatgactgtgcctgcgctgcccaaatccctcatatccctgtccctc agccataccaacatcctgatgctagactctgccagcctcgccggcctgcatgccctgcgcttcctattcatggac ggcaactgttattacaagaacccctgcaggcaggcactggaggtggccccgggtgccctccttggcctgggcaac ctcacccacctgtcactcaagtacaaccacctcactgtggtgccccgcaacctgccttccagcctggagtatctg ctgttgtcctacaaccgcatcgtcaaactggcgcctgaggacctggccaatctgaccgccctgcgtgtgctcgat 55 gtggggggaaattgccgccgctgcgaccacgctcccaacccctgcatggagtgccctcgtcacttcccccagcta

- 28 -

aaaaccaaggccttccagggcctaacacagctgcgcaagcttaacctgtccttcaattaccaaaagagggtgtcc tttgcccacctgtctctggcccttccttcgggagcctggtcgccctgaaggagctggacatgcacggcatcttc ttccgctcactcgatgagaccacgctccggccactggcccgcctgcccatgctccagactctgcgtctgcagatg aacttcatcaaccaggcccagctcggcatcttcagggccttccctggcctgcgctacgtggacctgtcggacaac cgcatcagcggagcttcggagctgacagccaccatgggggaggcagatggaggggaggaggaggtctggctgcagcct ggggaccttgctccggccccagtggacactcccagctctgaagacttcaggcccaactgcagcaccctcaacttc accttggatctgtcacggaacaacctggtgaccgtgcagccggagatgtttgcccagctctcgcacctgcagtgc ctgcgcctgagccacaactgcatctcgcaggcagtcaatggctcccagttcctgccgctgaccggtctgcaggtg ctagacctgtcccgcaataagctggacctctaccacgagcactcattcacggagctaccgcgactggaggccctg gacctcagctacaacagccagccctttggcatgcagggcgtgggccacaacttcagcttcgtggctcacctgcgc accetgegeeaccteageetggeeacaacaacatecacagecaagtgteecageagetetgeagtacgtegetg cgggccctggacttcagcggcaatgcactgggccatatgtgggccgagggagacctctatctgcacttcttccaa ggcctgagcggtttgatctggctggacttgtcccagaaccgcctgcacaccctcctgccccaaaccctgcgcaac ctccccaagagcctacaggtgctgcgtctccgtgacaattacctggccttctttaagtggtggagcctccacttc ctgcccaaactggaagtcctcgacctggcaggaaaccggctgaaggccctgaccaatggcagcctgctgctggc acccggctccggaggctggatgtcagctgcaacagcatcagcttcgtggcccccggcttcttttccaaggccaag gagctgcgagagctcaaccttagcgccaacgccctcaagacagtggaccactcctggtttgggcccctggcgagt gaggtgcaggctgccggtctgcccagccgggtgaagtgtggcagtccgggccagctccagggcctcagc atctttgcacaggacctgcgcctctgcctggatgaggccctctcctgggactgtttcgcc

5

10

15

20

25

30

35

40

In addition to the foregoing native rat, porcine, bovine, equine, and ovine TLR9 polypeptides and nucleic acid molecules encoding them, chimeric TLR9 polypeptides and nucleic acid molecules encoding them are provided by the invention. The chimeric polypeptides include at least one amino acid substitution based on a comparison of conserved and non-conserved amino acids among at least two of rat, murine, porcine, bovine, equine, ovine, canine, feline, and human TLR9. The information contained in a multiple sequence alignment of these various TLR9 polypeptide sequences, provided for example in Figure 1, can be used to identify and select individual amino acid positions and even individual amino acids to substitute in designing a chimeric TLR9. The substitution or substitutions can be effected using methods known to those of ordinary skill in molecular biology. Nucleic acids encoding the native or chimeric polypeptides of the invention can be inserted into an expression vector and used to express TLR9 polypeptide.

A conservative amino acid substitution shall refer to a substitution of a first amino acid for a second amino acid, wherein side chains of the first amino acid and the second amino acid share similar features in terms of hydrophobicity, size, aromaticity, or tendency to alter conformation. For example, conservative amino acid substitutions generally may be made between members within each of the following groups: hydrophobic (A, I, L, M, V), neutral (C, S, T), acidic (D, E), basic (H, K, N, Q, R), and aromatic (F, W, Y). A non-conservative amino acid substitution refers to any other amino acid substitution.

- 29 -

5

10

15

20

25

30

An expression vector for TLR9 will include at least a nucleotide sequence coding for a TLR9, or a fragment thereof coding for a functional TLR9 polypeptide, operably linked to a gene expression sequence which can direct the expression of the TLR9 nucleic acid within a eukaryotic or prokaryotic cell. A "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked. With respect to TLR9 nucleic acid, the "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the TLR9 nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPRT), adenosine deaminase, pyruvate kinase, β-actin promoter, and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus (e.g., SV40), papillomavirus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), cytomegalovirus (CMV), the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase (TK) promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein (MT) promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined nucleic acid coding sequence for a TLR9 polypeptide. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

- 30 -

Generally a nucleic acid coding sequence and a gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or control of the gene expression sequence. Thus the TLR9 nucleic acid coding sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the TLR9 nucleic acid coding sequence under the influence or control of the gene expression sequence. If it is desired that the TLR9 sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the TLR9 sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the TLR9 sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a TLR9 nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that TLR9 nucleic acid sequence such that the resulting transcript might be translated into the desired TLR9 protein or polypeptide.

5

10

15

20

25

30

A "TLR9 ligand" as used herein refers to a molecule that specifically binds a TLR9 polypeptide. In one embodiment the TLR9 ligand specifically binds a TLR9 polypeptide corresponding to at least a ligand-binding portion of the extracellular domain of TLR9. In most instances a TLR9 ligand will also induce TLR9 signaling when contacted with TLR9 under suitable conditions. TLR9 signaling refers to TLR/IL-1R signal transduction mediated through the TLR9, as described in further detail elsewhere herein. As mentioned above, CpG nucleic acids have been reported to be TLR9 ligands, but TLR9 ligands may include other entities as well, including, for example, small molecules. As also previously mentioned, there appears to be a species-specific preference for at least certain TLR9s and certain CpG motifs. As used herein, a species-preferred CpG DNA refers to a particular CpG DNA that is optimized for signal induction by a TLR9 of a particular species. A CpG DNA that is optimized for signal induction by a TLR9 of a particular species refers to a CpG DNA having a sequence that preferentially binds to and/or induces signaling by TLR9 of that species. For example, a human-preferred CpG DNA shall refer to a CpG DNA that optimally stimulates human TLR9 to signal through its TIR domain. Likewise, a murine-preferred CpG DNA

- 31 -

shall refer to a CpG DNA that optimally stimulates murine TLR9 to signal through its TIR domain. Examples of human-preferred and murine-preferred CpG DNA are ODN 2006 (SEQ ID NO:58) and 1668 (SEQ ID NO:60), respectively.

The binding and species specificity of TLR9s are believed to be influenced by key amino acids present in the extracellular domain of TLR9. Key amino acids in a TLR9 as used herein refer to those amino acids which contribute significantly to ligand binding and ligand specificity of a particular TLR9 polypeptide.

5

10

15

20

25

30

A "CpG nucleic acid" or a "CpG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e., "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanine and linked by a phosphate bond) which activates a component of the immune system. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

In one embodiment a CpG nucleic acid is represented by at least the formula:

5'-N₁X₁CGX₂N₂-3'

wherein X_1 and X_2 are nucleotides, N is any nucleotide, and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Pat. Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

An immunostimulatory nucleic acid molecule, including for example a CpG DNA, may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base. As

- 32 -

used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base-containing polymer. The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

5

10

15

20

25

30

The substituted purines and pyrimidines of the immunostimulatory nucleic acids include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The immunostimulatory nucleic acid is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' to 3' (or equivalent) order from left to right and that "A" denotes adenine, "C" denotes cytosine, "G" denotes guanine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

Immunostimulatory nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g., genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g., produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

5

10

15

20

25

30

The immunostimulatory nucleic acids can be produced on a large scale in plasmids, (see *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in the instant invention, the immunostimulatory nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the β-cyanoethyl phosphoramidite method (Beaucage SL and Caruthers MH, *Tetrahedron Let* 22:1859 (1981)); nucleoside H-phosphonate method (Garegg et al., *Tetrahedron Let* 27:4051-4054 (1986); Froehler et al., *Nucl Acid Res* 14:5399-5407 (1986); Garegg et al., *Tetrahedron Let* 27:4055-4058 (1986); Gaffney et al., *Tetrahedron Let* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

The immunostimulatory nucleic acid may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Immunostimulatory nucleic acids can be produced on a large scale in plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

A "stabilized immunostimulatory nucleic acid" shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an

WO 2004/026888

5

10

15

20

25

30

oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized immunostimulatory nucleic acids have a modified backbone. It has been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the immunostimulatory nucleic acids when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3' end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases. Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail in U.S. Pat. Nos. 6,194,388 and 6,207,646, the entire contents of which are incorporated herein by reference. It is believed that these modified oligonucleotides may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization. Both phosphorothioate and phosphodiester nucleic acids are active in immune cells.

Other stabilized immunostimulatory nucleic acids include: nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

Phosphorothioate nucleic acid molecules may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described. Uhlmann E and Peyman A (1990) Chem Rev 90:544; Goodchild J (1990) Bioconjugate Chem 1:165.

- 35 -

Other sources of immunostimulatory nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene be expressed in the cell.

Nucleic acid-binding fragments of TLRs are believed to include the extracytoplasmic (extracellular) domain or subportions thereof, such as those which include at least an MBD motif, a CXXC motif, or both an MBD motif and a CXXC motif.

Both mouse and human TLR9 have an N-terminal extension of approximately 180 amino acids compared to other TLRs. An insertion also occurs at amino acids 253-268, which is not found in TLRs 1-6 but is present in human TLR7 and human TLR8. This insert has two CXXC motifs which participate in forming a CXXC domain. The CXXC domain resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g., methyl-CpG binding protein-1 (MBD-1). Fujita N et al. (2000) *Mol Cell Biol* 20:5107-18. Both human and mouse TLR9 CXXC domains occur at aa 253-268:

CXXC motif: GNCXXCXXXXXXXCXXC SEQ ID NO:62

Human TLR9: GNCRRCDHAPNPCMEC SEQ ID NO:63

25 Murine TLR9: GNCRRCDHAPNPCMIC SEQ ID NO:64

An additional motif believed to be involved in CpG binding is the MBD motif, also found in MBD-1, listed below as SEQ ID NO:53. Fujita, N et al.(2000) *Mol Cell Biol* 20:5107-18; Ohki I et al. (1999) *EMBO J* 18:6653-61. Amino acids 524-554 of hTLR9 and aa 525-555 of mTLR9 correspond to the MBD motif of MBD-1 as shown:

MBD motif:

5

10

15

20

30

- 36 -

	MBD-1	R-XXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXXX-Y	SEQ ID NO:65
	hTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXXX-Y	SEQ ID NO:66
	mTLR9	Q-XXXXXX-K-X-D-X-Y-XXXXXXXXX-Q-L-XXXXXXX-Y	SEQ ID NO:67
5	hTLR9	Q-VLDLSRN-K-L-D-L-Y-HEHSFTELP-R-L-EALDLS-Y	SEQ ID NO:68
	mTLR9	Q-VLDLSHN-K-L-D-L-Y-HWKSFSELP-Q-L-QALDLS-Y	SEQ ID NO:69

10

15

20

25

30

Although the signaling functions of MBD-1 and TLR9 are quite different, the core D-X-Y is conserved and is believed to be involved in CpG binding.

According to another aspect of the invention, a screening method is provided for identifying an immunostimulatory compound. The method according to this aspect of the invention involves contacting a functional TLR9 with a test compound; detecting presence or absence of a response mediated by a TLR9 signal transduction pathway in the presence of the test compound arising as a result of an interaction between the functional TLR9 and the test compound; and determining the test compound is an immunostimulatory compound when the presence of a response mediated by the TLR9 signal transduction pathway is detected.

An immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell. A TLR9 ligand that is an immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell that expresses TLR9. A TLR9 ligand that is an immunostimulatory compound is also a natural or synthetic compound that is capable of inducing a TLR/IL-1R signal transduction pathway when contacted with a TLR9. Immunostimulatory compounds include but are not limited to immunostimulatory nucleic acids. The immunostimulatory compound can be, for example, a nucleic acid molecule, polynucleotide or oligonucleotide, a polypeptide or oligopeptide, a lipid or lipopolysaccharide, a small molecule.

A basis for certain of the screening assays is the presence of a functional TLR9 in a cell. The functional TLR9 in some instances is naturally expressed by a cell. In other instances, expression of the functional TLR9 can involve introduction or reconstitution of a species-specific TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an

5

10

15

20

25

30

immunostimulatory nucleic acid. In yet other instances, expression of the functional TLR9 can involve introduction of a chimeric or modified TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an immunostimulatory nucleic acid. Examples of cell lines lacking TLR9 or immunostimulatory nucleic acid responsiveness include, but are not limited to, 293 fibroblasts (ATCC CRL-1573), MonoMac-6, THP-1, U937, CHO, and any TLR9 knock-out. The introduction of the species-specific, chimeric or modified TLR9 into the cell or cell line is preferably accomplished by transient or stable transfection of the cell or cell line with a TLR9-encoding nucleic acid sequence operatively linked to a gene expression sequence (as described above). Methods for transient and for stable transfection of a cell are well known in the art.

The screening assays can have any of a number of possible readout systems based upon either TLR/IL-1R signaling pathway or other assays useful for assessing response to immunostimulatory nucleic acids. It has been reported that immune cell activation by CpG immunostimulatory sequences is dependent in some way on endosomal processing.

In certain embodiments, the readout for the screening assay is based on the use of native genes or, alternatively, cotransfected or otherwise co-introduced reporter gene constructs which are responsive to the TLR/IL-1R signal transduction pathway involving MyD88, TRAF, p38, and/or ERK. Häcker H et al. (1999) *EMBO J* 18:6973-6982. These pathways activate kinases including κB kinase complex and c-Jun N-terminal kinases. Thus reporter genes and reporter gene constructs particularly useful for the assays can include a reporter gene operatively linked to a promoter sensitive to NF-κB. Examples of such promoters include, without limitation, those for NF-κB, IL-1β, IL-6, IL-8, IL-12 p40, CD80, CD86, and TNF-α. The reporter gene operatively linked to the TLR-sensitive promoter can include, without limitation, an enzyme (e.g., luciferase, alkaline phosphatase, β-galactosidase, chloramphenicol acetyltransferase (CAT), etc.), a bioluminescence marker (e.g., greenfluorescent protein (GFP, U.S. Pat. No. 5,491,084), blue fluorescent protein, etc.), a surface-expressed molecule (e.g., CD25), and a secreted molecule (e.g., IL-8, IL-12 p40, TNF-α). In certain embodiments the reporter is selected from IL-8, TNF-α, NF-κB-luciferase (NF-κB-luc; Häcker H et al. (1999) *EMBO J* 18:6973-6982), IL-12 p40-luc (Murphy TL et al. (1995)

- 38 -

Mol Cell Biol 15:5258-5267), and TNF-luc (Häcker H et al. (1999) EMBO J 18:6973-6982). At least one of these reporter constructs (NF-κB-luc) is commercially available (Stratagene, La Jolla, CA). In assays relying on enzyme activity readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using FACS analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many such readout systems are well known in the art and are commercially available.

5

10

15

20

25

30

According to one embodiment of this method, comparison can be made to a reference immunostimulatory nucleic acid. The reference immunostimulatory nucleic acid may be any suitably selected immunostimulatory nucleic acid, including a CpG nucleic acid. In certain embodiments the screening method is performed using a plurality of test nucleic acids. In certain embodiments comparison of test and reference responses is based on comparison of quantitative measurements of responses in each instance.

In another aspect the invention provides a screening method for identifying species specificity of an immunostimulatory nucleic acid. The method involves contacting a TLR9 of a first species with a test immunostimulatory nucleic acid; contacting a TLR9 of a second species with the test immunostimulatory nucleic acid; measuring a response mediated by a TLR signal transduction pathway associated with the contacting the TLR9 of the first species with the test immunostimulatory nucleic acid; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the TLR9 of the second species with the test immunostimulatory nucleic acid; and comparing the two responses. The TLR9 may be expressed by a cell or it may be part of a cell-free system. The TLR9 may be part of a complex, with either another TLR or with another protein, e.g., MyD88, IRAK, TRAF, IkB, NF-kB, or functional homologues and derivatives thereof. Thus for example a given ODN can be tested against a panel of human fibroblast 293 fibroblast cells transfected with TLR9 from various species and optionally cotransfected with a reporter construct sensitive to TLR/IL-1R activation pathways. Thus in another aspect, the invention provides a method for screening species selectivity with respect to a given nucleic acid sequence.

Test compounds can include but are not limited to peptide nucleic acids (PNAs), antibodies, polypeptides, carbohydrates, lipids, hormones, and small molecules. Test

- 39 -

compounds can further include variants of a reference immunostimulatory nucleic acid incorporating any one or combination of the substitutions described above. Test compounds can be generated as members of a combinatorial library of compounds.

5

10

15

30

In preferred embodiments, the screening methods can be performed on a large scale and with high throughput by incorporating, e.g., an array-based assay system and at least one automated or semi-automated step. For example, the assays can be set up using multiple-well plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery devices suited to the geometry of the multiwell plate.

Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are well known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are well known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

The following examples are provided for illustrative purposes and are not meant to be limiting in any way.

Examples

Example 1. Cloning and Sequencing of Rat, Porcine, Bovine, Equine, Ovine, Canine, and Feline TLR9

Cells and Tissues. Lymphoid tissues, primarily spleen or blood mononuclear cells (PBMC) from five mammalian species were collected: mouse, pig, bovine, rat and horse. Spleen samples were collected in RNAlaterTM (Ambion[®], Austin, TX, USA), stabilized at 4°C overnight and stored at -70°C. Blood samples were centrifuged at 500 x g for 25 min at room temperature and the buffy coat, containing enriched PBMC, was then removed and stored at -70°C. The mouse specimen was used as a comparative positive control.

- 40 -

First-strand cDNA synthesis. Total RNA from the spleen and PBMC samples was isolated using a monophasic solution of phenol and guanidine isothiocyanate: TRIzolTM reagent (GIBCO BRL[®], Burlington, ON, Canada) according to the manufacturer's instructions. First-strand cDNA was synthesized from the total RNA using SUPERSCRIPTTM II reverse transcriptase (GIBCO BRL[®], Burlington, ON, Canada). Approximately 3 μg of total RNA was added to 50 pmoles of oligo(dT) primer [poly T₍₁₈₎]; the mixture was heated to 70°C for 10 min and subsequently chilled on ice. The following was added to the cooled reaction mixture: 1 μl of mixed dNTP stock containing 10 mM each dATP, dCTP, dGTP and dTTP (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) at neutral pH, 1X first strand buffer (50 mM Tris-HCl pH 8.3/ 75 mM KCl/ 3 mM MgCl₂) and 2 μl of 0.1 M DTT. The mixture was subsequently heated to 42°C for 2 min, followed by addition of 200 units of SUPERSCRIPTTM II reverse transcriptase. The reaction was carried out at 42°C for 50 min, followed by 70°C for 15 min. The first-strand cDNA was used as the template for subsequent polymerase chain reaction (PCR) amplifications.

5

10

15

20

25

30

mentioned species using primers designed from known mouse and human TLR9 sequence in Genbank: Accession AF314224 and AF259262, respectively. The primers were designed using the primer design software, Clone Manager 5 (Scientific and Educational Software, Durham, NC, USA). TLR9 gene-specific primers used were: forward primer 5'-ACCTTGCCTGCCTTCCTACCCTGTGA-3' (SEQ ID NO:37) and reverse primer 5'-GTCCGTGTGGGCCAGCACAAA-3' (SEQ ID NO:38). The 2.7 Kbp fragment was PCR amplified using Advantage® 2 DNA polymerase mix (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. PCR reaction volumes of 25 μl contained 15 pmoles of each primer, 0.2 mM of dNTP mix and 1 μl of reverse transcription reaction. PCR amplification was conducted by initial denaturation at 94°C for 1 min followed by 30 cycles of 94°C denaturation (15 sec), 65°C

PCR amplification. TLR9 gene was PCR amplified from each of the above-

Cloning and sequencing. The PCR amplified fragment was treated with 500 units of T4 DNA polymerase (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) for 15 min at room temperature prior to cleaning the reaction with QIAquick PCR purification kit (QIAGEN Inc., Mississauga, ON, Canada). The fragment was then ligated to pZErO™ - 2

annealing (45 sec) and 72°C extensions (2 min), with a final extension at 72°C for 5 min.

- 41 -

vector (Invitrogen[™] Life Technologies, Burlington, ON, Canada), treated with *Eco RV* restriction enzyme, using T4 DNA Ligase (GIBCO BRL[®], Burlington, ON, Canada). *E. coli* TOP 10 chemically competent cells (Invitrogen[™] Life Technologies, Burlington, ON, Canada) were used to transform ligated products. Plasmids containing the 2.7 Kbp fragment were sequenced using an automated DNA sequencer, CEQ[™] 2000XL DNA analysis system (Beckman Coulter Inc., Fullerton, CA, USA).

5

10

15

20

25

30

Sequences of the 2.7 Kbp fragment were derived from three clones of each species selected from independent PCR reactions to account for errors that may have been incurred during the PCR amplifications and to confirm the sequence data.

Nucleotide sequences of the rat, porcine, bovine, equine, ovine, canine, and feline TLR9 were extended and completed using standard 5' and 3' RACE PCR and primers designed using the sequences obtained from the 2.7 Kbp fragments.

Results. Nucleotide sequences of rat, porcine, bovine, equine, canine, and feline TLR9 cDNA obtained by the methods above are provided as SEQ ID NOs 3, 7, 11, 15, 19, 23, and 27, respectively. Deduced amino acid sequences are provided as SEQ ID NOs 1, 5, 9, 13, 17, 21, and 25, respectively. Deduced amino acid sequences of full-length murine and human TLR9 are provided as SEQ ID NOs 29 and 33, respectively.

Example 2. Comparison of Aligned Sequences for TLR9 from Various Mammalian Species.

Multiple sequence alignment of deduced amino acid sequences for feline, canine, bovine, mouse, ovine, porcine, horse, human, and rat TLR9 polypeptides was performed using Clustal W 1.82 (see, for example, www.cmbi.kun.nl/bioinf/tools/clustalw.shtml). In addition, paired sequence alignment of deduced amino acid sequences for murine and human TLR9 polypeptides was performed using Clustal W 1.82. The results of the multiple sequence alignment are presented in **Figure 1**. As will be appreciated from Figure 1, certain amino acids are highly conserved across all species examined. Similarly, certain amino acids differ only by conservative amino acid substitutions among the various species. In addition, it is evident that certain amino acids which are conserved between murine and human TLR9 are not conserved in other species. Furthermore, Figure 1 also indicates that certain amino acids are highly divergent across various species. The information provided by the comparison of multiple species adds significantly to the information available by comparison between only murine and human TLR9 sequences.

- 42 -

The putative transmembrane regions of the TLR9 polypeptides are indicated in boxes in Figure 1. Sequence upstream of each transmembrane region is extracellular domain and is believed to include sequence primarily responsible for binding to TLR9 ligands, including CpG DNA. The extracellular domains of feline, canine, bovine, mouse, ovine, porcine, horse, human, and rat TLR9 correspond to amino acids numbered 1-820, 1-822, 1-818, 1-821, 1-818, 1-819, 1-820, 1-820, and 1-821, respectively, as shown in Figure 1.

Figure 2 presents an evolutionary relatedness tree for six TLR9 polypeptides examined. The cladogram in Figure 2 was prepared using Clustal W (see above). As can be appreciated from this figure, murine and human TLR9 are nearly the most divergent TLR9s in this group. Surprisingly, human and horse TLR9 appear relatively closely related.

Example 3. Reconstitution of TLR9 Signaling in 293 Fibroblasts.

5

10

15

20

25

30

Mouse TLR9 cDNA (SEQ ID NO:31) and human TLR9 cDNA (SEQ ID NO:35) in pT-Adv vector (from Clonetech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

Since NF-κB activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-258; Muzio M et al. (1998) *J Exp Med* 187:2097-101), cells were transfected with hTLR9 or co-transfected with hTLR9 and an NF-κB-driven luciferase reporter construct. Human fibroblast 293 cells were transiently transfected with hTLR9 and a six-times NF-κB-luciferase reporter plasmid (NF-κB-luc) or with hTLR9 alone. After stimulus with CpG-ODN (2006, 2μM, TCGTCGTTTTGTCGTTTTGTCGTT, SEQ ID NO:58), GpC-ODN (2006-GC, 2μM, TGCTGCTTTTGTGCTTTTGTGCTT, SEQ ID NO:59), LPS (100 ng/ml) or media, NF-κB activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results representative of three independent experiments showed that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Independently, human fibroblast 293 cells were transiently transfected with mTLR9 and the NF-κB-luc construct or with mTLR9 alone. After stimulation with CpG-ODN (1668, 2μM; TCCATGACGTTCCTGATGCT, SEQ ID NO:60), GpC-ODN (1668-GC, 2μM;

TCCATGAGCTTCCTGATGCT, SEQ ID NO:61), LPS (100 ng/ml) or media, NF-kB activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results showed that expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG-DNA stimulation.

To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF-κB-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2x10⁶ cells/plate) with 16 μg of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe, Germany). Clones were tested for TLR9 expression by RT-PCR. The clones were also screened for IL-8 production or NF-κB-luciferase activity after stimulation with ODN. Four different types of clones were generated.

293-hTLR9-luc: expressing human TLR9 and 6-fold NF-κB-luciferase reporter

293-mTLR9-luc: expressing murine TLR9 and 6-fold NF-κB-luciferase reporter

293-hTLR9: expressing human TLR9

5

10

15

20

25

293-mTLR9: expressing murine TLR9

Results indicated that stable clones also responded to CpG-ODN.

Example 4. Similar ODN Sequence Specificity of TLR9 of Human and Equine TLR9.

 $3x10^6$ 293T cells were electroporated with $5\mu g$ NF- κB -luc plasmid and $5\mu g$ of either horse TLR9-pcDNA3.1 plasmid or humanTLR9-pcDNA3.1 plasmid at 200V, 975 μF . After the electroporation the cells were plated in 96-well cell culture plates at $2.5x10^4$ cells per well and grown overnight at 37°C. The cells were stimulated with the indicated concentration of ODN for 16h, after which the supernatant was removed and the cells lysed in lysis buffer and frozen for at least 2 hours at -80°C. Luciferase activity was measured by adding Luciferase Assay substrate from Promega. Values are given as fold specific induction over non-stimulated control. Results are shown in **Figure 3**.

As shown in Figure 3, ODN 2006 (TCGTCGTTTTGTCGTTTTGTCGTT; SEQ ID NO:58) has a strong specificity for human TLR9. ODN 1982

30 (TCCAGGACTTCTCAGGTT; SEQ ID NO:70) was the negative control ODN. ODN 5890 (TCCATGACGTTTTTGATGTT; SEQ ID NO:39) has a strong specificity for mouse

- 44 -

TLR9. This experiment demonstrates the similarity of horse TLR9 to human TLR9 in binding specificity, a result predicted by the evolutionary relatedness of horse TLR9 to human TLR9. Mouse TLR9 is more distant from horse TLR9 and human TLR9 in sequence homology, and ODN 5890 was not detected by either human or horse TLR9.

5

10

15

Example 5. Non-human, Non-murine Native Mammalian TLR9 Useful in Screening for Human-Preferred CpG DNA.

Native rat, porcine, bovine, equine, and ovine TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006). Rat, porcine, bovine, equine, or ovine TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

20

Example 6. Chimeric TLR9 Useful in Screening for Human-Preferred CpG DNA.

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

30

25

Example 7. Chimeric TLR9 Responsive to Both Human-Preferred and Murine-Preferred CpG DNA.

WO 2004/026888

- 45 -

PCT/US2003/029577

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006) and also screened for binding or TLR9 signaling activity when contacted with murine-preferred CpG DNA (ODN 1668). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in each of these assays are then used as the basis for screening for additional human-preferred CpG DNA and for screening for additional murine-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA or candidate murine-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA. Candidate murine-preferred CpG DNA exhibiting significant TLR9 signaling activity are selected as murine-preferred CpG DNA.

15

10

5

Equivalents

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages of the invention are not necessarily encompassed by each embodiment of the invention.

25

20

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

5

2. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.

10 j

3. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

4. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.

- 5. A vector comprising the nucleic acid of any of claims 3-4.
- 6. A cell comprising the vector of claim 5.

20

15

7. An antibody or fragment thereof that binds specifically to the polypeptide of any of claims 1-2.

25

8. A method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species, comprising:

aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species;

30

generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the

- 47 -

TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution;

5

10

15

20

25

30

generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

9. A method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9, comprising:

aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9;

generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution;

generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids.

10. The method according to claim 9, performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight, said weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

- 48 -

- 11. An isolated polypeptide comprising an amino acid sequence identical to SEQ ID NO:30 except for substitution of at least one key amino acid identifed according to the method of any of claims 9 or 10.
- 12. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide according to claim 11.
 - 13. A vector comprising the nucleic acid of claim 12.
 - 14. A cell comprising the vector of claim 13.
 - 15. An antibody that binds specifically to the polypeptide of claim 14.
 - 16. A screening method to identify a TLR9 ligand, comprising:
 contacting a polypeptide according to any of claims 1, 2, or 11 with a candidate TLR9 ligand;

measuring a signal in response to the contacting; and

identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling.

20

30

10

15

- 17. The method of claim 16, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.
- 18. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF-κB.
 - 19. The method of claim 17, wherein the candidate TLR9 ligand is an immunostimulatory nucleic acid.
 - 20. The method of claim 19, wherein the immunostimulatory nucleic acid is CpG DNA.

21. A screening method to identify species-specific CpG-motif preference of an isolated polypeptide of claim 2 or claim 11, comprising:

contacting an isolated polypeptide of claim 2 or claim 11 with a CpG DNA comprising a hexamer sequence selected from the group consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACGTT, G

measuring a signal in response to the contacting; and

5

identifying a species-specific CpG-motif preference when the signal in response to the contacting is consistent with TLR9 signaling.

- 22. The method of claim 21, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.
- 23. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF-κB.
 - 24. The method of claim 21, wherein the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

```
(SEQ ID NO:39),
         TCCATGACGTTTTTGATGTT
20
                                    (SEQ ID NO:40),
         TCCATAACGTTTTTGATGTT
                                    (SEQ ID NO:41),
         TCCATCACGTTTTTGATGTT
                                    (SEQ ID NO:42),
         TCCATTACGTTTTTGATGTT
                                    (SEQ ID NO:43),
         TCCATGGCGTTTTTGATGTT
                                    (SEQ ID NO:44),
         TCCATGCCGTTTTTGATGTT
25
                                    (SEQ ID NO:45),
         TCCATGTCGTTTTTGATGTT
                                    (SEQ ID NO:46),
         TCCATGATGTTTTTGATGTT
                                    (SEQ ID NO:47),
         TCCATGAAGTTTTTGATGTT
                                    (SEQ ID NO:48),
         TCCATGAGGTTTTTGATGTT
                                    (SEQ ID NO:49),
         TCCATGACATTTTTGATGTT
30
                                    (SEQ ID NO:50),
         TCCATGACCTTTTTGATGTT
                                    (SEQ ID NO:51),
         TCCATGACTTTTTTGATGTT
                                    (SEQ ID NO:52),
         TCCATGACGCTTTTGATGTT
                                    (SEQ ID NO:53),
         TCCATGACGATTTTGATGTT
                                    (SEQ ID NO:54),
         TCCATGACGGTTTTGATGTT
35
                                    (SEQ ID NO:55),
         TCCATGACGTCTTTGATGTT
                                    (SEQ ID NO:56), and
         TCCATGACGTATTTGATGTT
                                    (SEQ ID NO:57).
         TCCATGACGTGTTTGATGTT
```

Figure 1 (1/3)

feline	MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAA	60
canine	MGPCRGALHPLSLLVQAAALALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPRFSAAA	60
bovine	MGP-YCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
mouse	MGP-YCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
ovine	MGP-YCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGKVNCNWLFLKSVPRFSAGA	59
porcine	MGP-RCTLHPLSLLVQVTALAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAA	59
horse	MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAA	60
human	MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA	60
rat	MVLCRRTLHPLSLLVQAAVLAEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAE	60
	* : *******	U.
feline	PRGNVTSLSLYSNRIHHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFL	120
canine	PRGNVTSLSLYSNRIHHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNTFL	120
bovine	PRANVTSLSLISNRIHHLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFL	119
mouse	PRANVTSLSLISNRIHHLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFL	119
ovine	PRANVTSLSLISNRIHHLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFL	119
porcine	PRANVTSLSLLSNRIHHLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFL	119
horse	PRDNVTSLSLLSNRIHHLHDSDFAQLSNLQKLNLKWNCPPAGLSPMHFPCHMTIEPNTFL	120
human	PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFL	120
rat	PRSNITSLSLIANRIHHLHNLDFVHLPNVRQLNLKWNCPPPGLSPLHFSCRMTIEPKTFL	
	** *: **** : ***** : ** : : : ****** . *** : ** . * : ***	140
feline	AVPTLEELNLSYNSITTVPALPSSLVSLSLSRTNILVLDPANLAGLHSLRFLFLDGNCYY	100
canine	AVPTLEDLNLSYNSITTVPALPSSLVSLSLSRTNILVLDPATLAGLYALRFLFLDGNCYY	100
bovine	AVPTLEELNLSYNGITTVPALPSSLVSLSLSHTSILVLGPTHFTGLHALRFLYMDGNCYY	
mouse	AVPTLEELNLSYNGITTVPALPSSLVSLSLSHTSILVLGPTHFTGLHALRFLYMDGNCYY	— · -
ovine	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRTSILVLGPTHFTGLHALRFLYMDGNCYY	
porcine	AVPTLEELNLSYNSITTVPALPDSLVSLSLSRTNILVLDPTHLTGLHALRYLYMDGNCYY	
horse	AVPTLEELNLSYNGITTVPALPSSLVSLILSRTNILQLDPTSLTGLHALRFLYMDGNCYY	
human	AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYY	
rat	AMRMLEELNLSYNGITTVPRLPSSLTNLSLSHTNILVLDASSLAGLHSLRVLFMDGNCYY	
	*: **: *** * * * * * * * * * * * * * *	100
feline	KNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEYLLLSYNHIITLAPEDL	240
canine	KNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYLLLSYNHIITLAPEDL	240
bovine	MNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLLLSYNHIVTLAPEDL	239
mouse	MNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLLLSYNHIVTLAPEDL	239
ovine	KNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLLLSYNHIITLAPEDL	239
porcine	KNPCQGALEVVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLLLSYNHIVTLTPEDL	239
horse	KNPCGRALEVAPGALLGLGNLTHLSLKYNNLTTVPRSLPPSLEYLLLSYNHIVTLAPEDL	240
human	KNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDL	240
rat	KNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYLLLSYNLIVKLGAEDL	

feline	ANLTALRVLDVGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLEGLVLKDSSLYNLN	300
canine	ANLTALRVLDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD	300
bovine	ANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLE	299
mouse	ANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLE	299
ovine	ANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLE	299
porcine	ANLTALRVLDVGGNCRRCDHARNPCRECPKDHPKLHSDTFSHLSRLEGLVLKDSSLYNLD	299
horse	ANLTALRVLDVGGNCRRCDHARNPCVECPHKFPQLHSDTFSHLSRLEGLVLKDSSLYQLN	300
human	ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN	300
rat	ANLTSLRMLDVGGNCRRCDHAPDLCTECRQKSLDLHPQTFHHLSHLEGLVLKDSSLHSLN	300
	****:**:*********	
feline		360
canine		360
bovine		359
mouse	-	359
ovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSF	359
porcine	TRWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSF	
horse	PRWFRGLGNLTVLDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSFAHLTLAPSF	360
human		360
rat	SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSF **:.* .* ********* * . * . * . * . * . *	360

Figure 1 (2/3)

feline canine bovine mouse ovine porcine horse human rat	GSLLSLQELDIHGIFFRSLSKTTLQSLAHLPMLQRLHLQLNFISQAQLSIFGAFPGLRYV GSLVSLEKLDMHGIFFRSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFV GSLVSLEKLDMHGIFFRSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFV GGLVSLEKLDMHGIFFRSLTNTTLRPLTQLPKLQSLSLQLNFINQAELSIFGAFPSLLFV GHLRSLKELDMHGIFFRSLSETTLQPLVQLPMLQTLRLQMNFINQAQLSIFGAFPGLLYV GSLLSLQELDMHGIFFRSLSQKTLQPLARLPMLQRLYLQMNFINQAQLGIFKDFPGLRYI GSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYV	420 420 419 419 419 420 420 420
feline	DLSDNRISGAMELAAATGEVDGGERVRLPSGDLALGPPGTPSSEGFMPGCKTLNFTLD	478
canine	DLSDNRISGAAEPAAATGEVEADCGERVWPQSRDLALGPLGTPGSEAFMPSCRTLNFTLD	480
bovine	DLSDNRISGAATPAAALGEVDSRVEVWRLPRGLAPGPLDAVSSKDFMPSCN-LNFTLD	476
mouse	DLSDNRISGAATPAAALGEVDSRVEVWRLPRGLAPGPLDAVSSKDFMPSCN-LNFTLD	476
ovine	DLSDNRISGAARPVAALGEVDSGVEVWRWPRGLAPGPLAAVSAKDFMPSCN-LNFTLD	476
porcine	DLSDNRISGAARPVAITREVDGRERVWLPSRNLAPRPLDTLRSEDFMPNCKAFSFTLD	477
horse	DLSDNRISGAVEPVATTGEVDGGKKVWLTSRDLTPGPLDTPSSEDFMPSCKNLSFTLD	478
human		478
rat		479
	:*	
		620
feline	TOTALLE STATE OF THE STATE OF T	
canine	LSRNNLVTVQPEMEVRLARLQCLGLSHNSISQAVNGSQFVPLSNLRVLDLSHNKLDLYHG	536
bovine	DOINTING TO THE PROPERTY OF TH	536
mouse ovine	LSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLDLSYNKLDLYHG	536
		537
porcine horse	LSRNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQVLDLSHNKLDLYHG	538
human	LSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHE	538
rat	LSRNNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLKVLDLSYNKLDLYHS	539
	**** **: *** ** ** ** ** ** ** ** ** **	
feline canine bovine	1/01 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	598 600 596
mouse	RSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSA	596
ovine	RSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSA	596
porcine	RSFTELPRLEALDLSYNSQPFTMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSA	
horse	RSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPTLRYLSLAHNGIHSRVSQQLCST	598
human	HSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCST	598
rat	KSFSELPQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYST :**:***:*****************************	599
feline	SLRALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHTLLPRTLDNLPKSLRLL	658
canine	SLRALDFSGNTLSQMWAEGDLYLRFFQGLRSLVQLDLSQNRLHTLLPRNLDNLPKSLRLL	660
bovine	OTHER DEPONDED STATE DESCRIPTION OF STATE OF STA	656
mouse	SLRALDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQL	656
ovine	SLRALDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSKNHLHTLLPRHLDNLPKSLRQL	656
porcine	SLCALDFSGNDLSRMWAEGDLYLRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKSLKHL	657
horse	SLWALDFSGNSLSQMWAEGDLYLRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLL	658
human	SLRALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVL	658
rat	SVEYLDFSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKL *: ***** :::** * **** **:.* .*: ****:** * * *	659
	* *****	
feline	RLRDNYLAFFNWSSLVLLPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVAS	718
canine	RLRDNYLAFFNWSSLALLPKLEALDLAGNQLKALSNGSLPNGTQLQRLDLSGNSIGFVVP	720
bovine	RLRDNNLAFFNWSSLTVLPRLEALDLAGNQLKALSNGSLPPGIRLQKLDVSSNSIGFVIP	716
mouse	RLRDNNLAFFNWSSLTVLPRLEALDLAGNQLKALSNGSLPPGIRLQKLDVSSNSIGFVIP	716
ovine	RLRDNNLAFFNWSSLTVLPQLEALDLAGNQLKALSNGSLPPGTRLQKLDVSSNSIGFVTP	716
porcine	HLRDNNLAFFNWSSLTLLPKLETLDLAGNQLKALSNGSLPSGTQLRRLDLSGNSIGFVNP	717
horse	RLRNNYLAFFNWSSLTLLPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRNSIIFVVP	718
human	RLRDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAP	710 118
rat	SFRDNHLSFFNWSSLAFLPNLRDLDLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVP	113
	*** * * * * * * * * * * * * * * * * * *	

Figure 1 (3/3)

feline	SFFALATRLRELNLSANALKTVEPSWFGSLAGTLKVLDVTGNPLHCACGAAFVDFLLEVQ	778
canine	SFFALAVRLRELNLSANALKTVEPSWFGSLAGALKVLDVTANPLHCACGATFVDFLLEVQ	780
bovine	GFFVRATRLIELNLSANALKTVDPSWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERQ	776
mouse	GFFVRATRLIELNLSANALKTVDPSWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERO	776
ovine	GFFVLANRLKELNLSANALKTVDPFWFGRLTETLNILDVSANPLHCACGAAFVDFLLEMO	776
porcine	GFFALAKQLEELNLSANALKTVEPSWFGSMVGNLKVLDVSANPLHCACGATFVGFLLEVQ	777
horse	GFFALATRLRELNLSANALRTEEPSWFGFLAGSLEVLDVSANPLHCACGAAFVDFLLQVQ	778
human	GFFSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQ	778
rat	AFFALAVELKEVNLSHNILKTVDRSWFGPIVMNLTVLDVSSNPLHCACGAPFVDLLLEVQ	
Lac	** * * * * * * * * * * * * * * * * * *	779
feline	AAVPGLPGHVKCGSPGQLQGRSIFAQDLRLCLDEALSWDCFGLSLLTVALGLAVPMLHHL	838
canine	AAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDEALSWVCFSLSLLAVALSLAVPMLHQL	840
bovine	EAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGLSLLMVALGLAVPMLHHL	836
· - -		
mouse	EAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGLSLLMVALGLAVPMLHHL	836
ovine	AAVPGLSRRVTCGSPGQLQGRSIFAQDLRLCLDETLSLDCFGFSLLMVALGLAVPMLHHL	836
porcine	AAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFGISLLAMALGLVVPMLHHL	837
horse	AAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFGLSLLVVALGLAMPMLHHL	838
human	AAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHL	838
rat	TKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFGLSLLAVAVGTVLPLLQHL	839
246	****	000
	• • • • • • • • • • • • • • • • • • • •	
feline	CGWDLWYCFHLCLAWLPRRGRRRGADALPYDAFVVFDKAQSAVADWVYNELRVRLEER	896
canine	CGWDLWYCFHLCLAWLPRRGRRRGVDALAYDAFVVFDKAQSSVADWVYNELRVQLEER	898
bovine	CGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEER	894
	CGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWYNELRVQLEER	894
mouse		894
ovine	CGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAFVVFDKAQSAVADWVYNELRVQLEER	
porcine	CGWDLWYCFHLCLAWLPHRGQRRGADALFYDAFVVFDKAQSAVADWVYNELRVQLEER	895
horse	CGWDLWYCFHLGLAWLPRRGWQRGADALSYDAFVVFDKAQSAVADWVYNELRVRLEER	896
human	CGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEEC	898
rat	CGWDVWYCFHLCLAWLPLLTRGR-RSAQALPYDAFVVFDKAQSAVADWVYNELRVRLEER	898
	********* ** ** ** ** ** ************ ****	
~ ~ .		05.0
feline	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQRL	956
canine	RGRRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLARTDRVSGLLRASFLLAQQRL	958
bovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRL	954
mouse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRL	954
ovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRL	954
porcine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLLAQQRL	955
horse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQRL	956
human	RGRWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRL	958
rat	RGRRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQQRL	958
	*** ******************** :*** :*** :******	
feline	LEDRKDVVVLVILRPDAHRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNQ	
canine	LEDRKDVVVLVILCPDAHRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNR	
bovine	LEDRKDVVVLVILRPAAYRSRYVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNR	
mouse	LEDRKDVVVLVILRPAAYRSRYVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNR	1014
ovine	LEDRKDVVVLVILRPAAYRSRYVRLRQRLCRQSVLLWPHQPSGQGSFWANLGMALTRDNR	1014
porcine	LEDRKDVVVLVILRPDAYRSRYVRLRQRLCRQSVLLWPHQPRGQGSFWAQLGTALTRDNH	1015
horse	LEDRKDVVVLVILSPDARRSRYVRLRQRLCRQSVLFWPHQPSGQRSFWAQLGMALTRDNR	1016
human	LEDRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNH	
rat	LEDRKDVVVLVILRPDAHRSRYVRLRQRLCRQSVLFWPHQPNGQGSFWAQLSTALTRDNH	

feline	HFYNQNFCRGPTTAE	1031
canine	HFYNQNFCRGPTTA	1032
bovine	HFYNRNFCRGPTTAE	1029
mouse	HFYNRNFCRGPTTAE	
ovine	HFYNRNFCRGPTTAE	1029
porcine	HFYNRNFCRGPTTAE	1030
horse	HFYNQNFCRGPTMAE	1031
human	HFYNRNFCQGPTAE	1032
rat	HFYNRNFCRGPTAE	1032

Figure 2





Figure 3



SEQUENCE LISTING

- <110> Coley Pharmaceutical GmbH
 University of Saskatchewan
 Qiagen GmbH
- <120> TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES
- <130> C1041.70040WO00
- <150> US 60/412,479
- <151> 2002-09-19
- <160> 70
- <170> PatentIn version 3.1
- <210> 1
- <211> 1032
- <212> PRT
- <213> Rattus norvegicus
- <400> 1
- Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
 1 10 15
- Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30
- Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45
- Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn 50 55
- Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn 65 70 75 80
- Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
 85 90 95
- Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
 100 105 110
- Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu 115 120 125
- Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe

610 615 620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys 625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu 645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser 660 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn 675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn 740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Pro Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg 785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser 805 810 815

Arg Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Thr Val 820 825 830

Leu Pro Leu Gln His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe 835 840 845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Thr Arg Gly Arg Arg Ser 850 855

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln 865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu 885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp 900 905 910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr 915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Lys Val Ser 930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960

Asp Arg Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990

Leu Phe Trp Pro His Gln Pro Asn Gly Gln Gly Ser Phe Trp Ala Gln 995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg 1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu 1025 1030

<210> 2

<211> 821

<212> PRT

<213> Rattus norvegicus

<400> 2

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn 50 55 60

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn 65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 135 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala 145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro 180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 220

Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser 260 265 270

Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe 290 295 300

Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu 325 330 335

Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala 340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu 355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu 370 380

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala 405 410 415

Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr 420 425 430

Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val 435 440 445

Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser 450 455 460

Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu 465 470 480

Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495

Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala 500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp 515 520 525

Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu 530 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 555 560

Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser 575

Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val 580 585 590

Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly 595 600 605

Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe 610 620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys 635 630 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu 645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser 660 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn 675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn

725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn 740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Pro Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser 805 810 815

Arg Asp Cys Phe Gly 820

<210> 3

<211> 3099

<212> DNA

<213> Rattus norvegicus

<400> 3

atggttctct gtcgcaggac cctgcacccc ttgtctctcc tggtacaggc cgcagtgctg 60 gctgaggctc tggccctggg taccctgcct gccttcctac cctgtgaact gaagcctcat 120 ggcctggtag actgcaactg gctcttcctg aagtctgtgc ctcacttctc tgccgcagaa 180 ccccgttcca acatcaccag cctttccttg atcgccaacc gcatccacca cctgcacaac 240 ctcgactttg tccacctgcc caacgtgcga cagctgaacc tcaagtggaa ctgtccgccc 300 cctggcctca gccccttgca cttctcctgc cgcatgacca ttgagcccaa aaccttcctg 360 gctatgcgca tgctggaaga gctgaacctg agctataacg gtatcaccac tgtgccccgc 420 ctgcccagct ccctgacgaa tctgagccta agccacacca acatcctggt actcgatgcc 480 agcagcctcg ctggcctgca cagcctgcga gttctcttca tggacgggaa ctgctactac 540 aagaacccct gcaacgggc ggtgaacgtg accccggacg ccttcctggg cttgagcaac 600 ctcacccact tgtcccttaa gtataacaac ctcacagagg tgccccgcca actgccccc 660 agcctggagt acctcctgct gtcctataac ctcatcgtca agctgggggc cgaagaccta 720 gccaacctga cctcccttcg aatgcttgat gtgggtggga attgccgtcg ctgtgatcac 780

gcccccgacc tctgtacaga atgccggcag aagtcccttg atctgcaccc tcagactttc 840 900 catcacctga gccaccttga aggcctggtg ctgaaggaca gttctctcca ctcgctgaac tccaagtggt tccagggtct ggcgaacctc tcggtgctgg acctaagcga gaactttctc 960 tacgagagca tcaacaaaac cagcgccttt cagaacctga cccgtctgcg caagctcgac 1020 ctgtccttca attactgcaa gaaggtatcg ttcgcccgcc tccacctggc aagttccttc 1080 1140 aagagcetgg tgtcgctgca ggagctgaac atgaacggca tcttcttccg cttactcaac aagaacacgc tcaggtggct ggctggtctg cccaagctcc acacgctgca ccttcaaatg 1200 1260 aatttcatca accaggegea geteagegte tttagtacet teegageeet tegetttgtg gacctgtcca ataatcgcat cagcgggcct ccaacgctgt ccagagtcgc ccccgaaaag 1320 gcagacgagg cggagaaggg ggttccatgg cctgcaagtc tcaccccagc tctcccgagc 1380 actcccgtct caaagaactt catggtcagg tgtaagaacc tcagattcac catggacctg 1440 1500 tctcggaaca accaggtgac tatcaagcca gagatgttcg tcaacctctc ccatctccag 1560 tgtctgagcc tgagccacaa ctgcatcgcg caggctgtca atggctctca gttcctgccg 1620 ctgaccaacc tgaaggtgct ggacctgtcc tataacaagc tggacctgta ccattcgaaa 1680 tcgttcagtg agctcccaca gttgcaggcc ctggacctga gctacaacag ccagccattc agcatgcagg ggataggcca caacttcagt tttctggcca atctgtccag gttacagaac 1740 1800 cttagcctgg cacacaatga cattcacagc cgcgtgtcct cacgcctcta cagcacctca gtggagtatc tggacttcag cggcaacggt gtgggccgca tgtgggacga ggaggacctt 1860 tacctctatt tcttccaaga cctgagaagc ctgattcatc tggacctgtc tcagaataag 1920 ctgcacatcc tccggcccca gaacctcaac tacctcccca agagcctgac gaagctgagt ttccgtgaca atcacctctc tttctttaac tggagcagtc tggccttcct gcccaatctg 2040 2100 cgagacctgg acctggcagg caatctacta aaggccctga ccaacggcac cctgcctaat 2160 ggcacgetce tecagaaact ggatgteagt ageaacagta tegtetttgt ggteecagee ttctttgctc tggcggtaga gctaaaagag gtcaacctca gccataacat cctcaagact 2220 gtggatcgct cctggtttgg gcccattgtg atgaacctga cggttctaga cgtgagcagc 2280 2340 aaccetetge attgtgeetg eggtgeacce tttgtagaet tactgetgga agtgeagaee aaggtgcctg gcctggctaa cggtgtgaag tgtggcagtc cccgccagct gcagggccgc 2400 agcatctttg cgcaagacct gcggctgtgc ctggatgacg tcctttctcg ggactgcttt 2460 ggcctttcac tcctggctgt ggccgtgggc acggtgttgc ctttactgca gcatctctgc 2520 ggctgggacg tctggtactg tttccatctg tgcctggcat ggctaccttt gctgacccgt 2580

ggccggcgca gcgcccaagc tctcccttat gatgccttcg tggtgttcga taaggcgcag 2640 agcgcggttg ctgactgggt gtataacgag cttcgagtgc ggctagagga gcggcgcggt 2700 cgccgagccc tacgcttgtg tctggaggac cgagattggc tgcctggcca gacactcttc 2760 gagaacetet gggcetecat etatggeage egeaagaete tgtttgtget ggeceaeaeg 2820 gacaaggtca gtggcctcct gcgcaccagc ttcctgctgg ctcagcagcg cctgctggag 2880 2940 gaccgcaagg acgtggtggt gttggtgatc ctgcgccctg atgcccaccg ctcccgctac gtgcgactgc gccagcgcct ctgccgccag agtgtgctct tctggcccca tcagcccaac 3000 gggcagggca gcttctgggc ccagctgagt acagccctga ctagggacaa ccaccacttc 3060 tataaccgga acttctgccg gggacctaca gcagaatag 3099

<210> 4

<211> 2463

<212> DNA

<213> Rattus norvegicus

<400> 4 atggttctct gtcgcaggac cctgcacccc ttgtctctcc tggtacaggc cgcagtgctg 60 gctgaggctc tggccctggg taccctgcct gccttcctac cctgtgaact gaagcctcat 120 ggcctggtag actgcaactg gctcttcctg aagtctgtgc ctcacttctc tgccgcagaa 180 240 ccccgttcca acatcaccag cctttccttg atcgccaacc gcatccacca cctgcacaac 300 ctcgactttg tccacctgcc caacgtgcga cagctgaacc tcaagtggaa ctgtccgccc 360 cctggcctca gccccttgca cttctcctgc cgcatgacca ttgagcccaa aaccttcctg gctatgcgca tgctggaaga gctgaacctg agctataacg gtatcaccac tgtgccccgc ctgcccagct ccctgacgaa tctgagccta agccacacca acatcctggt actcgatgcc 480 agcagceteg etggeetgea cageetgega gttetettea tggaegggaa etgetaetae 540 aagaacccct gcaacgggc ggtgaacgtg accccggacg ccttcctggg cttgagcaac 600 ctcacccact tgtcccttaa gtataacaac ctcacagagg tgccccgcca actgccccc 660 agcctggagt acctcctgct gtcctataac ctcatcgtca agctgggggc cgaagaccta 720 gccaacctga cctcccttcg aatgcttgat gtgggtggga attgccgtcg ctgtgatcac 780 840 gcccccgacc tctgtacaga atgccggcag aagtcccttg atctgcaccc tcagactttc catcacctga gccaccttga aggcctggtg ctgaaggaca gttctctcca ctcgctgaac 900 960 tccaagtggt tccagggtct ggcgaacctc tcggtgctgg acctaagcga gaactttctc 1020 tacgagagca tcaacaaaac cagcgccttt cagaacctga cccgtctgcg caagctcgac

ctgtccttca	attactgcaa	gaaggtatcg	ttcgcccgcc	tccacctggc	aagttccttc	1080
aagagcctgg	tgtcgctgca	ggagctgaac	atgaacggca	tcttcttccg	cttactcaac	1140
aagaacacgc	tcaggtggct	ggctggtctg	cccaagctcc	acacgctgca	ccttcaaatg	1200
aatttcatca	accaggcgca	gctcagcgtc	tttagtacct	tccgagccct	tcgctttgtg	1260
gacctgtcca	ataatcgcat	cagcgggcct	ccaacgctgt	ccagagtcgc	ccccgaaaag	1320
gcagacgagg	cggagaaggg	ggttccatgg	cctgcaagtc	tcaccccagc	tctcccgagc	1380
actcccgtct	caaagaactt	catggtcagg	tgtaagaacc	tcagattcac	catggacctg	1440
tctcggaaca	accaggtgac	tatcaagcca	gagatgttcg	tcaacctctc	ccatctccag	1500
tgtctgagcc	tgagccacaa	ctgcatcgcg	caggctgtca	atggctctca	gttcctgccg	1560
ctgaccaacc	tgaaggtgct	ggacctgtcc	tataacaagc	tggacctgta	ccattcgaaa	1620
tcgttcagtg	agctcccaca	gttgcaggcc	ctggacctga	gctacaacag	ccagccattc	1680
agcatgcagg	ggataggcca	caacttcagt	tttctggcca	atctgtccag	gttacagaac	1740
cttagcctgg	cacacaatga	cattcacagc	cgcgtgtcct	cacgcctcta	cagcacctca	1800
gtggagtatc	tggacttcag	cggcaacggt	gtgggccgca	tgtgggacga	ggaggacctt	1860
tacctctatt	tcttccaaga	cctgagaagc	ctgattcatc	tggacctgtc	tcagaataag	1920
ctgcacatcc	tccggcccca	gaacctcaac	tacctcccca	agagcctgac	gaagctgagt	1980
ttccgtgaca	atcacctctc	tttctttaac	tggagcagtc	tggccttcct	gcccaatctg	2040
cgagacctgg	acctggcagg	caatctacta	aaggccctga	ccaacggcac	cctgcctaat	2100
ggcacgctcc	tccagaaact	ggatgtcagt	agcaacagta	tcgtctttgt	ggtcccagcc	2160
ttctttgctc	tggcggtaga	gctaaaagag	gtcaacctca	gccataacat	cctcaagact	2220
gtggatcgct	cctggtttgg	gcccattgtg	atgaacctga	cggttctaga	cgtgagcagc	2280
aaccctctgc	attgtgcctg	cggtgcaccc	tttgtagact	tactgctgga	agtgcagacc	2340
aaggtgcctg	gcctggctaa	cggtgtgaag	tgtggcagtc	cccgccagct	gcagggccgc	2400
agcatctttg	cgcaagacct	gcggctgtgc	ctggatgacg	tcctttctcg	ggactgcttt	2460
ggc						2463

<210> 5

<211> 1030

<212> PRT

<213> Sus scrofa

<400> 5

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val 1 5 10 15

Thr Ala Leu Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Ala Asn Val 50 55 60

Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr 100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr 145 150 155 160

His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly 180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu 210 225 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala 225 230 235

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn 395 400 Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg 485 490 495

Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn 500 505 510

Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser 515 520 525

His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro 530 540

Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met 545 550 555 560

Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu 565 570 575

Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln 580 585

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp 595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln 610 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His 625 630 635

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His
645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu 660 665 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu 675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg 690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe

705 710 715 720

Ala Leu Ala Lys Gln Leu Glu Glu Leu Asn Leu Ser Ala Asn Ala Leu 725 730 735

Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys
740 745 750

Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr 755 760 765

Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro 770 780

Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile
785 790 795 800

Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn 805 810 815

Cys Phe Gly Ile Ser Leu Leu Ala Met Ala Leu Gly Leu Val Val Pro 820 825 830

Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu 835 840 845

Cys Leu Ala Trp Leu Pro His Arg Gly Gln Arg Arg Gly Ala Asp Ala 850 855 860

Leu Phe Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val 865 870 875 880

Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg 885 890 895

Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro 900 905 910

Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg 915 920 925

Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu Leu 930 940

Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys 955 950

Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala Tyr Arg Ser Arg 965 970 975

Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp
980 985 990

Pro His Gln Pro Arg Gly Gln Gly Ser Phe Trp Ala Gln Leu Gly Thr 995 1000 1005

Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg Asn Phe Cys
1010 1015 1020

Arg Gly Pro Thr Thr Ala Glu 1025 1030

<210> 6

<211> 819

<212> PRT

<213> Sus scrofa

<400> 6

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val 1 5 10 15

Thr Ala Leu Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu 20, 30

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr 100 105 110

- 17 -

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr 145 150 155 160

His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu 210 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro 260 265 270

Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg 290 295 300

Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315

Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg 325 330 335

Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu 355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln 370 380

Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu 405 410 415

Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro 420 425 430

Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro 435 440 445

Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp 450 460

Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg 465 470 475 480

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg 485 490 495

Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn 500 505 510

Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser 515 520 525

His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro 530 540

Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met 545 550 555 560

Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu 565 570 575

Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln 580 585 590

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp 595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln 610 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His 625 630 635 640

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His
645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu 660 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu 675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg 690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe 705 710 715 720

Ala Leu Ala Lys Gln Leu Glu Glu Leu Asn Leu Ser Ala Asn Ala Leu
725 730 735

Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys 740 745 750

Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr 755 760 765

Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro 770 780

Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile 785 790 795 800

Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn 805 810 815

Cys Phe Gly

<210> <211> 3352

DNA <213> Sus scrofa

<400>

<212.>

gagcacgaac atccttcact gtagctgctg cccggtctgc cagccagacc ctttggagaa 60 gaccccactc cctgtcatgg gcccccgctg caccctgcac cccctttctc tcctggtgca 120 ggtgacagcg ctggctgcgg ctctggccca gggcaggctg cctgccttcc tgccctgtga 180 240 gctccagccc cacggcctgg tgaactgcaa ctggctcttc ctgaagtccg tgcccactt cteggeggea gegeeeggg ceaacgteae eageetetee ttaeteteea acegeateea 300 ccacctgcac gactccgact tcgtccacct gtccagccta cgaactctca acctcaagtg 360 gaactgcccg ccggctggcc tcagccccat gcacttcccc tgccacatga ccatcgagcc 420 caacacette etggeegtge ceaccetgga ggagetgaac etgagetaca acageateae 480 gaccgtgcct gccctgcccg actccctcgt gtccctgtcg ctgagccgca ccaacatcct 540 600 ggtgctagac cccacccacc tcactggcct acatgccctg cgctacctgt acatggatgg caactgctac tacaagaacc cctgccaggg ggcgctggag gtggtgccgg gtgccctcct 660 720 eggeetggge aaceteacae ateteteact caagtacaae aateteacgg aggtgeeceg 780 cagcetgeee eccageetgg agaceetget gttgteetae aaceaeattg teaceetgae gcctgaggac ctggccaatc tgactgccct gcgcgtgctt gatgtggggg ggaactgccg 840 900 ccgctgtgac catgcccgca acccctgcag ggagtgccca aaggaccacc ccaagctgca ctctgacacc ttcagccacc tgagccgcct cgaaggcctg gtgttgaaag acagttctct 960 ctacaacctg gacaccaggt ggttccgagg cctggacagg ctccaagtgc tggacctgag 1020 1080 tgagaacttc ctctacgact gcatcaccaa gaccacggcc ttccagggcc tggcccgact gcgcagcctc aacctgtcct tcaattacca caagaaggtg tcctttgccc acctgcacct 1140 1200 ggcaccctcc tttgggcacc tccggtccct gaaggagctg gacatgcatg gcatcttctt ccgctcgctc agtgagacca cgctccaacc tctggtccaa ctgcctatgc tccagaccct 1260 gcgcctgcag atgaacttca ttaaccaggc ccagctcagc atctttgggg ccttccctgg 1320 1380 cctgctgtac gtggacctat cggacaaccg catcagcgga gctgcaaggc cagtggccat tactagggag gtggatggta gggagagggt ctggctgcct tccaggaacc tcgctccacg 1440 1500 tccactggac actctccgct cagaggactt catgccaaac tgcaaggcct tcagcttcac

cttggacctg tctcggaaca acctggtgac aatccagtcg gagatgtttg ctcgcctctc 1560 acgcctcgag tgcctgcgcc tgagccacaa cagcatctcc caggcggtca atggctctca 1620 gtttgtgccg ctgaccagcc tgcgggtgct ggacctgtcc cacaacaagc tggacctgta 1680 tcacgggcgc tcgttcacgg agctgccgcg cctggaagca ctggacctca gctacaatag 1740 1800 ccagcccttt accatgcagg gtgtgggcca caacctcagc ttcgtggccc agctgcccgc 1860 cctgcgctac ctcagcctgg cgcacaatga catccatagc cgagtgtccc agcagctctg 1920 tagcgcctca ctgtgcgccc tggactttag cggcaacgat ctgagccgga tgtgggctga gggagacctc tatctccgct tcttccaagg cctaagaagc ctagtctggc tggacctgtc 1980 ccagaaccac ctgcacaccc tcctgccacg tgccctggac aacctcccca aaagcctgaa 2040 gcatctgcat ctccgtgaca ataacctggc cttcttcaac tggagcagcc tgaccctcct 2100 gcccaagctg gaaaccctgg acttggctgg aaaccagctg aaggccctaa gcaatggcag 2160 cctgccatct ggcacccagc tgcggaggct ggacctcagt ggcaacagca tcggctttgt 2220 gaaccctggc ttctttgccc tggccaagca gttagaagag ctcaacctca gcgccaatgc 2280 cctcaagaca gtggagccct cctggtttgg ctcgatggtg ggcaacctga aagtcctaga 2340 cgtgagcgcc aaccctctgc actgtgcctg tggggcgacc ttcgtgggct tcctgctgga 2400 ggtacaggct gccgtgcctg ggctgcccag ccgcgtcaag tgtggcagtc cggggcagct 2460 2520 ccagggccat agcatctttg cgcaagacct gcgcctctgc ctggatgaga ccctctcgtg gaactgtttt ggcatctcgc tgctggccat ggccctgggc ctggttgtgc ccatgctgca 2580 ccacctctgc ggctgggacc tctggtactg cttccacctg tgcctggcct ggctgccca 2640 ccgagggcag cggcggggcg cagacgccct gttctatgat gccttcgtgg tctttgacaa ageteagagt getgtggeeg aetgggtgta caaegagetg egggtgeage tggaggageg 2760 ccgtgggcgc cgcgcactgc gcctgtgcct ggaggagcga gactggttac ctggcaagac 2820 getettegag aacetgtggg ceteagteta cageageege aagaeeetgt ttgtgetgge 2880 ccacacggac cgtgtcagcg gcctcttgcg tgccagtttc ctgctggccc agcagcgcct 2940 getggaggae egeaaggaeg ttgtagtget ggtgateetg egeeegatg eetaeegete 3000 ccgctacgtg cggctgcgcc agcgcctctg ccgccagagt gtcctcctct ggccccacca 3060 gccccgtggg cagggcagct tctgggccca gctgggcaca gccctgacca gggacaacca 3120 ccacttctat aaccggaact tctgccgggg ccccacgaca gccgaatagc actgagtgac 3180 ageceagttg ecceagece cetggatttg cetetetgee tggggtgeec caacetgett 3240 tgctcagcca caccactgct ctgctccctg ttccccaccc cacccccag cctggcatgt 3300 -

aacatgtgcc caataaatgc taccggaggg ccaagaaaaa aaaaaaaa aa 3352 <210> 8 <211> 2457 <212> DNA <213> Sus scrofa <400> 8 atgggccccc gctgcaccct gcaccccctt tctctcctgg tgcaggtgac agcgctggct 60 gcggctctgg cccagggcag gctgcctgcc ttcctgccct gtgagctcca gccccacggc 120 ctggtgaact gcaactggct cttcctgaag tccgtgcccc acttctcggc ggcagcgccc 180 cgggccaacg tcaccagcct ctccttactc tccaaccgca tccaccacct gcacgactcc 240 gacttcgtcc acctgtccag cctacgaact ctcaacctca agtggaactg cccgccggct 300 ggcctcagcc ccatgcactt cccctgccac atgaccatcg agcccaacac cttcctggcc 360 gtgcccaccc tggaggagct gaacctgagc tacaacagca tcacgaccgt gcctgccctg 420 cccgactccc tcgtgtccct gtcgctgagc cgcaccaaca tcctggtgct agaccccacc 480 cacctcactg gcctacatgc cctgcgctac ctgtacatgg atggcaactg ctactacaag 540 aacccctgcc agggggcgct ggaggtggtg `ccgggtgccc tcctcggcct gggcaacctc 600 acacatetet caeteaagta caacaatete acggaggtge ceegcageet geeceecage 660 ctggagaccc tgctgttgtc ctacaaccac attgtcaccc tgacgcctga ggacctggcc 720 aatctgactg ccctgcgcgt gcttgatgtg ggggggaact gccgccgctg tgaccatgcc 780 cgcaacccct gcagggagtg cccaaaggac caccccaagc tgcactctga caccttcagc 840 cacctgagcc gcctcgaagg cctggtgttg aaagacagtt ctctctacaa cctggacacc 900 aggtggttcc gaggcctgga caggctccaa gtgctggacc tgagtgagaa cttcctctac 960 gactgcatca ccaagaccac ggccttccag ggcctggccc gactgcgcag cctcaacctg 1020 tccttcaatt accacaagaa ggtgtccttt gcccacctgc acctggcacc ctcctttggg 1080 cacctccggt ccctgaagga gctggacatg catggcatct tcttccgctc gctcagtgag 1140 accacgctcc aacctctggt ccaactgcct atgctccaga ccctgcgcct gcagatgaac 1200 ttcattaacc aggcccagct cagcatcttt ggggccttcc ctggcctgct gtacgtggac 1260 ctatcggaca accgcatcag cggagctgca aggccagtgg ccattactag ggaggtggat 1320 ggtagggaga gggtctggct gccttccagg aacctcgctc cacgtccact ggacactctc 1380 cgctcagagg acttcatgcc aaactgcaag gccttcagct tcaccttgga cctgtctcgg 1440 aacaacctgg tgacaatcca gtcggagatg tttgctcgcc tctcacgcct cgagtgcctg 1500

cgcctgagcc acaacagcat ctcccaggcg gtcaatggct ctcagtttgt gccgctgacc 1560 agcctgcggg tgctggacct gtcccacaac aagctggacc tgtatcacgg gcgctcgttc 1620 acggagetge egegeetgga ageaetggae etcagetaca atagecagee etttaceatg 1680 cagggtgtgg gccacaacct cagcttcgtg gcccagctgc ccgccctgcg ctacctcagc 1740 ctggcgcaca atgacatcca tagccgagtg tcccagcagc tctgtagcgc ctcactgtgc 1800 gccctggact ttagcggcaa cgatctgagc cggatgtggg ctgagggaga cctctatctc 1860 1920 cgcttcttcc aaggcctaag aagcctagtc tggctggacc tgtcccagaa ccacctgcac accetectge caegtgeect ggacaacete eccaaaagee tgaageatet geateteegt 1980 gacaataacc tggccttctt caactggagc agcctgaccc tcctgcccaa gctggaaacc 2040 ctggacttgg ctggaaacca gctgaaggcc ctaagcaatg gcagcctgcc atctggcacc 2100 cagctgcgga ggctggacct cagtggcaac agcatcggct ttgtgaaccc tggcttcttt 2160 gccctggcca agcagttaga agagctcaac ctcagcgcca atgccctcaa gacagtggag 2220 ccctcctggt ttggctcgat ggtgggcaac ctgaaagtcc tagacgtgag cgccaaccct 2280 ctgcactgtg cctgtggggc gaccttcgtg ggcttcctgc tggaggtaca ggctgccgtg 2340 cctgggctgc ccagccgcgt caagtgtggc agtccggggc agctccaggg ccatagcatc 2400 tttgcgcaag acctgcgcct ctgcctggat gagaccctct cgtggaactg ttttggc 2457

<210> 9

<211> 1029

<212> PRT

<213> Bos taurus

<400> 9

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala 1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Glu Gly Thr Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro His Gly Gln Val Asp Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50 55

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 , 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr

305					310					315					320
Asp	Tyr	Ile	Thr	Lys 325	Thr	Thr	Ile	Phe	Asn 330	Asp	Leu	Thr	Gln	Leu 335	Arg
Arg	Leu	Asn	Leu 340	Ser	Phe	Asn	Tyr	His 345	Lys	Lys	Val	Ser	Phe 350	Ala	His
Leu	His	Leu 355	Ala	Ser	Ser	Phe	Gly 360	Ser	Leu	Val	Ser	Leu 365	Glu	Lys	Leu
Asp	Met 370	His	Gly	Ile	Phe	Phe 375	Arg	Ser	Leu	Thr	Asn 380	Ile	Thr	Leu	Gln
'Ser 385	Leu	Thr	Arg	Leu	Pro 390	ГЛЗ	Leu	Gln	Ser	Leu 395	His	Leu	Gln	Leu	Asn 400
Phe	Ile	Asn	Gln	Ala 405	Gln	Leu	Ser	Ile	Phe 410	Gly	Ala	Phe	Pro	Ser 415	Leu
Leu	Phe	Val	Asp 420	Leu	Ser	Asp	Asn	Arg 425	Ile	Ser	Gly	Ala	Ala 430	Thr	Pro
Ala	Ala	Ala 435	Leu	Gly	Glu	Val	Asp 440	Ser	Arg	Val	Glu	Val 445	Trp	Arg	Leu
Pro	Arg 450	Gly	Leu	Ala	Pro	Gly 455	Pro	Leu	Asp	Ala	Val 460	Ser	Ser	ГЛЗ	Asp
Phe 465	Met	Pro	Ser	Сув	Asn 470	Leu	Asn	Phe	Thr	Leu 475	Asp	Leu	Ser	Arg	Asn 480
Asn	Leu	Val	Thr	Ile 485	Gln	Gln	Glu	Met	Phe 490		Arg	Leu	Ser	Arg 495	Leu
Gln	Cys	Leu	Arg 500	Leu	Ser	His	Asn	Ser 505		Ser	Gln	Ala	Val 510	Asn	Gly
Ser	Gln	Phe 515		Pro	Leu	Thr	Ser 520	Leu	Arg	Val	Leu	Asp 525		Ser	His
Asn	Lys	Leu	Asp	Leu	Tyr	His	Gly	Arg	Ser	Phe	Thr	Glu	Leu	Pro	Gln

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Ile Arg Leu Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Gly Phe Val Ile Pro Gly Phe Phe Val Arg Ala Thr Arg Leu Ile Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys Thr Val Asp Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu Lys Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe

755 760 765

Val Asp Phe Leu Leu Glu Arg Gln Glu Ala Val Pro Gly Leu Ser Arg
770 780

-.27 -

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Thr Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys 805 810 815

Phe Gly Leu Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met 820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys 835 840 845

Leu Ala His Leu Pro Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu 850 855 860

Leu Tyr Asp Ala Val Val Val Phe Asp Lys Val Gln Ser Ala Val Ala 865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly 900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys 915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg 930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp 945 950 955 960

Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr 965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro 980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Ile Ala 995 1000 1005

Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg 1010 1020

Gly Pro Thr Thr Ala Glu 1025

<210> 10

<211> 818

<212> PRT

<213> Bos taurus

<400> 10

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala 1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Glu Gly Thr Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro His Gly Gln Val Asp Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr 100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly 180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315 320

Asp Tyr Ile Thr Lys Thr Thr Ile Phe Asn Asp Leu Thr Gln Leu Arg 325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

Leu His Leu Ala Ser Ser Phe Gly Ser Leu Val Ser Leu Glu Lys Leu 355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Ile Thr Leu Gln 370 380

Ser Leu Thr Arg Leu Pro Lys Leu Gln Ser Leu His Leu Gln Leu Asn 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu 405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Thr Pro

420 425 430

Ala Ala Leu Gly Glu Val Asp Ser Arg Val Glu Val Trp Arg Leu 435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Asp Ala Val Ser Ser Lys Asp 450 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn 465 470 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu 485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser His 515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln 530 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys 580 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu 595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly 610 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr 625 630 635

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu 650 655

Arg	Leu	Arg	Asp 660	Asn	Asn	Leu	Ala	Phe 665	Phe	Asn	Trp	Ser	Ser 670	Leu	Thr		
Val	Leu	Pro 675	Arg	Leu	Glu	Ala	Leu 680	Asp	Leu	Ala	Gly	Asn 685	Gln	Leu	Lys		
Ala	Leu 690	Ser	Asn	Gly	Ser	Leu 695	Pro	Pro	Gly	Ile	Arg 700	Leu	Gln	Lys	Leu		
Asp 705	Val	Ser	Ser	Asn	Ser 710	Ile	Gly	Phe	Val	Ile 715	Pro	Gly	Phe	Phe	Val 720		
Arg	Ala	Thr	Arg	Leu 725	Ile	Glu	Leu	Asn	Leu 730	Ser	Ala	Asn	Ala	Leu 735	Lys		
Thr	Val	Asp	Pro 740	Ser	Trp	Phe	Gly	Ser 745	Leu	Ala	Gly	Thr	Leu 750	Lys	Ile	<u>.</u>	
Leu	Asp	Val 755	Ser	Ala	Asn	Pro	Leu 760	His	Cys	Ala	Cys	Gly 765	Ala	Ala	Phe		
Val	Asp 770	Phe	Leu	Leu	Glu	Arg 775	Gln	Glu	Ala	Val	Pro 780	Gly	Leu	Ser	Arg		
Arg 785	Val	Thr	Cys	Gly	Ser 790	Pro	Gly	Gln	Leu	Gln 795	Gly	Arg	Ser	Ile	Phe 800		
Thr	Gln	Asp	Leu	Arg 805	Leu	Cys	Leu	Asp	Glu 810	Thr	Leu	Ser	Leu	Asp 815	Cys		
Phe	Gly																
<210 <211 <212 <213	L> 3 2> E	.1 8191 NA Bos t	auru	ıs													
)> 1																
															accct		60
															tata		120
															cctgo		180
									•						tgtgd		240
cgca		ice g	gerg	gage	.c cc	cegg	ycca	atg	ccac	cag	cctc	ccct	ca a	tctc	caaco	3	300

360 gcatccacca cttgcatgac tctgacttcg tccacctgtc caacctgcgg gtcctcaacc tcaagtggaa ctgcccgccg gccggcctca gccccatgca cttcccctgc cgtatgacca 420 tcgagcccaa caccttcctg gctgtgccca ccctggagga gctgaacctg agctacaacg 480 gcatcacgac cgtgcctgcc ctgcccagtt ccctcgtgtc cctgtcgctg agccacacca 540 gcatcctggt gctaggcccc acccacttca ccggcctgca cgccctgcgc tttctgtaca 600 tggacggcaa ctgctactac atgaacccct gcccgcgggc cctggaggtg gccccaggcg 660 720 ccctcctcgg cctgggcaac ctcacgcacc tgtcgctcaa gtacaacaac ctcacggagg 780 tgccccgccg cctgccccc agcctggaca ccctgctgct gtcctacaac cacattgtca ecetggeace egaggacetg gecaacetga etgecetgeg egtgettgae gtgggtggga 840 actgeegeeg etgegaeeat geeegeaace eetgeaggga gtgeecaaag aactteecea 900 agctgcaccc tgacaccttc agtcacctga gccgcctcga aggcctggtg ttgaaggaca 960 1020 gttctctcta caaactagag aaagattggt tccgcggcct gggcaggctc caagtgctcg acctgagtga gaacttcctc tatgactaca tcaccaagac caccatcttc aacgacctga 1080 cccagctgcg cagactcaac ctgtccttca attaccacaa gaaggtgtcc ttcgcccacc 1140 tgcacctagc gtcctccttt gggagtctgg tgtccctgga gaagctggac atgcacggca 1200 tettetteeg eteceteace aacateaege teeagteget gaceeggetg eccaagetee 1260 agagtctgca tctgcagctg aacttcatca accaggccca gctcagcatc tttggggcct 1320 tecegageet getettegtg gaeetgtegg acaacegeat cageggagee gegaegeeag 1380 cggccgccct gggggaggtg gacagcaggg tggaagtctg gcgattgccc aggggcctcg 1440 1500 ctccaggccc gctggacgcc gtcagctcaa aggacttcat gccaagctgc aacctcaact 1560 tcaccttgga cctgtcacgg aacaacctgg tgacaatcca gcaagagatg tttacccgcc tetecegeet ceagtgeetg egeetgagee acaacageat etegeaggeg gttaatgget 1620 cccagttcgt gccgctgacc agcctgcgag tgctcgacct gtcccacaac aagctggacc 1680 tgtaccatgg gcgctcattc acggagctgc cgcagctgga ggcactggac ctcagctaca 1740 1800 acagecagee etteageatg cagggegtgg gecaeaacet cagettegtg geceagetge 1860 cctccctgcg ctacctcagc cttgcgcaca atggcatcca cagccgcgtg tcacagaagc 1920 tcagcagcgc ctcgttgcgc gccctggact tcagcggcaa ctccctgagc cagatgtggg 1980 ccgagggaga cctctatctc tgctttttca aaggcttgag gaacctggtc cagctggacc tgtccgagaa ccatctgcac accetcctgc ctcgtcacct ggacaacctg cccaagagcc 2040

tgcggcagct gcgtctccg	g gacaataacc	tggccttctt	caactggagc	agcctgaccg	2100
tcctgccccg gctggaagc	c ctggatctgg	caggaaacca	gctgaaggcc	ctgagcaacg	2160
gcagcctgcc gcctggcat	c cggctccaga	agctggacgt	gagcagcaac	agcatcggct	2220
tcgtgatccc cggcttctt	c gtccgcgcga	ctcggctgat	agagcttaac	ctcagcgcca	2280
atgccctgaa gacagtgga	ccctcctggt	tcggttcctt	agcagggacc	ctgaaaatcc	2340
tagacgtgag cgccaaccc	g ctccactgcg	cctgcggggc	ggcctttgtg	gacttcctgc	2400
tggagagaca ggaggccgt	g cccgggctgt	ccaggcgcgt	cacatgtggc	agtccgggcc	2460
agctccaggg ccgcagcat	c ttcacacagg	acctgcgcct	ctgcctggat	gagaccctct	2520
ccttggactg ctttggcct	c tcactgctaa	tggtggcgct	gggcctggca	gtgcccatgc	2580
tgcaccacct ctgtggctg	g gacctctggt	actgcttcca	cctgtgtctg	gcccatttgc	2640
cccgacggcg gcggcagcg	g ggcgaggaca	ccctgctcta	tgatgccgtc	gtggtcttcg	2700
acaaggtgca gagtgcagt	g gctgattggg	tgtacaacga	gctccgcgtg	cagctggagg	2760
agcgccgggg gcgccgggc	g ctccgcctct	gcctggagga	gcgagactgg	ctccctggta	2820
agacgctctt cgagaacct	g tgggcctcgg	tctacagcag	ccgcaagacc	atgttcgtgc	2880
tggaccacac ggaccgggt	c agcggcctcc	tgcgcgccag	cttcctgctg	gcccagcagc	2940
gcctgttgga ggaccgcaa	g gacgtcgtag	tgctggtgat	cctgcgcccc	gccgcctatc	3000
ggtcccgcta cgtgcggct	g cgccagcgcc	tctgccgcca	gagcgtcctc	ctctggcccc	3060
accagcccag tggccaggg	t agtttctggg	ccaacctggg	catagecetg	accagggaca	3120
accgtcactt ctataaccg	g aacttctgcc	ggggccccac	gacagccgaa	tagcacagag	3180
tgactgccca g					3191

<210> 12

<211> 2454

<212> DNA

<213> Bos taurus

<400> 12

atgggccct actgtgccc gcacccctt tctctctgg tgcaggcggc ggcactggca 60 gcggccctgg ccgagggcac cctgcctgcc ttcctgcct gtgagctcca gccccatggt 120 caggtggact gcaactggct gttcctgaag tctgtgccgc acttttcggc tggagccccc 180 cgggccaatg tcaccagcct ctccttaatc tccaaccgca tccaccactt gcatgactct 240 gacttcgtcc acctgtccaa cctgcggtc ctcaacctca agtggaactg cccgccggcc 300 ggcctcagcc ccatgcactt cccctgccgt atgaccatcg agcccaacac cttcctggct 360

420 gtgcccaccc tggaggagct gaacctgagc tacaacggca tcacgaccgt gcctgccctg cccagttccc tcgtgtccct gtcgctgagc cacaccagca tcctggtgct aggccccacc 480 cacttcaccg gcctgcacgc cctgcgcttt ctgtacatgg acggcaactg ctactacatg 540 aaccectgee egegggeet ggaggtggee ceaggegeee teeteggeet gggeaacete 600 acgcacctgt cgctcaagta caacaacctc acggaggtgc cccgccgcct gcccccagc 660 ctggacaccc tgctgctgtc ctacaaccac attgtcaccc tggcacccga ggacctggcc 720 aacctgactg ccctgcgcgt gcttgacgtg ggtgggaact gccgccgctg cgaccatgcc 780 840 cgcaacccct gcagggagtg cccaaagaac ttccccaagc tgcaccctga caccttcagt 900 cacctgagcc gcctcgaagg cctggtgttg aaggacagtt ctctctacaa actagagaaa gattggttcc gcggcctggg caggctccaa gtgctcgacc tgagtgagaa cttcctctat 960 gactacatca ccaagaccac catcttcaac gacctgaccc agctgcgcag actcaacctg 1020 teetteaatt accaeaagaa ggtgteette geceaeetge acctagegte eteetttggg 1080 agtctggtgt ccctggagaa gctggacatg cacggcatct tcttccgctc cctcaccaac 1140 atcacgetee agtegetgae eeggetgeee aageteeaga gtetgeatet geagetgaae 1200 ttcatcaacc aggcccagct cagcatcttt ggggccttcc cgagcctgct cttcgtggac 1260 ctgtcggaca accgcatcag cggagccgcg acgccagcgg ccgccctggg ggaggtggac 1320 1380 agcagggtgg aagtctggcg attgcccagg ggcctcgctc caggcccgct ggacgccgtc ageteaaagg actteatgee aagetgeaae eteaaettea eettggaeet gteaeggaae 1440 aacctggtga caatccagca agagatgttt acccgcctct cccgcctcca gtgcctgcgc 1500 ctgagccaca acagcatete geaggeggtt aatggeteee agttegtgee getgaecage ctgcgagtgc tcgacctgtc ccacaacaag ctggacctgt accatgggcg ctcattcacg 1620 gagetgeege agetggagge actggacete agetacaaca gecageeett cageatgeag 1680 ggcgtgggcc acaacctcag cttcgtggcc cagctgccct ccctgcgcta cctcagcctt 1740 gcgcacaatg gcatccacag ccgcgtgtca cagaagctca gcagcgcctc gttgcgcgcc 1800 ctggacttca gcggcaactc cctgagccag atgtgggccg agggagacct ctatctctgc 1860 tttttcaaag gcttgaggaa cctggtccag ctggacctgt ccgagaacca tctgcacacc 1920 ctcctgcctc gtcacctgga caacctgccc aagagcctgc ggcagctgcg tctccgggac 1980 aataacctgg ccttcttcaa ctggagcagc ctgaccgtcc tgccccggct ggaagccctg 2040 gatctggcag gaaaccagct gaaggccctg agcaacggca gcctgccgcc tggcatccgg 2100 ctccagaagc tggacgtgag cagcaacagc atcggcttcg tgatccccgg cttcttcgtc 2160

cgcgcgactc ggctgataga gcttaacctc agcgccaatg ccctgaagac agtggatccc 2220
tcctggttcg gttccttagc agggaccctg aaaatcctag acgtgagcgc caacccgctc 2280
cactgcgcct gcggggcggc ctttgtggac ttcctgctgg agagacagga ggccgtgccc 2340
gggctgtcca ggcgcgtcac atgtggcagt ccgggccagc tccagggccg cagcatcttc 2400
acacaggacc tgcgcctctg cctggatgag accctctcct tggactgctt tggc 2454

<210> 13

<211> 1031

<212> PRT

<213> Equus caballus

<400> 13

Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 . 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Asp Asn 50 55 60

Val Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro 145 150 155 160 Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro 180 185 190

Gly Ala Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe 260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe 290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu 370 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met 385 390 395 400

•

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser 550 · 555 Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu

His Thr Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln 645 650 655

Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 660 670

Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln 675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln 690 700

Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe 705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 735

Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu 740 745 750

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp 805 810 815

Asp Cys Phe Gly Leu Ser Leu Leu Val Val Ala Leu Gly Leu Ala Met 820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His 835 840 845

Leu Gly Leu Ala Trp Leu Pro Arg Arg Gly Trp Gln Arg Gly Ala Asp 850 855

Ala Leu Ser Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala

865 870 875 880

Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg 885 890 895

Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu 900 905 910

Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser 915 920 925

Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Gln Val Ser Gly Leu 930 940

Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg 945 950 955 960

Lys Asp Val Val Leu Val Ile Leu Ser Pro Asp Ala Arg Arg Ser 970 975

Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Phe 980 985 990

Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly 995 1000 1005

Met Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln Asn Phe 1010 1015 1020

Cys Arg Gly Pro Thr Met Ala Glu 1025 1030

<210> 14

<211> 820

<212> PRT

<213> Equus caballus

<400> 14

Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu

WO 2004/026888

35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Asp Asn 50 55 60

PCT/US2003/029577

Val Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp 70 75 80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 . 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro 145 150 155 160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro 180 185 190

Gly Ala Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe 260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe 290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu 370 375 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly 405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu 420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu 435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu 450 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser 465 470 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser 485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val 500 505 510

- 42 -

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 660 665 670 Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp 805 810 815

Asp Cys Phe Gly 820

<210> 15

<211> 3391

<212> DNA

<213> Equus caballus

<400> ctctgttctc tgagctgttg ccgcgtgaag ggactgcgag cacaaagcat cctcctctgc 60 agctgctgcc cagtgtgcca gctggaccct ctggatcatc tcccactccc tgtcatgggc 120 ccttgccatg gtgccctgca gcccctgtct ctcctggtgc aggcggccat gctggccgtg 180 gctctggccc aaggcaccct gcctcccttc ctgccctgtg agctccagcc ccacggcctg 240 gtgaactgca actggctgtt cctgaagtcc gtgccccact tctcagcagc agcacccgg 300 gacaatgtca ccagcctttc cttgctctcc aaccgcatcc accacctcca cgactccgac 360 tttgcccaac tgtccaacct gcagaaactc aacctcaaat ggaactgccc gccagccggc 420 ctcagcccca tgcacttccc ctgccacatg accatcgagc ccaacacttt cctggctgta 480 540 ageteceteg tgtecetgat cetgageege accaacatee tgcagetaga ecceaceage 600 ctcacgggcc tgcatgccct gcgcttccta tacatggatg gcaactgcta ctacaagaac 660 ccctgcgggc gggccctgga ggtggcccca ggcgccctcc ttggcctggg caacctcacc 720 cacctgtcac tcaagtacaa caacctcaca acggtgcccc gcagcctgcc ccctagcctg 780 gagtacctgc tgttgtccta caaccacatt gtcaccctgg cacctgagga cctggccaat 840 ctgactgccc tgcgtgtgct cgatgtgggt ggaaactgcc gccgctgtga ccatgcacgc 900 aacccctgcg tggagtgccc acataaattc ccccagctgc actccgacac cttcagccac 960

ctaagccgcc tagaaggcct cgtgttgaag gatagttctc tctaccagct gaaccccaga 1020 tggttccgtg gcctgggcaa cctcacagtg ctcgacctga gtgagaactt cctctacgac 1080 tgcatcacca aaaccaaggc attccagggc ctggcccagc tgcgaagact caacttgtcc 1140 1200 ttcaattacc ataagaaggt gtccttcgcc cacctgacgc tggcaccctc cttcgggagc ctgctctccc tgcaggaact ggacatgcat ggcatcttct tccgctcact cagccagaag 1260 acgctccagc cactggcccg cctgcccatg ctccagcgtc tgtatctgca gatgaacttc 1320 atcaaccagg cccagctcgg catcttcaag gacttccctg gtctgcgcta catagacctg 1380 tcagacaacc gcatcagtgg agctgtggag ccggtggcca ccacagggga ggtggatggt 1440 gggaagaagg tctggctgac atccagggac ctcactccag gcccactgga cacccccagc 1500 tctgaggact tcatgccaag ctgcaagaac ctcagcttca ccttggacct gtcacggaac 1560 aacctggtaa cagtccagcc agagatgttt gcccagctct cgcgcctcca gtgcctgcgc 1620 ctgagccaca acagcatete geaggeggte aatggeteae agttegtgee actgaecage 1680 ctgcaggtgc tggacctgtc ccataacaaa ctggacctgt accatgggcg ctcgtttacg 1740 1800 gagetgeege gaetggagge cetggaeete agetacaaca gecageeett cageatgegg ggtgtgggcc acaacctcag ctttgtggcc cagctgccca ccctgcgcta cctcagcctg 1860 1920 gcacacaatg gcatccacag ccgtgtgtcc cagcagctct gcagcacctc gctgtgggcc 1980 ctggacttca gcggcaattc cctgagccag atgtgggctg agggagacct ctatctccgc ttcttccaag gcctgagaag cctaatccgg ctagacctgt cccagaatcg tctgcatacc 2040 ctcctgccat gcaccctggg caacctcccc aagagcttgc agctgctgcg tctccgtaac 2100 2160 aattacctgg ccttcttcaa ttggagcagc ctgaccctcc tgcccaacct ggaaaccctg gacctggctg gaaaccagct gaaggctctg agcaatggca gcctgccttc tggcacccag 2220 2280 ctccagaggc tggacgtcag caggaacagc atcatcttcg tggtccctgg cttctttgct 2340 ctggccacga ggctgcgaga gctcaacctc agtgccaacg ccctcaggac agaggagccc teetggtttg gttteetage aggeteeett gaagteetag atgtgagege caaccetetg 2400 cactgcgcct gtggggcagc ctttgtggac ttcctgctgc aggttcaggc tgccgtgcct 2460 2520 ggtctgccca gccgcgtcaa gtgtggcagt ccgggccagc tccagggccg cagcatcttc gcacaagacc tgcgcctctg cctggacaag tccctctcct gggactgttt tggtctctca 2580 ttgctggttg tggccctggg cctggccatg cctatgttgc accacctctg cggctgggac 2640 2700 ctctggtact gcttccacct gggcctggcc tggctgcccc ggcgggggtg gcagcggggc

geggatgeee tgagetatga tgeetttgtg gtettegaea aggeaeagag egeagtggee 2760 gactgggtgt acaatgaact gcgggtgcgg ctagaggagc gccgtgggcg ccgggcgctc 2820 cgcctgtgtc tggaggagcg tgactggcta cctggcaaga cgctgttcga aaacctgtgg 2880 gcctcagtct acagcagccg caagatgctg tttgtgctgg cccacacgga ccaggtcagt 2940 ggcctcttgc gtgccagctt cctgctggcc cagcagcgtc tgctggagga ccgcaaggac 3000 gttgtggtgc tggtaatcct gagccctgac gcccgccgtt cccgttacgt gcggctgcgc 3060 cagcgcctct gccgccagag tgtcctcttc tggccccacc agcctagtgg ccagcgcagc 3120 ttctgggccc agctaggcat ggccctgacc agggacaacc gccacttcta taaccagaac 3180 ttctgccggg gcccgacgat ggctgagtag cacagagtga cagcctggca tgtacaaccc 3240 ccagccctga ccttgcctct ctgcctatga tgcccagtct gcctcactct gtgacgcccc 3300 tgctctgcct ccgccaccct caccctggc atacagcagg cactcaataa atgccactgg 3360 3391 caggccaaac agccaaaaaa aaaaaaaaaa a

<210> 16

<211> 2460

<212> DNA

<213> Equus caballus

<400> 16

atgggccctt gccatggtgc cctgcagccc ctgtctctcc tggtgcaggc ggccatgctg 60 120 geegtggete tggcccaagg caccetgeet ceetteetge cetgtgaget ceageeceae ggcctggtga actgcaactg gctgttcctg aagtccgtgc cccacttctc agcagcagca 180 ccccgggaca atgtcaccag cctttccttg ctctccaacc gcatccacca cctccacgac 240 tccgactttg cccaactgtc caacctgcag aaactcaacc tcaaatggaa ctgcccgcca 300 gccggcctca gccccatgca cttcccctgc cacatgacca tcgagcccaa cactttcctg 360 420 gctgtaccca ccctggagga gctgaacctg agctacaacg gcatcacgac tgtgcctgcc ctgcccagct ccctcgtgtc cctgatcctg agccgcacca acatcctgca gctagacccc 480 accagcetca egggeetgea tgeeetgege tteetataca tggatggeaa etgetaetae 540 aagaacccct gcgggcggc cctggaggtg gccccaggcg ccctccttgg cctgggcaac 600 ctcacccacc tgtcactcaa gtacaacaac ctcacaacgg tgccccgcag cctgcccct 660 720 agcctggagt acctgctgtt gtcctacaac cacattgtca ccctggcacc tgaggacctg gccaatctga ctgccctgcg tgtgctcgat gtgggtggaa actgccgccg ctgtgaccat 780 gcacgcaacc cctgcgtgga gtgcccacat aaattccccc agctgcactc cgacaccttc 840

agccacctaa	gccgcctaga	aggcctcgtg	ttgaaggata	gttctctcta	ccagctgaac	900
cccagatggt	tccgtggcct	gggcaacctc	acagtgctcg	acctgagtga	gaacttcctc	960
tacgactgca	tcaccaaaac	caaggcattc	cagggcctgg	cccagctgcg	aagactcaac	1020
ttgtccttca	attaccataa	gaaggtgtcc	ttcgcccacc	tgacgctggc	accctccttc	1080
gggagcctgc	tctccctgca	ggaactggac	atgcatggca	tcttcttccg	ctcactcagc	1140
cagaagacgc	tccagccact	ggcccgcctg	cccatgctcc	agcgtctgta	tctgcagatg	1200
aacttcatca	accaggccca	gctcggcatc	ttcaaggact	tccctggtct	gcgctacata	1260
gacctgtcag	acaaccgcat	cagtggagct	gtggagccgg	tggccaccac	aggggaggtg	1320
gatggtggga	agaaggtctg	gctgacatcc	agggacctca	ctccaggccc	actggacacc	1380
cccagctctg	aggacttcat	gccaagctgc	aagaacctca	gcttcacctt	ggacctgtca	1440
cggaacaacc	tggtaacagt	ccagccagag	atgtttgccc	agctctcgcg	cctccagtgc	1500
ctgcgcctga	gccacaacag	catctcgcag	gcggtcaatg	gctcacagtt	cgtgccactg	1560
accagcctgc	aggtgctgga	cctgtcccat	aacaaactgg	acctgtacca	tgggcgctcg	1620
tttacggagc	tgccgcgact	ggaggccctg	gacctcagct	acaacagcca	gcccttcagc	1680
atgcggggtg	tgggccacaa	cctcagcttt	gtggcccagc	tgcccaccct	gcgctacctc	1740
agcctggcac	acaatggcat	ccacagccgt	gtgtcccagc	agctctgcag	cacctcgctg	1800
tgggccctgg	acttcagcgg	caattccctg	agccagatgt	gggctgaggg	agacctctat	1860
ctccgcttct	tccaaggcct	gagaagccta	atccggctag	acctgtccca	gaatcgtctg	1920
cataccctcc	tgccatgcac	cctgggcaac	ctccccaaga	gcttgcagct	gctgcgtctc	1980
cgtaacaatt	acctggcctt	cttcaattgg	agcagcctga	ccctcctgcc	caacctggaa	2040
accctggacc	tggctggaaa	ccagctgaag	gctctgagca	atggcagcct	gccttctggc	2100
acccagctco	agaggctgga	cgtcagcagg	aacagcatca	tcttcgtggt	ccctggcttc	2160
tttgctctgg	ccacgaggct	gcgagagctc	aacctcagtg	ccaacgccct	caggacagag	2220
gagccctcct	ggtttggttt	cctagcaggc	tcccttgaag	tcctagatgt	gagcgccaac	2280
cctctgcact	gegeetgtgg	ggcagccttt	gtggacttcc	tgctgcaggt	tcaggctgcc	2340
gtgcctggto	tgcccagccg	cgtcaagtgt	ggcagtccgg	gccagctcca	gggccgcagc	2400
atcttcgcac	aagacctgcg	cctctgcctg	gacaagtccc	tctcctggga	ctgttttggt	2460

<210> 17

<211> 1029

<212> PRT

<213> Ovis aries

<400> 17

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala 1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315 320

Asp Tyr Ile Thr Lys Thr Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg 325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu 355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg 370 380

Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn 395 400

1

١

Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu 405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro 420 425 430

Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp
435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp 450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn 465 . 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu 485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr 515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln 530 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu 595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly 610 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr 625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr 660 670

Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys 675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu 690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val 705 710 715 720

Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile 740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe 755 760 765

Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg 770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys 815

Phe Gly Phe Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met 820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys 835 840 845

Leu Ala His Leu Pro Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu 850 860

Leu Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val Ala 865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly 885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly 900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys
915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg

930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp 945 950 955 960

Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr 965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro 980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Met Ala 995 1000 1005

Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg 1010 1015 1020

Gly Pro Thr Thr Ala Glu 1025

<210> 18

<211> 818

<212> PRT

<213> Ovis aries

<400> 18

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala 1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr

100 105 ' 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315 320

Asp Tyr Ile Thr Lys Thr Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg 325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu 355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg 370 380

Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn 390 395 400

Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu 405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro 420 425 430

Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp 435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp 450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn 465 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu 485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr 515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln 530 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575

- 54 -

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys 725 730 Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys

Phe Gly

<210> 19
<211> 3199
<212> DNA
<213> Ovis aries

19 <400> gtcggcacgg gaagtgagcg ccaagcatcc ttccctgcag ctgccgccca acttgcccgc 60 cagaccetet ggagaageeg cattecetge catgggeece tactgtgeec egeaceeet 120 180 ttctctcctg gtgcaggcgg cggcgctggc agcagccctg gcccagggca ccctgcctgc 240 cttcctgccc tgtgagctcc agccccgggg taaggtgaac tgcaactggc tgttcctgaa gtctgtgccg cgcttttcgg ccggagcccc ccgggccaat gtcaccagcc tctccttaat 300 360 ctccaaccgc atccaccact tgcacgactc tgacttcgtc cacctgtcca acctgcgggt 420 cctcaacctc aagtggaact gcccgccggc cggcctcagc cccatgcact tcccctgccg 480 catgaccatc gagcccaaca ccttcctggc tgtgcccacc ctggaggagc tgaacctgag ctacaatggc atcacgaccg tgcctgccct gcccagttct ctcgtatccc tgtcgctgag 540 ccgcaccage atcctggtgc taggccccac ccacttcacc ggcctgcacg ccctgcgctt 600 660 tetgtacatg gacggcaact gctactataa gaacccctgc cagcaggccg tggaggtggc 720 cccaggcgcc ctccttggcc tgggcaacct cacgcacctg tcgctcaagt acaacaacct 780 cacggaggtg ccccgccgcc tgccccccag cctggacacc ctgctgctgt cctacaacca catcatcacc ctggcacccg aggacctggc caatctgact gccctgcgtg tgcttgatgt 900 gggcgggaac tgccgccgct gcgaccacgc ccgcaacccc tgcagggagt gcccaaagaa 960 cttccccaag ctgcaccctg acaccttcag ccacctgagc cgcctcgaag gcctggtgtt 1020 gaaggacagt tctctctaca aactagagaa agactggttc cgcggcctgg gcaggctcca agtgctcgac ctgagtgaga acttcctcta tgactacatc accaagacca ccatcttcag 1080 gaacctgacc cagctgcgca gactcaacct gtccttcaat taccacaaga aggtgtcctt 1140 cgcccacctg caactggcac cctcctttgg gggcctggtg tccctggaga agctggacat 1200 1260 gcacggcatc ttcttccgct ccctcaccaa caccacgctc cggccgctga cccagctgcc caagetecag agtetgagte tgeagetgaa etteateaae eaggeegage teageatett 1320 tggggccttc ccgagcctgc tcttcgtgga cctgtcggac aaccgcatca gcggagctgc 1380 gaggccggtg gccgccctcg gggaggtgga cagcggggtg gaagtctggc ggtggcccag 1440

gggcctcgct ccaggcccgc tggccgccgt cagcgcaaag gacttcatgc caagctgcaa 1500 1560 cctcaacttc accttggacc tgtcacggaa caacctggtg acgatccagc aggagatgtt 1620 tacccgcctc tcccgcctcc agtgcctgcg cctgagccac aacagcatct cgcaggcggt taatggctcg cagttcgtgc cgctgacccg cctgcgagtg ctcgacctgt cctacaacaa 1680 gctggacctg taccatgggc gctcgttcac ggagctgccg cagctggagg cactggacct 1740 1800 cagctacaac agccagccct tcagcatgca gggcgtgggc cacaacctca gcttcgtggc 1860 ccagctgccg tccctgcgct acctcagcct tgcgcacaac ggcatccaca gccgcgtgtc acagaagete ageagegeet egetgegege cetggaette ageggeaact ceetgageea 1920 gatgtgggcc gagggagacc tctatctctg cttcttcaaa ggcttgagga acctggtcca 1980 gctggacctg tccaagaacc acctgcacac cctcctgcct cgtcacctgg ataacctgcc 2040 caagagcctg cggcagctgc gtctccggga caataacctg gccttcttca actggagcag 2100 cctgactgtt ctgccccagc tggaagccct ggatctggcg ggaaaccagc tgaaggccct 2160 gagcaacggc agcctgccac ctggcacccg gctccagaag ctggacgtga gcagcaacag 2220 2280 categgettt gtgaccettg gettetttgt eettgecaae eggetgaaag agettaacet cagcgccaac gccctgaaga cagtggatcc cttctggttc ggtcgcttaa cagagaccct 2340 gaatatecta gacgtgageg ceaaceeget ceaetgtgee tgeggggegg cetttgtgga 2400 2460 cttcctgctg gagatgcagg cggccgtgcc tgggctgtcc aggcgcgtca cgtgtggcag teegggeeag eteeagggee geageatett egeaeaggae etgegeetet geetggatga 2520 gaccetetee ttggactget ttggettete getgetaatg gtggegetgg geetggeggt 2580 gcccatgctg caccacctct gtggctggga cctgtggtac tgcttccacc tgtgtctggc 2640 2700 ccatttgccc cgacggcggc ggcagcgggg cgaggacacc ctgctctacg atgccttcgt 2760 ggtcttcgac aaggcgcaga gtgcagtggc cgactgggtg tacaacgagc tccgcgtgca gctggaggag cgccgcggc gccgggcgct ccgcctctgc ctggaggagc gagactggct 2820 ccctggcaag acgctcttcg agaacctgtg ggcctcggtc tacagcagcc gtaagaccat 2880 gttcgtgctg gaccacacgg accgggtcag tggcctcctg cgcgccagct tcctgctggc 2940 ccagcagcgc ctgttggagg accgcaagga tgtcgtggtg ctggtgatcc tgcgccccgc 3000 cgcctaccgg tcccgctacg tgcggctgcg ccagcgcctc tgccgccaga gcgtcctcct 3060 ctggccccac cagcccagtg gccagggtag cttctgggcc aacctgggca tggccctgac 3120 cagggacaac cgccacttct ataaccggaa cttctgccgg ggccccacga cagccgaata 3180

gcacagagtg actgcccag 3199

<210> 20 <211> 2454 <212> DNA

<213> Ovis aries

<400> 20

atgggcccct actgtgcccc gcaccccctt tctctcctgg tgcaggcggc ggcgctggca 60 120 gcagccctgg cccagggcac cctgcctgcc ttcctgccct gtgagctcca gccccggggt aaggtgaact gcaactggct gttcctgaag tctgtgccgc gcttttcggc cggagccccc 180 cgggccaatg tcaccagcct ctccttaatc tccaaccgca tccaccactt gcacgactct 240 300 gacttcgtcc acctgtccaa cctgcgggtc ctcaacctca agtggaactg cccgccggcc 360 ggcctcagcc ccatgcactt cccctgccgc atgaccatcg agcccaacac cttcctggct gtgcccaccc tggaggagct gaacctgagc tacaatggca tcacgaccgt gcctgccctg 420 cccagttctc tcgtatccct gtcgctgagc cgcaccagca tcctggtgct aggccccacc 480 cacttcaccg gcctgcacgc cctgcgcttt ctgtacatgg acggcaactg ctactataag 540 aacccctgcc agcaggccgt ggaggtggcc ccaggcgccc tccttggcct gggcaacctc 600 acgcacctgt cgctcaagta caacaacctc acggaggtgc cccgccgcct gccccccagc 660 ctggacaccc tgctgctgtc ctacaaccac atcatcaccc tggcacccga ggacctggcc 720 780 aatctgactg ccctgcgtgt gcttgatgtg ggcgggaact gccgccgctg cgaccacgcc cgcaaccct gcagggagtg cccaaagaac ttccccaagc tgcaccctga caccttcagc 840 cacctgagcc gcctcgaagg cctggtgttg aaggacagtt ctctctacaa actagagaaa 900 gactggttcc gcggcctggg caggctccaa gtgctcgacc tgagtgagaa cttcctctat 960 1020 gactacatca ccaagaccac catcttcagg aacctgaccc agctgcgcag actcaacctg tccttcaatt accacaagaa ggtgtccttc gcccacctgc aactggcacc ctcctttggg 1080 ggcctggtgt ccctggagaa gctggacatg cacggcatct tcttccgctc cctcaccaac 1140 accacgetee ggeegetgae ceagetgeee aageteeaga gtetgagtet geagetgaae 1200 1260 ttcatcaacc aggccgagct cagcatcttt ggggccttcc cgagcctgct cttcgtggac 1320 ctgtcggaca accgcatcag cggagctgcg aggccggtgg ccgccctcgg ggaggtggac 1380 ageggggtgg aagtetggeg gtggeecagg ggeetegete caggeeeget ggeegeegte agcgcaaagg acttcatgcc aagctgcaac ctcaacttca ccttggacct gtcacggaac 1440 1500 aacctggtga cgatccagca ggagatgttt acccgcctct cccgcctcca gtgcctgcgc

ctgagccaca acagcatete geaggeggtt aatggetege agttegtgee getgaeeege 1560 ctgcgagtgc tcgacctgtc ctacaacaag ctggacctgt accatgggcg ctcgttcacg 1620 gagetgeege agetggagge aetggaeete agetacaaca gecageeett cageatgeag 1680 ggcgtgggcc acaacctcag cttcgtggcc cagctgccgt ccctgcgcta cctcagcctt 1740 , gegeacaaeg geatecaeag eegegtgtea eagaagetea geagegeete getgegegee 1800 ctggacttca gcggcaactc cctgagccag atgtgggccg agggagacct ctatctctgc 1860 ttcttcaaag gcttgaggaa cctggtccag ctggacctgt ccaagaacca cctgcacacc 1920 ctcctgcctc gtcacctgga taacctgccc aagagcctgc ggcagctgcg tctccgggac 1980 aataacctgg ccttcttcaa ctggagcagc ctgactgttc tgccccagct ggaagccctg 2040 gatctggcgg gaaaccagct gaaggccctg agcaacggca gcctgccacc tggcacccgg 2100 ctccagaagc tggacgtgag cagcaacagc atcggctttg tgacccctgg cttctttgtc 2160 cttgccaacc ggctgaaaga gcttaacctc agcgccaacg ccctgaagac agtggatccc 2220 ttctggttcg gtcgcttaac agagaccctg aatatcctag acgtgagcgc caacccgctc 2280 cactgtgcct gcggggcggc ctttgtggac ttcctgctgg agatgcaggc ggccgtgcct 2340 gggctgtcca ggcgcgtcac gtgtggcagt ccgggccagc tccagggccg cagcatcttc 2400 gcacaggacc tgcgcctctg cctggatgag accctctcct tggactgctt tggc 2454

<210> 21

<211> 1032

<212> PRT

<213> Canis familiaris

<400> 21

Met Gly Pro Cys Arg Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Ala Leu Ala Leu Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Pro Arg Gly Asn 50 55

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp

70 75 80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 150

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe 260 265 270

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly 275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe 290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365

Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu 370 380

Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu 385 390 395 400

Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly 405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu 420 425 430

Pro Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val
435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly
450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp 465 470 475 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln 500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu 515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr 530 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro

545 550 · 555 560

Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu 565 570 575

Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg 580 585 590

Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser 595 600 605

Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg 610 620

Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn 625 630 635

Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser 645 650 655

Leu Arg Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp 660 670

Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly 675 680 685

Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln 690 695 700

Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro
705 710 715 720

Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala 725 730 735

Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly 740 745 750

Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys
755 760 765

Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro 770 780

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly 785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu 805 810 815

Ser Trp Val Cys Phe Ser Leu Ser Leu Leu Ala Val Ala Leu Ser Leu 820 825 830

Ala Val Pro Met Leu His Gln Leu Cys Gly Trp Asp Leu Trp Tyr Cys 835 840 845

Phe His Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Arg Gly 850 860

Val Asp Ala Leu Ala Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln 865 870 875 880

Ser Ser Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu 885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp 900 905 910

Trp Val Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr 915 920 925

Ser Ser Arg Lys Thr Leu Phe Val Leu Ala Arg Thr Asp Arg Val Ser 930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Cys Pro Asp Ala His 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln 995 1000 1005

Leu Gly Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Thr Ala 1025 1030

<210> 22

<211> 822

<212> PRT

<213> Canis familiaris

<400> 22

Met Gly Pro Cys Arg Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Leu Ala Leu Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Pro Arg Gly Asn 50 55

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp

70

75

80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 155 160

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro 180 185 190

Gly Ala Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe 260 , 265 270

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly 275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe 290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365

Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu 370 380

Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu 385 390 395 400

Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu 420 425 430

Pro Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val
435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly 450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp 465 470 475 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln 500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu 515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr 530 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro 545 550 555 560

Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu 565 570 575

Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg 580 585 590

Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser 595 600 605

Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg 610 620

Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn 625 630 635 640

Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser 645 650 655

Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp

660	665	670
660	665	670

Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly 675 680 685

Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln 690 695 700

Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro 705 710 715 720

Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala 725 730 735

Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly
740 745 750

Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys
755 760 765

Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro
770 780

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly
785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu 805 810 815

Ser Trp Val Cys Phe Ser 820

<210> 23

<211> 3334

<212> DNA

<213> Canis familiaris

<400> 23

aggaagggc tgtgagctcc aagcatcett teetgeaget getgeecage etgeeageca 60
gaccetetgg agaageecee geteectgte atgggeecet geegtggege eetgeaceee 120
etgtetetee tggtgeagge tgeeggeta geeetggeee tggeecaggg caccetgeet 180
geetteetge eetgtgaget eeageecat ggeetggtga aetgeaaetg getgtteete 240
aagteegtge eeegettete ggeagetgea eeeegggta aegteaceag eettteettg 300

360 tactccaacc gcatccacca cctccatgac tatgactttg tccacttcgt ccacctgcgg 420 cgtctcaatc tcaagtggaa ctgcccgccc gccagcctca gccccatgca ctttccctgt 480 cacatgacca ttgagcccaa caccttcctg gctgtgccca ccctagagga cctgaatctg agctataaca gcatcacgac tgtgcccgcc ctgcccagtt cgcttgtgtc cctgtccctg 540 600 ageegeacea acateetggt getggaceet gecaceetgg caggeettta tgeeetgege 660 ttcctgttcc tggatggcaa ctgctactac aagaacccct gccagcaggc cctgcaggtg gccccaggtg ccctcctggg cctgggcaac ctcacacacc tgtcactcaa gtacaacaac 720 780 ctcaccgtgg tgccgcgggg cctgccccc agcctggagt acctgctctt gtcctacaac 840 cacatcatca ccctggcacc tgaggacctg gccaatctga ctgccctgcg tgtcctcgat gtgggtggga actgtcgccg ctgtgaccat gcccgtaacc cctgcaggga gtgccccaag 900 ggcttccccc agctgcaccc caacaccttc ggccacctga gccacctcga aggcctggtg 960 1020 ttgagggaca gctctctcta cagcctggac cccaggtggt tccatggcct gggcaacctc atggtgctgg acctgagtga gaacttcctg tatgactgca tcaccaaaac caaagccttc 1080 tacggcctgg cccggctgcg cagactcaac ctgtccttca attatcataa gaaggtgtcc 1140 tttgcccacc tgcatctggc atcctccttc gggagcctac tgtccctgca ggagctggac 1200 atacatggca tettetteeg etegeteage aagaceaege teeagteget ggeeeaeetg 1260 1320 cccatgctcc agegtctgca tctgcagttg aactttatca gccaggccca gctcagcatc ttcggcgcct tccctggact gcggtacgtg gacttgtcag acaaccgcat cagtggagct 1380 gcagagcccg cggctgccac aggggaggta gaggcagact gtggggagag agtctggcca 1440 cagtcccggg accttgctct gggcccactg ggcacccccg gctcagaggc cttcatgccg agetgeagga cecteaactt cacettggae etgtetegga acaacetagt gaetgtteag 1560 ccggagatgt ttgtccggct ggcgcgcctc cagtgcctgg gcctgagcca caacagcatc 1620 tegeaggegg teaatggete geagttegtg cetetgagea acetgegggt getggacetg 1680 tcccataaca agctggacct gtaccacggg cgctcgttca cggagctgcc gcggctggag 1740 gccttggacc tcagctacaa cagccagccc ttcagcatgc ggggcgtggg ccacaatctc 1800 agetttgtgg cacagetgee ageeetgege taceteagee tggegeacaa tggeatecae 1860 agccgcgtgt cccagcagct ccgcagcgcc tcgctccggg ccctggactt cagtggcaat 1920 accetgagee agatgtggge egagggagae etetatetee gettetteea aggeetgaga 1980 agectggtte agetggacet gteccagaat egectgeata eceteetgee aegeaacetg 2040 gacaacctcc ccaagagcct gcggctcctg cggctccgtg acaattacct ggctttcttc 2100

aactggagca	gcctggccct	cctacccaag	ctggaagccc	tggacctggc	gggaaaccag	2160
ctgaaggccc	tgagcaatgg	cagcttgccc	aacggcaccc	agctccagag	gctggacctc	2220
agcggcaaca	gcatcggctt	cgtggtcccc	agcttttttg	ccctggccgt	gaggcttcga	2280
gagctcaacc	tcagcgccaa	cgccctcaag	acggtggagc	cctcctggtt	tggttccctg	2340
gcgggtgccc	tgaaagtcct	agacgtgacc	gccaacccct	tgcattgcgc	ttgcggcgca	2400
accttcgtgg	acttcttgct	ggaggtgcag	gctgcggtgc	ccggcctgcc	tagccgtgtc	2460
aagtgcggca	gcccgggcca	gctccagggc	cgcagcatct	tcgcacagga	cctgcgcctc	2520
tgcctggacg	aagcgctctc	ctgggtctgt	ttcagcctct	cgctgctggc	tgtggccctg	2580
agcctggctg	tgcccatgct	gcaccagctc	tgtggctggg	acctctggta	ctgcttccac	2640
ctgtgcctgg	cctggctgcc	ccggcggggg	cggcggcggg	gtgtggatgc	cctggcctat	2700
gacgccttcg	tggtcttcga	caaggcgcag	agctcggtgg	cggactgggt	gtacaatgag	2760
ctgcgggtac	agctagagga	gcgccgtggg	cgccgggcgc	tacgcctgtg	tctggaggaa	2820
cgtgactggg	tacccggcaa	aaccctcttc	gagaacctct	gggcctcagt	ttacagcagc	2880
cgcaagacgc	tgtttgtgct	ggcccgcacg	gacagagtca	gcggcctcct	gcgtgccagc	2940
ttcctgctgg	cccaacagcg	cctgctggag	gaccgcaagg	acgtcgtggt	gctggtgatc	3000
ctgtgccccg	acgcccaccg	ctcccgctat	gtgcggctgc	gccagcgcct	ctgccgccag	3060
agtgtcctcc	tctggcccca	ccagcccagt	ggccagcgca	gcttctgggc	ccagctgggc	3120
acggccctga	ccagggacaa	ccgccacttc	tacaaccaga	acttctgccg	gggccccacg	3180
acagcctgat	aggcagacag	cccagcacct	tegegeceet	acaccctgcc	tgtctgtctg	3240
ggatgcccga	cctgctggct	ctacaccgcc	gctctgtctc	ccctacaccc	agccctggca	3300
taaagcgacc	gctcaataaa	tgctgctggt	agac			3334

<210> 24

<400> 24

atgggccct gccgtggcgc cctgcaccc ctgtctccc tggtgcaggc tgccgcgcta 60 gccctggccc tggcccaggg caccctgcct gccttcctgc cctgtgagct ccagccccat 120 ggcctggtga actgcaactg gctgttcctc aagtccgtgc cccgcttctc ggcagctgca 180 ccccgcggta acgtcaccag cctttccttg tactccaacc gcatccacca cctccatgac 240 tatgactttg tccacttcgt ccacctgcgg cgtctcaatc tcaagtggaa ctgcccgcc 300

<211> 2466

<212> DNA

<213> Canis familiaris

gccagcctca g	gccccatgca	ctttccctgt	cacatgacca	ttgagcccaa	caccttcctg	360
gctgtgccca d	ccctagagga	cctgaatctg	agctataaca	gcatcacgac	tgtgcccgcc	420
ctgcccagtt d	cgcttgtgtc	cctgtccctg	agccgcacca	acatcctggt	gctggaccct	480
gccaccctgg o	caggccttta	tgccctgcgc	ttcctgttcc	tggatggcaa	ctgctactac	540
aagaacccct c	gccagcaggc	cctgcaggtg	gccccaggtg	ccctcctggg	cctgggcaac	600
ctcacacacc t	tgtcactcaa	gtacaacaac	ctcaccgtgg	tgccgcgggg	cctgcccccc	660
agcctggagt a	acctgctctt	gtcctacaac	cacatcatca	ccctggcacc	tgaggacctg	720
gccaatctga c	ctgccctgcg	tgtcctcgat	gtgggtggga	actgtcgccg	ctgtgaccat	780
gcccgtaacc c	cctgcaggga	gtgccccaag	ggcttccccc	agctgcaccc	caacaccttc	840
ggccacctga g	gccacctcga	aggcctggtg	ttgagggaca	gctctctcta	cagcctggac	900
cccaggtggt t	ccatggcct	gggcaacctc	atggtgctgg	acctgagtga	gaacttcctg	960
tatgactgca t	caccaaaac	caaagccttc	tacggcctgg	cccggctgcg	cagactcaac	1020
ctgtccttca a	attatcataa	gaaggtgtcc	tttgcccacc	tgcatctggc	atcctccttc	1080
gggagcctac t	gtccctgca	ggagctggac	atacatggca	tcttcttccg	ctcgctcagc	1140
aagaccacgc t	ccagtcgct	ggcccacctg	cccatgctcc	agcgtctgca	tctgcagttg	1200
aactttatca g	gccaggccca	gctcagcatc	ttcggcgcct	tccctggact	gcggtacgtg	1260
gacttgtcag a	acaaccgcat	cagtggagct	gcagagcccg	cggctgccac	aggggaggta	1320
gaggcagact g	gtgggagag	agtctggcca	cagtcccggg	accttgctct	gggcccactg	1380
ggcacccccg g	gctcagaggc	cttcatgccg	agctgcagga	ccctcaactt	caccttggac	1440
ctgtctcgga a	caacctagt	gactgttcag	ccggagatgt	ttgtccggct	ggcgcgcctc	1500
cagtgcctgg g	gcctgagcca	caacagcatc	tcgcaggcgg	tcaatggctc	gcagttcgtg	1560
cctctgagca a	cctgcgggt	gctggacctg	tcccataaca	agctggacct	gtaccacggg	1620
cgctcgttca c	ggagctgcc	gcggctggag	gccttggacc	tcagctacaa	cagccagccc	1680
ttcagcatgc g	gggcgtggg	ccacaatctc	agctttgtgg	cacagetgee	agccctgcgc	1740
tacctcagcc t	ggcgcacaa	tggcatccac	agccgcgtgt	cccagcagct	ccgcagcgcc	1800
tcgctccggg c	cctggactt	cagtggcaat	accctgagcc	agatgtgggc	cgagggagac	1860
ctctatctcc g	cttcttcca	aggcctgaga	agcctggttc	agctggacct	gtcccagaat	1920
cgcctgcata c	cctcctgcc	acgcaacctg	gacaacctcc	ccaagagcct	gcggctcctg	1980
cggctccgtg a	caattacct	ggctttcttc	aactggagca	gcctggccct	cctacccaag	2040

ctggaagccc	tggacctggc	gggaaaccag	ctgaaggccc	tgagcaatgg	cagcttgccc	2100
aacggcaccc	agctccagag	gctggacctc	agcggcaaca	gcatcggctt	cgtggtcccc	2160
agctttttg	ccctggccgt	gaggcttcga	gagctcaacc	tcagcgccaa	cgccctcaag	2220
acggtggagc	cctcctggtt	tggttccctg	gcgggtgccc	tgaaagtcct	agacgtgacc	2280
gccaacccct	tgcattgcgc	ttgcggcgca	accttcgtgg	acttcttgct	ggaggtgcag	2340
gctgcggtgc	ccggcctgcc	tagccgtgtc	aagtgcggca	gcccgggcca	gctccagggc	2400
cgcagcatct	tcgcacagga	cctgcgcctc	tgcctggacg	aagcgctctc	ctgggtctgt	2460
ttcagc						2466

<210> 25

<211> 1031

<212> PRT

<213> Felis catus

<400> 25

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 155 160

Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe 260 265 270

Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe 290 295 300

His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu 370 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly 405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu 420 425 430

Leu Ala Ala Thr Gly Glu Val Asp Gly Gly Glu Arg Val Arg Leu 435 440 445

1

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu 450 455

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser 475 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser 485 490 495

Arg Leu Gln Cys Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val 500 505 510

Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu 515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu 530 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser 545 550 550

Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala 565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser 580 585

Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605

Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe

610 . 615 620

Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg 650 655

Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 660 670

Leu Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln 675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln 690 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe 705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu 740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815

Asp Cys Phe Gly Leu Ser Leu Leu Thr Val Ala Leu Gly Leu Ala Val 820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His 835 840 845

÷

Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Gly Ala Asp 850 860

Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala 865 870 875 880

Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg 885 890 895

Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu 900 905 910

Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser 915 920 925

Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu 930 940

Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg 945 950 955 960

Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His Arg Ser 965 970 975

Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu 980 985 990

Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly 995 1000 1005

Thr Ala Leu Thr Arg Asp Asn Gln His Phe Tyr Asn Gln Asn Phe 1010 1020

Cys Arg Gly Pro Thr Thr Ala Glu 1025 1030

<210> 26

<211> 820

<212> PRT

<213> Felis catus

<400> 26

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 155 160

Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg .Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

•

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe 260 265 270

Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe 290 295 300

His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu 370 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly 405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu 420 425 430

Leu Ala Ala Thr Gly Glu Val Asp Gly Glu Arg Val Arg Leu
435 440 445

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu
450 460

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser 485 490 495

Arg Leu Gln Cys Leu Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val 500 505 510

Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu 515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu 530 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser 545 550 550

Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala 565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser 580 590

Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605

Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe 610 620

Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg 650 655

Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 660 670

Leu Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln 675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln 690 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe 705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala

725 730 735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu 740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815

Asp Cys Phe Gly 820

<210> 27

<211> 3235

<212> DNA

<213> Felis catus

<400> 27

agggtctgcg agctccaggc attcttctct gccatcgctg cccagtctgc catccagacc 60 ctctggagaa gccccactc cctgtcatgg gcccctgcca tggcgccctg cacccctgt 120 ctctcctggt gcaggctgcc gcgctggccg tggccctggc ccagggcacc ctgcctgcct 180 ttctgccctg tgagctccag cgccacggcc tggtgaattg cgactggctg ttcctcaagt 240 ccgtgcccca cttctcggcg gcagcgcccc gtggtaacgt caccagcctt tccctgtact 300 ccaaccgcat ccaccacctc cacgactccg actttgtcca cctgtccagc ctgcggcgtc 360 tcaacctcaa atggaactgc ccacccgcca gcctcagccc catgcacttc ccctgtcaca 420 tgaccattga gccccacacc ttcctggccg tgcccaccct ggaggagctg aacctgagct 480 acaacagcat cacgacagta cccgccctgc ccagttccct cgtgtccctg tccttgagcc 540 gtaccaacat cctggtgctg gaccctgcca acctcgcagg gctgcactcc ctgcgctttc 600 tgttcctgga tggcaactgc tactacaaga acccctgccc gcaggccctg caggtggccc 660 cgggcgccct ccttggcctg ggcaacctta cgcacctgtc actcaagtac aacaacctca 720 ctgcggtgcc ccgcggcctg cccccagcc tggagtacct gctattgtcc tacaaccaca 780

tcatcaccct ggcacctgag gacctggcca acctgaccgc cctgcgtgtg ctcgatgtgg 840 gtgggaactg ccgtcgctgt gaccacgccc gcaacccctg tatggagtgc cccaagggct 900 tecegeacet geaceetgae acetteagee acetgaacea cetegaagge etggtgttga 960 aggacagete tetetacaae etgaaceeca gatggtteca tgeeetggge aaceteatgg 1020 tgctggacct gagtgagaac ttcctatatg actgcatcac caaaaccaca gccttccagg 1080 gcctggccca gctgcgcaga ctcaacttgt ctttcaatta ccacaagaag gtgtcctttg 1140 cccacctgca tctggcgccc tccttcggga gcctgctctc cctgcagcag ctggacatgc 1200 1260 atggcatctt cttccgctcg ctcagcgaga ccacgctccg gtcgctggtc cacctgccca tgctccagag tctgcacctg cagatgaact tcatcaatca ggcccagctc agcatcttcg 1320 gggccttccc tggcctgcga tacgtggacc tgtcagacaa ccgcataagt ggagccatgg 1380 agctggcggc tgccacgggg gaggtggatg gtggggagag agtccggctg ccatctgggg 1440 acctagetet gggcccaceg ggcaceceta geteegaggg etteatgeca ggetgcaaga 1500 ccctcaactt caccttggac ctgtcacgga acaacctagt gacaatccag ccagagatgt 1560 ttgcccggct ctcgcgcctc cagtgcctgc tcctgagccg caacagcatc tcgcaggcag 1620 tcaacggctc acaatttatg ccgctgacca gcctgcaggt gctggacctg tcccataaca 1680 agetggacet gtaccatggg cgctctttca cggagetgcc gcggctggag gccctggace 1740 tcagctacaa cagccagccc ttcagcatgc agggcgtggg tcacaacctc agctttgtgg 1800 cacagetgee ggeeetgege tateteagee tggegeacaa egacateeae ageegtgtgt 1860 cccagcagct ctgcagcgcc tcgctgcggg ccttggactt cagcggcaat gccttgagcc 1920 ggatgtgggc cgagggagac ctgtatctcc acttcttccg aggcctgagg agcctggtcc ggttggatct gtcccagaat cgcctgcata ccctcttgcc acgcaccctg gacaacctcc 2040 ccaagagcct gcggctgctg cgtctccgtg acaattatct ggctttcttc aactggagca 2100 gcctggtcct cctcccagg ctggaagccc tggacctggc gggaaaccag ctgaaggccc 2160 tgagcaacgg cagcttgcct aatggaaccc agctccagag gctggacctc agcagcaaca 2220 gtatcagctt cgtggcctcc agcttttttg ctctggccac caggctgcga gagctcaacc 2280 tcagtgccaa cgccctcaag acggtggagc cctcctggtt cggttctcta gcgggcaccc 2340 tgaaagtcct agatgtgact ggcaaccccc tgcactgcgc ctgtggggcg gccttcgtgg 2400 acttcttgct ggaggtgcag gctgcagtgc ccggcctgcc aggccacgtc aagtgtggca 2460 gtccaggtca gctccagggc cgcagcatct ttgcgcagga tctgcgcctc tgcctggatg 2520 aggccctctc ctgggactgt tttggcctct cgctgctgac cgtggccctg ggcctggccg 2580

tgcccatgct gcaccacctc tgtggctggg acctctggta ctgcttccac ctgtgcctgg 2640 cctggctgcc ccggcgggg cggcgggg gcgcggatgc cctgccctac gatgcctttg 2700 2760 tggtcttcga caaggcacag agcgcggtgg ccgactgggt gtacaacgag ctgcgggtac ggctagagga gcgccgtgga cgccgagcgc tccgcctgtg cctggaggaa cgtgactggc 2820 tacccggtaa aacgctcttt gagaacctgt gggcctcagt ttacagcagc cgcaagatgc 2880 tgtttgtgct ggcccacaca gacagggtca gcggcctctt gcgcgccagc tttctgctgg 2940 3000 cccagcagcg cctgctggag gaccgcaagg acgttgtggt gctggtgatc ctgcgcccg acgcccaccg ctcccgctat gtgcggctgc gccagcgcct ctgccgccag agcgtcctcc 3060 3120 tctggcccca ccagcccagt ggccagcgca gcttctgggc ccagctgggc acggccctga ccagggacaa ccagcacttc tataaccaga acttctgccg gggccccacg acggcagagt 3180 gaccgcccag caccccaage etectacace ttgcctgtet geetgggatg eeggg 3235

<210> 28

<211> 2460

<212> DNA

<213> Felis catus

<400> 28

atgggcccct gccatggcgc cctgcacccc ctgtctctcc tggtgcaggc tgccgcgctg 60 gccgtggccc tggcccaggg caccctgcct gcctttctgc cctgtgagct ccagcgccac 120 ggcctggtga attgcgactg gctgttcctc aagtccgtgc cccacttctc ggcggcagcg 180 ccccgtggta acgtcaccag cctttccctg tactccaacc gcatccacca cctccacgac 240 tccgactttg tccacctgtc cagcctgcgg cgtctcaacc tcaaatggaa ctgcccaccc gccagcctca gccccatgca cttcccctgt cacatgacca ttgagcccca caccttcctg 360 gccgtgccca ccctggagga gctgaacctg agctacaaca gcatcacgac agtacccgcc 420 480 ctgcccagtt ccctcgtgtc cctgtccttg agccgtacca acatcctggt gctggaccct gccaaceteg cagggetgea etecetgege tttetgttee tggatggeaa etgetaetae 540 aagaacccct gcccgcaggc cctgcaggtg gccccgggcg ccctccttgg cctgggcaac 600 660 cttacgcacc tgtcactcaa gtacaacaac ctcactgcgg tgccccgcgg cctgccccc agcctggagt acctgctatt gtcctacaac cacatcatca ccctggcacc tgaggacctg 720 780 gccaacctga ccgccctgcg tgtgctcgat gtgggtggga actgccgtcg ctgtgaccac 840 gcccgcaacc cctgtatgga gtgccccaag ggcttcccgc acctgcaccc tgacaccttc 900 agccacctga accacctcga aggcctggtg ttgaaggaca gctctctcta caacctgaac

cccagatggt	tccatgccct	gggcaacctc	atggtgctgg	acctgagtga	gaacttccta	960
tatgactgca	tcaccaaaac	cacagccttc	cagggcctgg	cccagctgcg	cagactcaac	1020
ttgtctttca	attaccacaa	gaaggtgtcc	tttgcccacc	tgcatctggc	gccctccttc	1080
gggagcctgc	tctccctgca	gcagctggac	atgcatggca	tcttcttccg	ctcgctcagc	1140
gagaccacgc	tccggtcgct	ggtccacctg	cccatgctcc	agagtctgca	cctgcagatg	1200
aacttcatca	atcaggccca	gctcagcatc	ttcggggcct	tccctggcct	gcgatacgtg	1260
gacctgtcag	acaaccgcat	aagtggagcc	atggagctgg	cggctgccac	gggggaggtg	1320
gatggtgggg	agagagtccg	gctgccatct	ggggacctag	ctctgggccc	accgggcacc	1380
cctagctccg	agggcttcat	gccaggctgc	aagaccctca	acțtcacctt	ggacctgtca	1440
cggaacaacc	tagtgacaat	ccagccagag	atgtttgccc	ggctctcgcg	cctccagtgc	1500
ctgctcctga	gccgcaacag	catctcgcag	gcagtcaacg	gctcacaatt	tatgccgctg	1560
accagcctgc	aggtgctgga	cctgtcccat	aacaagctgg	acctgtacca	tgggcgctct	1620
ttcacggagc	tgccgcggct	ggaggccctg	gacctcagct	acaacagcca	gcccttcagc	1680
atgcagggcg	tgggtcacaa	cctcagcttt	gtggcacagc	tgccggccct	gcgctatctc	1740
agcctggcgc	acaacgacat	ccacagccgt	gtgtcccagc	agctctgcag	cgcctcgctg	1800
cgggccttgg	acttcagcgg	caatgccttg	agccggatgt	gggccgaggg	agacctgtat	1860
ctccacttct	tccgaggcct	gaggagcctg	gtccggttgg	atctgtccca	gaatcgcctg	1920
cataccctct	tgccacgcac	cctggacaac	ctccccaaga	gcctgcggct	gctgcgtctc	1980
cgtgacaatt	atctggcttt	cttcaactgg	agcagcctgg	tcctcctccc	caggctggaa	2040
gccctggacc	tggcgggaaa	ccagctgaag	gccctgagca	acggcagctt	gcctaatgga	2100
acccagetcc	agaggctgga	cctcagcagc	aacagtatca	gcttcgtggc	ctccagcttt	2160
tttgctctgg	ccaccaggct	gcgagagctc	aacctcagtg	ccaacgccct	caagacggtg	2220
gageceteet	ggttcggttc	tctagcgggc	accctgaaag	tcctagatgt	gactggcaac	2280
cccctgcact	gcgcctgtgg	ggcggccttc	gtggacttct	tgctggaggt	gcaggctgca	2340
gtgcccggcc	tgccaggcca	cgtcaagtgt	ggcagtccag	gtcagctcca	gggccgcagc	2400
atctttgcgc	aggatctgcg	cctctgcctg	gatgaggccc	tctcctggga	ctgttttggc	2460

<210> 29 .

<211> 1032

<212> PRT

<213> Mus musculus

<400> 29

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn 50 55

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala 145 150 150

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro 180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu

225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser 260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe 290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu 325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala 340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu 355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu 370 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala 405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Glu Glu 435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser 450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala 500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp 515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu 530 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val 580 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly 595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe 610 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn 625 630 635

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr 660 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn 675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960

Asp Arg Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln 995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu 1025 1030

<210> 30

<211> 821

<212> PRT

<213> Mus musculus

<400> 30

Met Val Leu Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met 100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala 145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro 180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser 260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe 290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu 325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala

340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu 355 360

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu 370 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala 405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr 420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Glu Glu 435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser 450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu 465 470 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala 500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp 515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu 530 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 550

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser 565 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val 580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly 595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe 610 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn 625 630 635

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
. 645 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr 660 ' 665 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn 675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn 725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn 740 745 750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser 805 810 815 Trp Asp Cys Phe Gly 820

<210> 31 <211> 3200 <212> DNA

<213> Mus musculus

<400> 31

tgtcagaggg agcctcggga gaatcctcca tctcccaaca tggttctccg tcgaaggact 60 ctgcacccct tgtccctcct ggtacaggct gcagtgctgg ctgagactct ggccctgggt 120 accetgeetg cetteetace etgtgagetg aageeteatg geetggtgga etgeaattgg 180 ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgctccaa catcacccgc 240 ctctccttga tctccaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc 300 aacctgcggc agctgaacct caagtggaac tgtccaccca ctggccttag ccccctgcac 360 ttctcttgcc acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag 420 ctgaacctga gctataatgg tatcaccact gtgccccgac tgcccagctc cctggtgaat 480 ctgagcctga gccacaccaa catcctggtt ctagatgcta acagcctcgc cggcctatac 540 agcctgcgcg ttctcttcat ggacgggaac tgctactaca agaacccctg cacaggagcg 600 gtgaaggtga ccccaggcgc cctcctgggc ctgagcaatc tcacccatct gtctctgaag 660 tataacaacc tcacaaaggt gccccgccaa ctgcccccca gcctggagta cctcctggtg 720 tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttcga 780 gtacttgatg tgggtgggaa ttgccgtcgc tgcgaccatg cccccaatcc ctgtatagaa 840 tgtggccaaa agtccctcca cctgcaccct gagaccttcc atcacctgag ccatctggaa 900 ggcctggtgc tgaaggacag ctctctccat acactgaact cttcctggtt ccaaggtctg 960 gtcaacctct cggtgctgga cctaagcgag aactttctct atgaaagcat caaccacacc 1020 aatgcctttc agaacctaac ccgcctgcgc aagctcaacc tgtccttcaa ttaccgcaag 1080 aaggtateet ttgeeegeet eeacetggea agtteettea agaacetggt gteactgeag 1140 gagctgaaca tgaacggcat cttcttccgc tcgctcaaca agtacacgct cagatggctg 1200 gccgatctgc ccaaactcca cactctgcat cttcaaatga acttcatcaa ccaggcacag 1260 ctcagcatct ttggtacctt ccgagccctt cgctttgtgg acttgtcaga caatcgcatc 1320 agtgggcctt caacgctgtc agaagccacc cctgaagagg cagatgatgc agagcaggag 1380 gagctgttgt ctgcggatcc tcacccagct ccactgagca cccctgcttc taagaacttc 1440

atggacaggt gtaagaactt caagttcacc atggacctgt ctcggaacaa cctggtgact	1500
atcaagccag agatgtttgt caatctctca cgcctccagt gtcttagcct gagccacaac	1560
tccattgcac aggctgtcaa tggctctcag ttcctgccgc tgactaatct gcaggtgctg	1620
gacctgtccc ataacaaact ggacttgtac cactggaaat cgttcagtga gctaccacag	1680
ttgcaggccc tggacctgag ctacaacagc cagcccttta gcatgaaggg tataggccac	1740
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac	1800
attcataccc gtgtgtcctc acatctcaac agcaactcag tgaggtttct tgacttcagc	1860
ggcaacggta tgggccgcat gtgggatgag gggggccttt atctccattt cttccaaggc	1920
ctgagtggcc tgctgaagct ggacctgtct caaaataacc tgcatatcct ccggccccag	1980
aaccttgaca acctccccaa gagcctgaag ctgctgagcc tccgagacaa ctacctatct	2040
ttctttaact ggaccagtct gtccttcctg cccaacctgg aagtcctaga cctggcaggc	2100
aaccagctaa aggccctgac caatggcacc ctgcctaatg gcaccctcct ccagaaactg	2160
gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgctct ggcggtcgag	2220
ctgaaagagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg	2280
cccattgtga tgaacctgac agttctagac gtgagaagca accctctgca ctgtgcctgt	2340
ggggcagcct tcgtagactt actgttggag gtgcagacca aggtgcctgg cctggctaat	2400
ggtgtgaagt gtggcagccc cggccagctg cagggccgta gcatcttcgc acaggacctg	2460
cggctgtgcc tggatgaggt cctctcttgg gactgctttg gcctttcact cttggctgtg	2520
gccgtgggca tggtggtgcc tatactgcac catctctgcg gctgggacgt ctggtactgt	2580
tttcatctgt gcctggcatg gctacctttg ctggcccgca gccgacgcag cgcccaagct	2640
ctcccctatg atgccttcgt ggtgttcgat aaggcacaga gcgcagttgc ggactgggtg	2700
tataacgagc tgcgggtgcg gctggaggag cggcgcggtc gccgagccct acgcttgtgt	2760
ctggaggacc gagattggct gcctggccag acgctcttcg agaacctctg ggcttccatc	2820
tatgggagcc gcaagactct atttgtgctg gcccacacgg accgcgtcag tggcctcctg	2880
cgcaccagct tcctgctggc tcagcagcgc ctgttggaag accgcaagga cgtggtggtg	2940
ttggtgatcc tgcgtccgga tgcccaccgc tcccgctatg tgcgactgcg ccagcgtctc	3000
tgccgccaga gtgtgctctt ctggccccag cagcccaacg ggcagggggg cttctgggcc	3060
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg	3120
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatctt catgcctggt	3180
tcccgagttg ctctgcctgc .	3200

<210> 32

<211> 2463

<212> DNA

<213> Mus musculus

<400> 32

atggttctcc gtcgaaggac tctgcacccc ttgtccctcc tggtacaggc tgcagtgctg 60 gctgagactc tggccctggg taccctgcct gccttcctac cctgtgagct gaagcctcat 120 ggcctggtgg actgcaattg gctgttcctg aagtctgtac cccgtttctc tgcggcagca 180 tectgeteca acateaeceg ceteteettg atetecaace gtatecacea eetgeacaae 240 300 tecgaetteg tecacetgte caacetgegg cagetgaace teaagtggaa etgtecacee actggcctta gcccctgca cttctcttgc cacatgacca ttgagcccag aaccttcctg 360 gctatgcgta cactggagga gctgaacctg agctataatg gtatcaccac tgtgccccga 420 ctgcccagct ccctggtgaa tctgagcctg agccacacca acatcctggt tctagatgct 480 aacagcctcg ccggcctata cagcctgcgc gttctcttca tggacgggaa ctgctactac 540 aagaacccct gcacaggagc ggtgaaggtg accccaggcg ccctcctggg cctgagcaat 600 660 ctcacccatc tgtctctgaa gtataacaac ctcacaaagg tgccccgcca actgccccc 720 agcctggagt acctcctggt gtcctataac ctcattgtca agctggggcc tgaagacctg 780 gccaatctga cctcccttcg agtacttgat gtgggtggga attgccgtcg ctgcgaccat gcccccaatc cctgtataga atgtggccaa aagtccctcc acctgcaccc tgagaccttc 840 catcacctga gccatctgga aggcctggtg ctgaaggaca gctctctcca tacactgaac 900 tetteetggt tecaaggtet ggteaacete teggtgetgg acetaagega gaactttete tatgaaagca tcaaccacac caatgccttt cagaacctaa cccgcctgcg caagctcaac 1020 ctgtccttca attaccgcaa gaaggtatcc tttgcccgcc tccacctggc aagttccttc 1080 1140 aagaacctgg tgtcactgca ggagctgaac atgaacggca tcttcttccg ctcgctcaac aagtacacgc tcagatggct ggccgatctg cccaaactcc acactctgca tcttcaaatg 1200 aacttcatca accaggcaca gctcagcatc tttggtacct tccgagccct tcgctttgtg 1260 gacttgtcag acaatcgcat cagtgggcct tcaacgctgt cagaagccac ccctgaagag 1320 gcagatgatg cagagcagga ggagctgttg tctgcggatc ctcacccagc tccactgagc 1380 acceptgett ctaagaactt catggacagg tgtaagaact tcaagttcac catggacctg 1440 1500 tctcggaaca acctggtgac tatcaagcca gagatgtttg tcaatctctc acgcctccag 1560 tgtcttagcc tgagccacaa ctccattgca caggctgtca atggctctca gttcctgccg

ctgactaatc tgcaggtgct ggacctgtcc cataacaaac tggacttgta ccactggaaa 1620 tcgttcagtg agctaccaca gttgcaggcc ctggacctga gctacaacag ccagccttt 1680 agcatgaagg gtataggcca caatttcagt tttgtggccc atctgtccat gctacacagc 1740 cttagcctgg cacacaatga cattcatacc cgtgtgtcct cacatctcaa cagcaactca 1800 gtgaggtttc ttgacttcag cggcaacggt atgggccgca tgtgggatga ggggggcctt 1860 tatctccatt tcttccaagg cctgagtggc ctgctgaagc tggacctgtc tcaaaataac 1920 ctgcatatcc tccggcccca gaaccttgac aacctcccca agagcctgaa gctgctgagc 1980 ctccgagaca actacctatc tttctttaac tggaccagtc tgtccttcct gcccaacctg 2040 gaagteetag acctggcagg caaccageta aaggeeetga ccaatggcae cetgeetaat 2100 ggcaccctcc tccagaaact ggatgtcagc agcaacagta tcgtctctgt ggtcccagcc 2160 ttcttcgctc tggcggtcga gctgaaagag gtcaacctca gccacaacat tctcaagacg 2220 gtggatcgct cctggtttgg gcccattgtg atgaacctga cagttctaga cgtgagaagc 2280 aaccctctgc actgtgcctg tggggcagcc ttcgtagact tactgttgga ggtgcagacc 2340 aaggtgcctg gcctggctaa tggtgtgaag tgtggcagcc ccggccagct gcagggccgt 2400 agcatcttcg cacaggacct gcggctgtgc ctggatgagg tcctctcttg ggactgcttt 2460 ggc 2463

<400> 33

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 1 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn 50 55

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

<210> 33

<211> 1032

<212> PRT

<213> Homo sapiens

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser 130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser 145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe 260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe 290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu

PCT/US2003/029577 WO 2004/026888 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val

Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly 545 550 555

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser 580 585

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe 610 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser 660 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg 675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg 690 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe 705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu 740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val 820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His 835 840 845

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp 850 860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln 865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu 885 890 895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp 900 905 910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr 915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser 930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln 995 1000 1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg 1010 1015 1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu 1025 1030

<210> 34

<211> 820

<212> PRT

<213> Homo sapiens

<400> 34

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn 50 55

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 . 120 . 125 .

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser 130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser 145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr 210 220

Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe 260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe 290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu 325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala 340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu 370 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu

420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu 435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu 450 460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser 465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser 485 490 495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val 500 505 510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu 515 520 525

Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu 530 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly 545 550 550 560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr 565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser 580 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe 610 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln 645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser 660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg 675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg 690 695 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe 705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 . 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
770 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815

Asp Cys Phe Ala 820

<210> 35

<211> 3352

<212> DNA

<213> Homo sapiens

<400> 35

aggetggtat aaaaatetta etteetetat tetetgagee getgetgeee etgtgggaag 60
ggacetegag tgtgaageat eetteeetgt agetgetgte eagtetgeee geeagaeeet 120
etggagaage eeetgeeee eageatggt ttetgeegea gegeeetgea eeegetgtet 180
eteetggtge aggeeateat getggeeatg accetggeee tgggtaeett geetgeette 240
etaeeetgtg ageteeagee eeaeggeetg gtgaaetgea aetggetgtt eetgaagtet 300

gtgccccact tctccatggc agcaccccgt ggcaatgtca ccagcctttc cttgtcctcc 360 aaccgcatcc accacctcca tgattctgac tttgcccacc tgcccagcct gcggcatctc 420 aacctcaagt ggaactgccc gccggttggc ctcagcccca tgcacttccc ctgccacatg 480 accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac 540 aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc cctcagccat 600 accaacatcc tgatgctaga ctctgccagc ctcgccggcc tgcatgccct gcgcttccta 660 ttcatggacg gcaactgtta ttacaagaac ccctgcaggc aggcactgga ggtggccccg 720 ggtgccctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctcact 780 gtggtgcccc gcaacctgcc ttccagcctg gagtatctgc tgttgtccta caaccgcatc 840 gtcaaactgg cgcctgagga cctggccaat ctgaccgccc tgcgtgtgct cgatgtggc 900 ggaaattgcc gccgctgcga ccacgctccc aacccctgca tggagtgccc tcgtcacttc 960 1020 ccccagctac atcccgatac cttcagccac ctgagccgtc ttgaaggcct ggtgttgaag gacagttctc tctcctggct gaatgccagt tggttccgtg ggctgggaaa cctccgagtg 1080 ctggacctga gtgagaactt cctctacaaa tgcatcacta aaaccaaggc cttccagggc 1140 ctaacacagc tgcgcaagct taacctgtcc ttcaattacc aaaagagggt gtcctttgcc 1200 1260 cacctgtctc tggccccttc cttcgggagc ctggtcgccc tgaaggagct ggacatgcac ggcatcttct tccgctcact cgatgagacc acgctccggc cactggcccg cctgcccatg 1320 ctccagactc tgcgtctgca gatgaacttc atcaaccagg cccagctcgg catcttcagg 1380 gccttccctg gcctgcgcta cgtggacctg tcggacaacc gcatcagcgg agcttcggag 1440 ctgacagcca ccatggggga ggcagatgga ggggagaagg tctggctgca gcctggggac 1500 cttgctccgg ccccagtgga cactcccagc tctgaagact tcaggcccaa ctgcagcacc 1560 ctcaacttca ccttggatct gtcacggaac aacctggtga ccgtgcagcc ggagatgttt 1620 gcccagctct cgcacctgca gtgcctgcgc ctgagccaca actgcatctc gcaggcagtc 1680 aatggctccc agttcctgcc gctgaccggt ctgcaggtgc tagacctgtc ccgcaataag 1740 ctggacctct accacgagca ctcattcacg gagctaccgc gactggaggc cctggacctc 1800 agctacaaca gccagccctt tggcatgcag ggcgtgggcc acaacttcag cttcgtggct 1860 cacctgcgca ccctgcgcca cctcagcctg gcccacaaca acatccacag ccaagtgtcc 1920 cagcagetet geagtacgte getgegggee etggaettea geggeaatge aetgggeeat 1980 atgtgggccg agggagacct ctatctgcac ttcttccaag gcctgagcgg tttgatctgg 2040

ctggacttgt	cccagaaccg	cctgcacacc	ctcctgcccc	aaaccctgcg	caacctcccc	2100
aagagcctac	aggtgctgcg	tctccgtgac	aattacctgg	ccttctttaa	gtggtggagc	2160
ctccacttcc	tgcccaaact	ggaagtcctc	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcacccgg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttcg	tggcccccgg	cttcttttcc	aaggccaagg	agctgcgaga	gctcaacctt	2340
agcgccaacg	ccctcaagac	agtggaccac	tcctggtttg	ggcccctggc	gagtgccctg	2400
caaatactag	atgtaagcgc	caaccctctg	cactgcgcct	gtggggcggc	ctttatggac	2460
ttcctgctgg	aggtgcaggc	tgccgtgccc	ggtctgccca	gccgggtgaa	gtgtggcagt	2520
ccgggccagc	tccagggcct	cagcatcttt	gcacaggacc	tgcgcctctg	cctggatgag	2580
gccctctcct	gggactgttt	cgccctctcg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctgggac	ctctggtact	gcttccacct	gtgcctggcc	2700
tggcttccct	ggcgggggcg	gcaaagtggg	cgagatgagg	atgccctgcc	ctacgatgcc	2760
ttcgtggtct	tcgacaaaac	gcagagcgca	gtggcagact	gggtgtacaa	cgagcttcgg	2820
gggcagctgg	aggagtgccg	tgggcgctgg	gcactccgcc	tgtgcctgga	ggaacgcgac	2880
tggctgcctg	gcaaaaccct	ctttgagaac	ctgtgggcct	cggtctatgg	cagccgcaag	2940
acgctgtttg	tgctggccca	cacggaccgg	gtcagtggtc	tcttgcgcgc	cagcttcctg	3000
ctggcccagc	agcgcctgct	ggaggaccgc	aaggacgtcg	tggtgctggt	gatcctgagc	3060
cctgacggcc	gccgctcccg	ctacgtgcgg	ctgcgccagc	gcctctgccg	ccagagtgtc	3120
ctcctctggc	cccaccagcc	cagtggtcag	cgcagcttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cggaacttct	gccagggacc	cacggccgaa	3240
tagccgtgag	ccggaatcct	gcacggtgcc	acctccacac	tcacctcacc	tctgcctgcc	3300
tggtctgacc	ctcccctgct	cgcctccctc	accccacacc	tgacacagag	ca	3352

<210> 36

<400> 36

<211> 2460

<212> DNA

<213> Homo sapiens

atgggtttet geegeagege eetgeaceeg etgtetetee tggtgeagge cateatgetg 60 geeatgacee tggeeetggg tacettgeet geetteetae eetgtgaget eeageeeeae 120 ggeetggtga actgeaactg getgtteetg aagtetgtge eecaettete eatggeagea 180 eecegtggea atgteaceag eettteettg teeteeaace geateeacea eetecatgat 240

300 tctgactttg cccacctgcc cagcctgcgg catctcaacc tcaagtggaa ctgcccgccg gttggcctca gccccatgca cttcccctgc cacatgacca tcgagcccag caccttcttg 360 420 gctgtgccca ccctggaaga gctaaacctg agctacaaca acatcatgac tgtgcctgcg 480 ctgcccaaat ccctcatatc cctgtccctc agccatacca acatcctgat gctagactct gccagcctcg ccggcctgca tgccctgcgc ttcctattca tggacggcaa ctgttattac 540 aagaacccct gcaggcaggc actggaggtg gccccgggtg ccctccttgg cctgggcaac 600 ctcacccacc tgtcactcaa gtacaacaac ctcactgtgg tgccccgcaa cctgccttcc 660 720 agcctggagt atctgctgtt gtcctacaac cgcatcgtca aactggcgcc tgaggacctg 780 gccaatctga ccgccctgcg tgtgctcgat gtgggcggaa attgccgccg ctgcgaccac gctcccaacc cctgcatgga gtgccctcgt cacttccccc agctacatcc cgataccttc 840 agccacctga gccgtcttga aggcctggtg ttgaaggaca gttctctctc ctggctgaat 900 gccagttggt tccgtgggct gggaaacctc cgagtgctgg acctgagtga gaacttcctc 960 tacaaatgca tcactaaaac caaggccttc cagggcctaa cacagctgcg caagcttaac 1020 ctgtccttca attaccaaaa gagggtgtcc tttgcccacc tgtctctggc cccttccttc 1080 gggagcctgg tcgccctgaa ggagctggac atgcacggca tcttcttccg ctcactcgat 1140 gagaccacgc teeggeeact ggeeegeetg eccatgetee agactetgeg tetgeagatg 1200 aacttcatca accaggccca gctcggcatc ttcagggcct tccctggcct gcgctacgtg 1260 gacctgtcgg acaaccgcat cagcggagct tcggagctga cagccaccat gggggaggca 1320 1380 gatggagggg agaaggtctg gctgcagcct ggggaccttg ctccggcccc agtggacact cccagctctg aagacttcag gcccaactgc agcaccctca acttcacctt ggatctgtca 1440 cggaacaacc tggtgaccgt gcagccggag atgtttgccc agctctcgca cctgcagtgc 1500 ctgcgcctga gccacaactg catctcgcag gcagtcaatg gctcccagtt cctgccgctg 1560 accggtctgc aggtgctaga cctgtcccgc aataagctgg acctctacca cgagcactca 1620 ttcacggagc taccgcgact ggaggccctg gacctcagct acaacagcca gccctttggc 1680 atgcagggcg tgggccacaa cttcagcttc gtggctcacc tgcgcaccct gcgccacctc 1740 agcctggccc acaacaacat ccacagccaa gtgtcccagc agctctgcag tacgtcgctg 1800 1860 cgggccctgg acttcagcgg caatgcactg ggccatatgt gggccgaggg agacctctat 1920 ctgcacttct tccaaggcct gagcggtttg atctggctgg acttgtccca gaaccgcctg 1980 cacaccetee tgeeceaaac eetgegeaac eteceeaaga geetacaggt getgegtete cgtgacaatt acctggcctt ctttaagtgg tggagcctcc acttcctgcc caaactggaa 2040

gtcctc	gacc	tggcaggaaa	ccggctgaag	gccctgacca	atggcagcct	gcctgctggc	2100
acccgg	ctcc	ggaggctgga	tgtcagctgc	aacagcatca	gcttcgtggc	ccccggcttc	2160
ttttcca	aagg	ccaaggagct	gcgagagctc	aaccttagcg	ccaacgccct	caagacagtg	2220
gaccact	tcct	ggtttgggcc	cctggcgagt	gccctgcaaa	tactagatgt	aagcgccaac	2280
cctctg	cact	gcgcctgtgg	ggcggccttt	atggacttcc	tgctggaggt	gcaggctgcc	2340
gtgccc	ggtc	tgcccagccg	ggtgaagtgt	ggcagtccgg	gccagctcca	gggcctcagc	2400
atcttt	gcac	aggacctgcg	cctctgcctg	gatgaggccc	tctcctggga	ctgtttcgcc	2460
<210><211><211><212><213>	37 26 DNA Art:	ificial seq	ıence				
<220> <223>	Synt	thetic oligo	onucleotide				
<400> accttg		ccttcctacc	ctgtga				26
<210><211><212><213>	21 DNA	ificial seq	uence				
<220> <223>	Syn	thetic olig	onucleotide				
<400> gtccgt		gccagcacaa	a				21
<210><211><212><213>	20 DNA	ificial seq	uence				
<220> <223>	Synt	thetic olig	onucleotide				
	39 acgt	ttttgatgtt					20
<210><211><212><213>	DNA	ificial seq	uence				
<220> <223>	Syn	thetic olige	onucleotide				

<400> tccata	40 acgt ttttgatgtt	20
<210><211><212><213>	20	
<220> <223>	Synthetic oligonucleotide	
<400> tccatc	41 acgt ttttgatgtt	20
<210><211><212><213>	20	
<220> <223>	Synthetic oligonucleotide	
<400> tccatt	42 acgt ttttgatgtt	20
<210><211><212><213>	20	
<220> <223>	Synthetic oligonucleotide	
<400> tccatg	43 gcgt ttttgatgtt	20
<210><211><211><212><213>	20	
<220> <223>	Synthetic oligonucleotide	
<400> tccatgo	44 ccgt ttttgatgtt	20
<220>		

<223> Synthetic oligonucleotide <400> 45 tccatgtcgt ttttgatgtt 20 <210> 46 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 46 tccatgatgt ttttgatgtt 20 <210> 47 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 47 tccatgaagt ttttgatgtt 20 <210> 48 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 48 tccatgaggt ttttgatgtt 20 <210> 49 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 49 tccatgacat ttttgatgtt 20 <210> 50 <211> 20 <212> DNA

PCT/US2003/029577

WO 2004/026888

<213> Artificial sequence

<220>		
<223>	Synthetic oligonucleotide	
<400>		20
tccatga	ecct ttttgatgtt	20
0.1.0		
<210>		
<211>		
<212>	Artificial sequence	
\Z137	ALCITICIAL DOGACIO	
<220>	o	
<223>	Synthetic oligonucleotide	
<400>		20
tccatg	actt ttttgatgtt	20
0.7.0	50	
<210>		
<211><212>	20 DNA	
	Artificial sequence	
<220>	a	
<223>	Synthetic oligonucleotide	
<400>		20
tccatg	acgc ttttgatgtt	20
.010.	EO	
<210><211>		
<212>		
	Artificial sequence	
<220>	Synthetic oligonucleotide	
<223>	Synchetic Offgondereotiae	
<400>		20
tccatg	acga ttttgatgtt	
<210>	54	
<211>		
<212>		
	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	54	
	gacgg ttttgatgtt	20
<210>	55 ·	
<211>		
<212>		
<213>	Artificial sequence	

<220> <223>	Synthetic oligonucleotide	
<400> tccatga	55 acgt ctttgatgtt	20
<210><211><212>	20 DNA	
<213>	Artificial sequence	
<220> <223>	Synthetic oligonucleotide	
<400> tccatga	56 acgt atttgatgtt	20
<211> <212>	57 20 DNA Artificial sequence	
<220> <223>	Synthetic oligonucleotide	
<400> tccatg	57 acgt gtttgatgtt	20
<210><211><212><213>	24	
<220> <223>	Synthetic oligonucleotide	
<400> tcgtcg	58 tttt gtcgttttgt cgtt	24
<210><211><212><213>	59 24 DNA Artificial sequence	
<220> <223>	Synthetic oligonucleotide	
<400> tgctgc	59 tttt gtgcttttgt gctt	24
<210><211><212>	60 20 DNA	

```
<213> Artificial sequence
<220>
<223> Synthetic oligonucleotide
<400> 60
tccatgacgt tcctgatgct
                                                                    20
<210> 61
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Synthetic oligonucleotide
<400> 61
tccatgagct tcctgatgct
                                                                    20
<210> 62
<211> 16
<212> PRT
<213> Artificial sequence
<220>
<223> Consensus oligopeptide
<220>
<221> MISC_FEATURE
<222> (4)..(5)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (7)..(12)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222>
      (14)..(15)
<223> Any amino acid
<400> 62
Gly Asn Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
1
                                   10
                                                       15
<210> 63
<211> 16
<212> PRT
<213> Homo sapiens
<400> 63
```

```
Gly Asn Cys Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys
                                   10
                                                      15
<210> 64
<211> 16
<212> PRT
<213> Mus musculus
<400> 64
Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Ile Cys
1
               5
                                   10
                                                      15
<210> 65
<211> 31
<212> PRT
<213> Artificial sequence
<220>
<223> Consensus oligopeptide
<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid
<220>
<221> MISC FEATURE
<222> (12)..(12)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid
<400> 65
Arg Xaá Xaa Xaa Xaa Xaa Xaa Arg Xaa Asp Xaa Tyr Xaa Xaa Xaa
```

- 112 -

10

15

Xaa Xaa Xaa Xaa Xaa Arg Ser Xaa Xaa Xaa Xaa Xaa Xaa Tyr 20 25 <210> 66 <211> 31 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (2)..(8) <223> Any amino acid <220> <221> MISC_FEATURE <222> (10)..(10) <223> Any amino acid <220> <221> MISC_FEATURE <222> (12)..(12) <223> Any amino acid <220> <221> MISC_FEATURE <222> (14)..(22) <223> Any amino acid <220> <221> MISC_FEATURE (25)..(30) <222> <223> Any amino acid <400> 66 Gln Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Arg Leu Xaa Xaa Xaa Xaa Xaa Xaa Tyr 20 25 30 <210> 67

<211> 31 <212> PRT <213> Mus musculus <220> <221> MISC_FEATURE <222> (2)..(8) Any amino acid

<223>

```
<220>
<221>
      MISC_FEATURE
<222>
      (10)..(10)
      Any amino acid
<223>
<220>
      MISC_FEATURE
<221>
      (12)..(12)
<222>
      Any amino acid
<223>
<220>
<221>
      MISC_FEATURE
<222>
      (14)..(22)
<223> Any amino acid
<220>
<221> MISC_FEATURE
      (25)..(30)
<222>
<223>
      Any amino acid
<400> 67
Gln Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa
1
                                   10
                                                       15
Xaa Xaa Xaa Xaa Xaa Gln Leu Xaa Xaa Xaa Xaa Xaa Tyr
            20
                               25
                                                   30
<210> 68
<211>
      31
<212> PRT
<213> Homo sapiens
<400> 68
Gln Val Leu Asp Leu Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His
1
                                   10
                                                       15
Ser Phe Thr Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr
           20
                               25
<210> 69
<211> 31
<212> PRT
<213> Mus musculus
<400> 69
```

Gln Val Leu Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys

10 15

Ser Phe Ser Glu Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr 25

<210> 70
<211> 20
<212> DNA
<213> Artificial sequence

PCT/US2003/029577

20

WO 2004/026888

<220>
<223> Synthetic oligonucleotide

<400> 70
tccaggactt ctctcaggtt

- 115 -